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ABSTRACT
The stretch reflex circuit is one of the most primitive circuits of mammalian system and serves
mainly to control the length of the muscle. It consists of four elements: the stretch sensor (muscle
spindle/ intrafusal fiber lie parallel between extrafusal, contractile musculature), extrafusal muscle
fiber, sensory neuron and motoneuron. The basic principle of the stretch reflex arc circuit is as
follows: whenever there is a sudden stretch in a muscle, it needs to compensate back to its original
length so as to prevent any kind of injury. It performs this compensation process using a simple
negative feed back circuit called the stretch reflex arc. Any form of stretch in a muscle activates the
stretch sensors (muscle spindle/ intrafusal fiber) lying deep in each muscle. After the stretch
sensors get activated, it sends a train of signals to the spinal cord through the sensory neurons.
The sensory neurons relay this information to the motoneuron. The motoneuron performs the
necessary information processing and sends the message to the extrafusal fibers so as to
compensate for the sudden stretch action. The motoneuron conveys this message to the extrafusal
fibers by communicating through the special synaptic junctions called neuromuscular junctions.
Based on this information, the extrafusal fibers act accordingly so as to counter the effect of
sudden stretch. This is also called the monosynaptic stretch reflex that involves a single synapse
between a sensory neuron and a motoneuron. To date studying these stretch reflex circuits is only
feasible in animal models. Almost no effort has been made to tissue engineer such circuits for a
better understanding of the complex development and repair processes of the stretch reflex circuit
formation. The long-term goal of this research is to tissue engineer a cellular prototype of the entire
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stretch reflex circuit. The specific theme of this dissertation research was to tissue engineer the
motoneuron to muscle segment of the stretch reflex arc circuit utilizing micro-fabrication, interface
design and defined medium formulations. In order to address this central theme, the following
hypothesis has been proposed. The first part of the hypothesis is that microfabrication technology,
interface design and defined medium formulations can be effectively combined to tissue engineer
the motoneuron to muscle segment of the stretch reflex arc. The second part of the hypothesis is
that different growth factors, hormones, nanoparticles, neurotransmitters and synthetic substrate
can be optimally utilized to regenerate the adult mammalian spinal cord neurons so as to replace
the embryonic motoneurons in the stretch reflex tissue engineered construct with adult
motoneurons. In this body of work, the different tissue engineering strategies and technologies
have been addressed to enable the recreation of a in vitro cellular prototype of the stretch reflex
circuit with special emphasis on building the motoneuron to muscle segment of the circuit. In order
to recreate the motoneuron to muscle segment of the stretch reflex arc, a successful methodology
to tissue engineer skeletal muscle and motoneuron was essential. Hence the recreation of the
motoneuron to muscle segment of the stretch reflex circuit was achieved in two parts. In the part 1
(Chapters 2-5), the challenges in skeletal muscle tissue engineering were examined. In part 2
(Chapters 6-7), apart from tissue engineering the motoneuron to muscle segment, the real time
synaptic activity between motoneuron and muscle segment were studied using extensive video
recordings. In part 3 (Chapters 8-10), an innovative attempt had been made to tissue engineer the
adult mammalian spinal cord neurons so that in future this technology could utilized to replace the
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embryonic neurons used in the stretch reflex circuit with adult neurons. The advantage of using
adult neurons is that it provides a powerful tool to study older neurons since these neurons are
more prone to age related changes, neurodegenerative disorders and injuries. This study has
successfully demonstrated the recreation of the motoneuron to muscle segment of the stretch
reflex arc and further demonstrated the successful tissue engineering strategies to grow adult
mammalian spinal cord neurons. The different cell culture technologies developed in these studies
could be used as powerful tools in nerve-muscle tissue engineering, neuro-prosthetic devices and
in regenerative medicine.
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CHAPTER 1: GENERAL INTRODUCTION
Tissue engineering is a complex interdisciplinary field[1]. According to the definition given by
Robert Langer and Charles Vacanti in their review paper in the May 14, 1993 issue of Science,
“Tissue engineering is an interdisciplinary field that applies the principles of engineering and the life
sciences toward the development of biological substitutes that restore, maintain, or improve tissue
function”[2, 3]. Before this definition was coined, at the 1992 UCLA symposium on tissue
engineering, “Eugene Bell defined tissue engineering in terms of a more specific list of goals"[4, 5]:
1. “Providing cellular prostheses or replacement parts for the human body”.
2. “Providing formed non-cellular replacement parts capable of inducing regeneration”.
3. “Providing tissue or organ-like model systems populated with cells for basic research and for
many applied uses such as the study of diseased states using aberrant cells”.
4. “Providing vehicles for delivering engineered cells to the organism”.
5. “Surfacing non-biological devices to create hybrid devices and systems”[4, 5].

Tissue engineering has an interdisciplinary root. Tissue engineering has evolved from the
integration of knowledge from diverse fields namely; cell and developmental biology, basic medical
and veterinary sciences, transplantation science, biomaterials, biophysics, biomechanics and
biomedical engineering[6]. Figure 1 indicates how these diverse areas of science, engineering and
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clinical medicine, contribute to the development of tissue engineering.

Success of tissue engineering is dependent upon successful cell culture technologies,
biocompatible substrates and interfacing biological components with bio-hybrid systems [2, 3, 6].
Since tissue engineering involves constructing tissue and/or organ-like model systems as well as
defining the surface of non-biological devices to create hybrid devices and systems, the major
prerequisites to successfully achieve these goals are the following:
1. Developing a uniform cell isolation and cell culture methodology.
2. Understanding the growth factor requirements of the cells and developing defined mediums.
3. Understanding cell-cell and cell-matrix interactions to develop advanced biomaterials.
4. Employing surface engineering tools to characterize and modify the surface properties of
biomaterials.
5. Enabling micro-fabrication technologies and interface design for integrating live cells with biohybrid (bio-MEMS) devices for advance research in tissue engineering, development of biosensor
devices and designing the next generation of prosthetic devices.

2

Figure 1. Interdisciplinary roots of tissue engineering

3

During last 15 years, efforts have been made by different research groups to develop in vitro
micro-scale tissue engineered systems that combines the use of a defined medium with a
chemically defined surface[7-25]. The main objective for developing such defined tissue
engineered systems is to study cell differentiation, cell signaling, physiological information
processing and to fabricate biological networks and bio-hybrid devices by patterning cells in a
desired geometry. Most of the efforts have been made to develop such systems with a single cell
type such as brain neurons, sensory neurons, retinal neurons, endothelial cells and
cardiomyocytes[7-24, 26-51].

The next level of challenge in micro-scale tissue engineering is to develop in vitro systems to study
the interaction of two, three or more cell types in a defined system that will more closely
approximate an in vivo tissue of biological subsystem. Some simple examples are attempts to
study the interaction between brain neurons and spinal cord neurons, motoneuron and sensory
neurons, bipolar neurons and the amacrine cells of the eye, sympathetic neurons with heart
muscle, renal sympathetic neurons and the renal vessels, the tubules, and the juxtaglomerular
granular cells of kidney. It is feasible to study such cellular interactions by fabricating patterned
networks of interacting cell types on a bio-hybrid device. The objective for building these tissue
engineered networks is to mimic the different interacting organ systems of a body. Such defined
tissue engineered systems could be used as powerful tools in getting a better understanding of the
complex physiology that exists in mammalian systems. In this dissertation research work, an
4

attempt has been made to fabricate a defined, micro-scale tissue engineered system to study the
interaction of two different interacting cell types.

The specific theme of this dissertation research was to tissue engineer the motoneuron to muscle
segment of the stretch reflex arc circuit utilizing micro-fabrication, interface design and defined
medium formulations. In order to address this central theme, the following hypothesis has been
proposed. The first part of the hypothesis is that microfabrication technology, interface design and
defined medium formulations can be effectively combined to tissue engineer the motoneuron to
muscle segment of the stretch reflex arc. The second part of the hypothesis is that different growth
factors, hormones, nanoparticles, neurotransmitters and synthetic substrate can be optimally
utilized to regenerate the adult mammalian spinal cord neurons so as to replace the embryonic
motoneurons in the stretch reflex tissue engineered construct with adult motoneurons.

The concept of the reflex circuit was originated in 16th century with Descartes[52], who believed
that animals were mechanical devices that transformed sensory stimuli into motor responses. In
1924, British physiologist Charles Sherrington and his student E.G.T Liddell described the stretch
reflex circuit[53-55]. The stretch reflex circuit is one of the most primitive circuits of mammalian
system and serves mainly to control the length of the muscle. It consists of four elements: the
stretch sensor (muscle spindle/ intrafusal fiber lie parallel between extrafusal, contractile
musculature), extrafusal muscle fiber, sensory neuron and motoneuron (see figure 2). The basic
5

principle of the stretch reflex arc circuit is as follows: whenever there is a sudden stretch in a
muscle, it needs to compensate back to its original length so as to prevent any kind of injury. It
performs this compensation process using a simple negative feed back circuit called the stretch
reflex arc. Any form of stretch in a muscle activates the stretch sensors (muscle spindle/ intrafusal
fiber) lying deep in each muscle. After the stretch sensors get activated, it sends a train of signals
to the spinal cord through the sensory neurons. The sensory neurons relay this information to the
motoneuron.
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Figure 2. Stretch reflex arc circuit
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The motoneuron performs the necessary information processing and sends the message to the
extrafusal fibers so as to compensate for the sudden stretch action. The motoneuron conveys this
message to the extrafusal fibers by communicating through the special synaptic junctions called
neuromuscular junctions. Based on this information, the extrafusal fibers act accordingly so as to
counter the effect of sudden stretch. This is also called the monosynaptic stretch reflex that
involves a single synapse between a sensory neuron and a motoneuron. The reflex time of the
monosynaptic reflex is extremely short (about 20 ms)[56, 57]. Formation of most of the stretch
reflex circuits in animals are developmentally regulated by different growth factors and cell types in
a temporal fashion. Hence to date studying these stretch reflex circuits is only feasible in animal
models[58-74]. Although recent advancements in developmental biology has shed new lights on
the development of such circuits, almost no effort has been made to tissue engineer such circuits
for a better understanding of the complex development and repair processes of the stretch reflex
circuit formation[75].

The long-term goal of this research is to tissue engineer a cellular prototype of the entire stretch
reflex circuit. However achieving this goal was not possible in a single dissertation, so the focus of
my dissertation research was on two main objectives. The first goal was to develop a cantileverbased bio-MEMS device to measure communication between a motoneuron and myotube in a
defined medium formulation (supplemented with specific growth factors) (Figure 3). In figure 3, the
experimental system design has been shown. Such a circuit would be able to act as a defined in
8

vitro tool in studying spasticity, spinal cord injury, amyotrophic lateral sclerosis (ALS) and for
development of bio-mimetic prosthetics. The second goal was to develop tissue-engineering
strategies using different growth factors, hormones, nanoparticles, neurotransmitters and synthetic
substrate for growing adult mammalian spinal cord neurons, so that in the future, these adult
motoneurons could replace the embryonic neurons in the stretch reflex arc circuit model. It is
important to develop adult models so as to study the age related neurodegenerative diseases,
neuro-muscular disorders and injuries.

The work has been divided into three independent parts which constitute the three main topics of
the thesis. The three parts are as follows:
Part 1: Skeletal muscle tissue engineering
Part 2: Tissue engineering neuro-muscular junction (NMJ)
Part 3: Tissue engineering adult mammalian spinal cord
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Figure 3. A cantilever-based bio-MEMS device to measure communication between a motoneuron
and myotube. Each component of the system has been marked with a number (1-14). The detail of
each part of the device has been explained below: 1. Custom cantilever arrays; 2. Detailed layout
of pattern on cantilever array; 3. Individual cantilever; 4. Site for motoneuron plating on patterned
substrate; 5. Site for sensory neuron plating on patterned substrate; 6. Barrier between
motoneuron and sensory neuron plating sites; 7. Site for skeletal muscle myotube formation; 8.
Putative neuromuscular junction site between motoneuron and skeletal muscle; 9. Deflection of
cantilever due to muscle contraction after receiving signal from motoneuron; 10. Source for laser
beam; 11. Laser beam falling on skeletal muscle on top of cantilever; 12. Reflecting laser beam;
13. Reflecting laser beam changes angle due to bending of cantilever caused by contracting
myotubes; 14. Photo-detector measuring the change in angle θ

10

In part 1, skeletal muscle tissue engineering strategies have been discussed. This part consisted of
four independent experiments (chapter 2-5). In this series of experiments, a chemically defined,
serum-free medium was developed to grow functional myotubes from a dissociated culture of
muscle cells. A synthetic substrate was used for this study. Myotubes were characterized
morphologically, immunocytochemically and electrophysiologically. Further, myotubes were
integrated with a cantilever based bio-hybrid device to study muscle physiology. In chapter 2, a
systematic study was carried out describing the role of individual growth factors involved in
myotube formation and the development of a defined medium for muscle culture. In chapter 3, the
defined model system was utilized to study skeletal muscle differentiation[76]. In chapter 4, a
detailed protocol for bio-hybrid device development and integration of the myotubes in the device
has been documented[77]. In chapter 5, a significant improvement had been made in medium
formulation that has enabled long term survival of myotubes, structural development of the
excitation-contraction (E-C) coupling apparatus as well as neonatal myosin heavy chain (MHC)
expression. This system could be used as a powerful tool to study skeletal muscle differentiation,
skeletal muscle tissue engineering, muscular dystrophy and to carry out functional assay of the
myotubes.

In part 2, mammalian neuromuscular junction (NMJ) tissue engineering strategies have been
developed. In these experiments, for the first time, a defined medium had been developed which
promoted in vitro mammalian NMJ formation. It has been achieved by systematic integration of the
11

media developed in part 1 with additional factors known to promote neuronal growth. Further, a
simple, novel culture technique had been documented to coculture motoneuron and muscle. This
part consisted of two independent experiments (chapters 6-7). In chapter 6, the first preliminary
medium was developed which promoted neuromuscular junction formation[78]. In chapter 7, a
significant improvement was made over the preliminary medium. The improved medium detailed in
chapter 7 promoted neonatal myosin heavy chain expression in muscle, longer survival and
increased neuromuscular junction formation. These are the first chemically defined medium which
promoted mammalian neuromuscular junction formation in vitro. Further, this is the first evidence
which shows that neuromuscular junction formation can be achieved on a synthetic substrate
which is free from all known extracellular matrix components. These studies offers a basic system
that can be utilized for studying the communication between the motoneuron to muscle segment of
the stretch reflex circuit, nerve-muscle tissue engineering, regenerative medicine and development
of limb prosthetics.

In part 3, tissue engineering strategies have been developed for adult mammalian spinal cord cells.
In this set of experiments, functional adult mammalian spinal cord neurons have been grown using
a synthetic silane substrate and a medium was developed using different growth factors,
hormones, nanoparticles and neurotransitters. This part consisted of three experiments (chapter 810). In chapter 8, a chemically defined, serum-free medium was developed to culture adult rat
spinal cord neurons on a synthetic, silane substrate. The cells were characterized morphologically,
12

immunocytochemically and electrophysiologically. Thirty percent of the neurons were electrically
active in this culture model[79]. In chapter 9, the neuroprotective activity of Cerium oxide
nanoparticles in adult rat spinal cord neurons in culture was assessed. The culture system
developed in chapter 8 was used for this experiment. A significant increase in the neuronal survival
was observed following nanoparticle treatment. This finding raised the possibility that in the future,
Cerium oxide nanoparticles could be used in nanomedicine for spinal cord therapy[80]. In chapter
8, only 30% of the neurons were electrically active. This would limit the use of this model for
functional studies. In chapter 10, the role of neurotransmitters in enhancing the functionality of the
adult mammalian spinal cord neurons in culture was discovered. It was shown that the electrical
activity of most of the neurons could be restored by applying multiple neurotransmitters in a
temporal manner. Sixty percent of the neurons regained their electrical activity by temporal
application of multiple neurotransmitters. For the first time; it was shown that exogenous
application of neurotransmitters could be used as a therapeutic tool in tissue engineering nerve
constructs and in regenerative medicine. Apart from documenting the work in “Experimental
Neurology”[81], a patent has been filed on this work.

In chapter 11, these advance muscle and nerve tissue engineering technologies are discussed in
context of translational research as useful biomedical engineering tools in studying the stretch
reflex arc circuit, neuromuscular junction formation and function, spinal cord injury, muscle
development, muscle disorders and in developing advance strategies in regenerative medicine.
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CHAPTER 2: DEVELOPMENT OF A NOVEL SERUM-FREE CELL CULTURE MODEL OF
SKELETAL MUSCLE DIFFERENTIATION BY SYSTEMATIC INVESTIGATION OF THE ROLE
OF DIFFERENT GROWTH FACTORS IN MYOTUBE FORMATION

Introduction
The major goal of this study is to develop a serum-free cell culture model to study skeletal muscle
differentiation and to get a better understanding of the process by which individual skeletal muscle
cells migrate and align together to form functional, contractile, multinucleated myotubes [1-11].
The serum-free defined cell culture model involved the development of a chemically defined
medium supplemented with different growth factors and the use of a synthetic, biocompatible
silane substrate for cell growth. We have formulated the chemically defined medium by
systematically studying the effects of individual growth factors on myotube formation in vitro. The
biocompatible silane substrate, N-1[3-(trimethoxysilyl) propyl] diethylenetriamine (DETA) was
developed to provide a uniform growth surface for mammalian cell types as diverse as
hippocampal neurons and endothelial cells [12, 13].

Furthermore, the ease of applying

photolithographic patterning techniques to these biomimetic substrates facilitates controlled cellular
adhesion and outgrowth [13-17].

In vivo and in vitro studies carried out in last two decades have indicated that skeletal muscle
differentiation involves the specific interaction of multiple growth factors with both the myocyte and
the subsequently developing myotubes. The different growth factors which have been implicated in
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skeletal muscle differentiation includes vitronectin, bFGF, CT1, GDNF, BDNF, NT3, and NT4 [1-10,
18] Specifically, the role bFGF plays in limb morphogenesis has been elucidated [19, 20]
Additionally, the roles of NT3 and NT4 in the survival and normal development of skeletal muscle
fibers has been documented [21, 22].

Although skeletal muscle development is a very well studied model, limited success had been
achieved in generating different muscle phenotypes in culture[7, 8]. This limited success was
mostly due to non-availability of a defined culture model. All the culture models relied heavily on
the use of serum[23-41]. The use of serum further posed a serious challenge in successful tissue
engineering of the skeletal muscle for therapeutic applications. Till date, no systematic in vitro
study has been carried out optimally combining different growth factors to develop a chemically
defined medium. In this study we have analyzed the effects of bFGF, CT1, GDNF, BDNF, NT3,
NT4, and vitronectin on myocyte fusion and skeletal muscle differentiation.

Through this analysis, we developed a simple chemical and growth factor based medium
formulation and proposed a novel technique which promotes formation of robust, functional,
contractile, multinucleated myotubes in culture. We have immunocytochemically characterized the
different morphologies of myotubes using embryonic myosin heavy chain (MHC) antibody (F1.652).
We further observed that this novel technique, which promoted robust myotube formation, also
supported nerve-muscle coculture. We had provided immunocytochemical evidences of muscle27

nerve coculture. We believe this chemically defined formulation and the proposed development
model will be useful tools in studying myocyte biocompatibility, muscle differentiation, myopathies,
muscle tissue engineering and neuromuscular junction formation.
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Methods and Materials
Surface modification
Glass coverslips (Thomas Scientific 6661F52, 22 x 22mm No.1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 minutes at 100 mTorr. The DETA (United Chemical
Technologies Inc. T2910KG) films were formed by the reaction of the cleaned surface with a 0.1%
(v/v) mixture of the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated
coverslips were heated to just below the boiling point of the toluene, rinsed with toluene, reheated
to just below the boiling temperature, and then oven dried[42, 43].

Surface characterization
Surfaces were characterized by contact angle measurements using an optical contact angle
goiniometer (KSV Instruments, Cam 200) and by X-ray photoelectron spectroscopy (XPS) (Kratos
Axis 165). XPS survey scans, as well as high-resolution N1s and C1s scans, utilizing
monochromatic Al Kα excitation, were obtained.

Skeletal muscle culture and serum free medium
The skeletal muscle was dissected from the thighs of the hind limbs of fetal rat (17-18 days old).
The tissue was collected in a sterile 15-ml centrifuge tube containing 1 ml of phosphate-buffered
saline (calcium and magnesium-free) (Gibco 14200075). The tissue was enzymatically dissociated
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using 1 ml of 0.05% of trypsin-EDTA (Gibco 25300054) solution for 30 minutes in a 37°C water
bath (100 rpm). After 30 minutes the trypsin solution was removed and 2 ml of L15 + 10% fetal calf
serum (Gibco 16000044) was added to terminate the trypsin action. The tissue was then
mechanically triturated. The supernatant was then transferred to a 15-ml centrifuge tube. The
same process was repeated two times by adding 2 ml of L15 + 10% FBS each time. The 6 ml cell
suspension obtained after mechanical trituration was suspended on a 2 ml, 4% BSA (Sigma
A3059) (prepared in L15 medium) cushion and centrifuged at 300 g for 10 minutes at 4°C. The
pellet obtained was washed 5 times with L!5 medium then resuspended in 10 ml of L15 and plated
in 100 mm uncoated dishes for 30 min. The non-attached cells were removed, centrifuged on a
4% BSA cushion, and plated on the coverslips. The cells were plated at a density of 700-1000
cells/mm2. The cells attached to the substrate in 1 h. The serum-free medium (containing different
growth factors) was added to the culture dish after 1 h and the cells were maintained in a 5% CO2
incubator (relative humidity 85%). Half of the medium was change after every 4 days[43].

Coculture of three cell types in the defined medium
We developed a simple coculture technique for the growth and differentiation of skeletal muscle*
DRG(Sensory Neurons)* Spinal Cord. We mix the dissociated muscle cells with dissociated
sensory neurons (DRG) and the spinal cord cells. The sensory neurons (DRG) isolation protocol
was described in earlier paper[44]. In brief, DRG was isolated from embryonic day 14 (E14) rat
embryos and dissociated using trypsin and the resulting single cell suspension was mixed with the
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dissociated muscle cells in the serum-free medium. Similarly, we dissected out the whole spinal
cord from E14 embryo and dissociated it in trypsin solution, and subsequently the single cell
suspension of spinal cord cells were mixed with the mixture of dissociated muscle and DRG cell
suspension. The combined three cell suspension was then plated in the coverslips at a density of
800 cells/mm2. After 30 minutes, the well containing coverslips were filled with serum-free medium
(Figure 4). The first medium change was done at day 4 as described in figure 4 and the cultures
were maintained for 3 weeks.
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Figure 4. Flow chart showing the technique to grow robust myotubes and muscle-nerve cocultures:
The formulation IX and the medium change protocol which is most optimal for myotube and
coculture growth.
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Immunocytochemistry of skeletal muscle
Coverslips were prepared for immunocytochemical analysis as previously described[43]. Briefly,
coverslips were rinsed with PBS, fixed in -20°C methanol for 5-7 min, washed in PBS, incubated in
PBS supplemented with 1% BSA and 0.05% saponin (permeabilization solution) for 10 minutes,
and blocked for 2h with 10% goat serum and 1% BSA. Cells were incubated overnight with primary
antibodies against embryonic myosin heavy chain (F1.652) (Developmental Studies Hybridoma
Bank) diluted (1:5) in the blocking solution. Cells were washed with PBS and incubated with the
secondary antibody (Cy3 conjugated anti-mouse, Jackson Labs., 1:200 dilution in PBS) for 2
hours. After 2 hours the coverslips were rinsed with PBS and mounted on glass slides and
observed in confocal microscope.

Immunocytochemistry of cocultures
Double staining with neurofilament 150 and embryonic myosin heavy chain: Co-cultures were
processed for immunocytochemistry as described above. Next, cells were incubated overnight at 4
°C with rabbit anti-neurofilament M polyclonal antibody, 150 kD (AB1981, diluted 1:2000;
Millipore/Chemicon, Temecula, CA, USA) and fetal MHC (F1.652, IgG, Developmental Studies
Hybridoma Bank, diluted 1:5). After overnight incubation, the coverslips were rinsed three times
with PBS and then incubated with the appropriate secondary antibodies for 2 h. After rinsing three
times in PBS, the coverslips were mounted with Vectashield_DAPI mounting medium onto glass
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slides. The coverslips were visualized and images collected using a confocal microscope
(UltraVIEW™ LCI, PerkinElmer). Controls without primary antibody were negative.

AChR labeling of the myotubes
AChRs were labeled as described previously[14] by incubating cultures with 5*10-8 M of αbungarotoxin, Alexa Fluor® 488 conjugate (B-13422; Invitrogen/Molecular Probes, Carlsbad, CA,
USA)for 1.5 h at 37 °C before observation. Following incubation in α-bungarotoxin, the cultures
were fixed as mentioned above for further staining with embryonic myosin heavy chain (F1.652)
antibodies.
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Results and Discussion
DETA surface modification and characterization
Static contact angle and XPS analysis was used for the validation of the surface modifications and
for monitoring the quality of the surfaces. Stable contact angles (40.64° ± 2.9 /mean ± SD)
throughout the study indicated high reproducibility and quality of the DETA coatings and were
similar to previously published results[42, 43, 45-47]. Based on the ratio of the N (401 and 399 eV)
and the Si 2p3/2 peaks, XPS measurements indicated that a monolayer of DETA was formed on the
coverslips.

Development of serum free medium formulation
The results have been summarized in Table 1. In the following paragraph we will discussion the
effects of different growth factors present in nine different formulations. Unless otherwise stated,
half of the medium was changed every three to four days.

Formulation I (F I) was the basal medium. It consisted of Leibovitz’s medium and M199 in 3:1 ratio
(v/v). The basal medium did not promote myotube formation. The cells died after 4 days in culture.

In formulation II (F II) vitronectin was added to the basal medium. Myotube formation was not
observed. Cells did not survive in the culture for more than 4 days.
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In formulation III (F III) B27 supplement was added to formulation II (F II). The cells survive for 810 days but there was no myotube formation.
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Table 1. Development of chemically defined serum-free medium by systematically adding
individual growth factors in the culture. Each of these experimental trials had been carried out
atleast 6 times (n≥6).
Components of the Medium Formulation
F

Myotube
L15:M199

Vt

B27

bFGF

CT1

BDNF

GDNF

NT3

NT4

Properties

3:1
I

+

*

*

*

*

*

*

*

*

(---)

II

+

+

*

*

*

*

*

*

*

(---)

III

+

+

+

*

*

*

*

*

*

(- +)

IV

+

+

+

+

*

*

*

*

*

(+++)

V

+

+

+

*

+

*

*

*

*

(+)

VI

+

+

+

+

+

*

*

*

*

(±±±)

VII

+

+

+

+

+

+

+

*

*

(±±±±)

VIII

+

+

+

+

+

+

+

+

+

(±±±±)

IX

+

+

+

+

+

+

+

+

+

(±±±±±)

The following abbreviations and signs had been used in the table.
F: Formulation number indicating the components added in the medium. If it indicates “+” sign, that
means the factor had been added. If it indicates “*”, that means the component had been omitted.
L15: Leibovitz’s medium
Vt: Vitronectin
B27: B27 supplement
bFGF: Basic fibroblast growth factor
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CT1: Cardiotrophin 1
BDNF: Brain derived neurotrophic factor
GDNF: Glial derived neurotrophic factor
NT3: Neurotrophin 3
NT4: Neurotrophin 4
(---): No myotube formation
(- +): No myotube formation but cells survive for 8-10 days
(+): Small myotubes consisting of 4-6 nuclei
(+++): Robust myotube formation (10-30 nuclei) but along with that lot of fibroblast also proliferated
in the culture
(±±±): Robust myotube formation (10-30 nuclei) with reduction in fibroblast proliferation
(±±±±): Robust myotube formation (10-30 nuclei) and significant reduction in fibroblast
proliferation
(±±±±±): Robust myotube formation (10-30 nuclei), minimal fibroblast proliferation and further
supports nerve-muscle co-culture
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In formulation IV (F IV) bFGF was added to formulation III (F III). Addition of bFGF led to formation
of robust myotubes. Myotubes started appearing by day 2 in culture. Contracting myotubes were
observed by day 4. Fifty percent of the total area of the coverslip was covered with the myotubes.
The myotubes survived for 10-12 days in culture. Many myotubes popped out off of the coverslip
due to extensive contractions. Extensive proliferation of fibroblasts was also observed in the
culture.

In formulation V (F V) CT1 was added to formulation III (F III). Addition of CT1 lead to formation of
small myotubes with 4-6 nuclei. Myotubes started appearing by day 2 in culture. By day 4 most of
these small myotubes exhibited mild contractions. Ten percent of the total area of the coverslips
had contractile myotubes. Myotubes survived for 6-7 days in culture. Formulation V had no bFGF
in it, but we observed small myotube formation even without its presence.

In formulation VI (F VI) both bFGF and CT1 were added to the formulation III (F III). Robust
myotube formation was observed with reduction in fibroblast proliferation. Fibroblast proliferation
was less as compared to formulation IV (F IV) where only bFGF was added. Sixty percent of the
total surface area of the coverslips were covered with contractile myotubes. Most of the myotubes
started contracting by day 4. Myotubes exhibited extensive contractions and survived for 10-12
days in the culture.
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In formulation VII (F VII) GDNF and BDNF were added to formulation VI (F VI). Robust myotube
formation and significant reduction in fibroblast proliferation was observed. The presence of GDNF
and BDNF significantly reduced fibroblast proliferation and increased the total surface area
covered with myotubes. Almost 65% of the total surface area of the coverslip was covered with
contractile myotubes and most of the myotubes initiated contractions by day 4.

In formulation VIII (F VIII) NT3 and NT4 were added to formulation VII (F VII). We did not observe
any significant qualitative difference from formulation VII (F VII). Functionally, the myotubes
started contracting by day 2.

Additionally, significantly reduced fibroblast proliferation was

observed compared to formulation III (F III).

In formulation IX (F IX) no additional growth factors were added; instead two changes were made
in growth factor application. First, instead of replacing half the medium during the first change, the
entire medium was replaced. Second, in the process of changing the whole medium, bFGF was
withdrawal, resulting in the following formulation: Neurobasal/ vitronectin/ B27/ CT1/ GDNF/ BDNF/
NT3/ NT4. These two changes brought about a significant increase in the total number of
myotubes. The final medium formulation has been enumerated in Table 2 and the medium change
protocol has been described in the flowchart indicated in Figure 4. By day 6, 90% of the total
surface area of the coverslip was covered with robust, contractile myotubes. Additionally, there was
minimal fibroblast contamination. The contractions started by day 2. The myotubes survived in the
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culture for 16-20 days. All of the different morphologies of myotubes observed in the culture were
stained with embryonic myosin heavy chain antibodies (Figure 5 A-D). Chain-like (Figure 2.2 A),
branched (Figure 5 B), spindle shaped (Figure 5 C) and cylinder like (Figure 5 D) morphologies of
myotubes were observed in the culture. The clustering of acetylcholine receptors on the membrane
surface of the different morphologies of myotubes are shown in figure 4 E-H. All the myotubes
showed clustering of acetylcholine receptors on their membrane surface.
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Table 2: Composition of novel serum-free medium for a 500 ml sample.
S.

Component(s)

Catalogue #

Company

Amount

1.

L15

Invitrogen

11415064

375 ml

2.

M199

Invitrogen

11150059

125 ml

3.

Vitronectin

Sigma

V0132

50 µg

4.

B27

Invitrogen

17504044

10 ml

5.

Basic FGF

Invitrogen

13256029

10ng/ml

6.

CT1

Cell Sciences

CRC700B

10 µg

7.

GDNF

Invitrogen

10907012

10 µg

8.

BDNF

Invitrogen

10908019

10 µg

9.

NT3

Cell Science

CRN 500B

10 µg

10.

NT4

Cell Science

CRN 501B

10 µg

11.

Sodium Bicarbonate

Fisher

5233500

0.7 g

12.

Osmolarity

320-325 mOsm

13.

pH

7.3

No.
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Figure 5. Different morphologies of myotubes stained with embryonic myosin heavy chain
antibodies (Red) and clustering of acetylcholine receptor (Green) on the membrane surface of
myotubes. Scale bar was 50 µm. A. Chain like morphology of myotubes. B. Branched morpjology
of myotubes.C. Spindle shaped morphology of a single myotube.D. Cylinder shaped morphology of
a single myotube.E-H. Different morphologies of myotubes showing the clustering of acetylcholine
receptors (Green) on the membrane surface of different myotubes.
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Medium formulation IX (F IX) and the subsequent change at day 4, further supported nerve-muscle
co-culture (Figure 6 A-F). In figure 6 A, we observed the sensory neurons along with the myotubes
in the cultures. The sensory neurons were seen as large cell bodies. In figure 6 B, the neuron
process is shown to run parallel to the myotubes. In figure 6 C, multipolar cell morphologies of
motoneurons, along with the large sensory neurons were observed. In figure 6 D, branched,
striated myotubes, and the neuron process crossing over the myotube is shown. In figure 6 E-F
wrapping of neuron process on the three dimensional structure of myotubes indicated the
possibility of their innervation.
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Figure 6. Coculture of skeletal muscle* sensory neurons (DRG)* spinal cord neurons: All the
neurons were stained with antibody against neurofilament-M (150 KD) (Red) and the myotubes
were stained with antibody against embryonic myosin heavy chain (F 1.652) (Green). Scale bar for
was 75 µm. A. The large sensory neurons (DRG) were seen stained with NF 150 (Red). The
neurons are shown with white arrow. The myotubes stained with F1.652 (Green) were seen in the
same field. B. The neuron process in red were seen running parallel with the myotubes (Green).C.
The multipolar motoneuron was seen in close proximity with the myotubes. In the frame we also
observed multiple large sensory neurons. All the neurons were pointed out bu white arrows. D. A
bundle of multiple processes of neurons crossed the striated, branched myotube. E. A single
multipolar motoneurons was observed to form a wrapping around the mytotube.F. Neuron
processes formed wrapping on the myotubes.
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In this study we have described the step-by-step development of a novel serum-free in vitro cell
culture system resulting in the formation of robust, contracting, multinucleate myotubes from
dissociated skeletal muscle cells obtained from hind limbs of fetal rats. Step-by step development
consisted of experimentally evaluating the effect of individual growth factors on myocyte survival
and subsequent myotube formation. We concluded the study by showing that the most optimal
formulation i.e formulation IX (F IX) supported muscle as well as nerve-muscle co-culture growth.

We have empirically developed a serum-free medium supporting the survival, proliferation and
fusion of fetal rat myoblasts into contractile myotubes. The rational for selecting these growth
factors (vitronectin, B27, bFGF, CT1, GDNF, BDNF, NT3 and NT4) is solely based on the
distribution of their receptors in the developing myotubes in rat fetus.

Role of Vitronectin
We added vitronectin to the culture medium because vitronectin receptors promotes cell adhesion
and fulfill an anchoring function during the skeletal muscle differentiation process in vitro[48, 49].
Addition of vitronectin by itself did not promote myotube formation.

Role of B27
Previously we had documented that B27 supplement supported cardiomyocyte growth[46]. So B27
supplement was added in the culture medium as a serum-replacement. Addition of B27
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supplement promoted cell survival but did not promote myotube formation.

Role of bFGF and the controversy concerning the role of bFGF in differentiation
Basic fibroblast growth factor (FGF-2) is a 17-kDa member of the heparin binding growth factors.
Basic FGF plays a complex yet poorly understood role in skeletal muscle differentiation. Several
studies have indicated that bFGF promotes limb development yet there have been in vitro studies
indicating that bFGF promotes division of skeletal muscle cells but inhibits the differentiation
process and it has been documented that terminal differentiation of the skeletal muscle occurs in
G1 phase and is repressed by fibroblast growth factor [19, 20, 50-57]. Interestingly, in our study,
even in the presence of bFGF, most myoblasts fused and differentiated to form functional
myotubes. Our in vitro results support the hypothesis that there are at least two different pools of
myoblasts present in the developing limb bud. In one population, bFGF promotes differentiation
and in the other population it inhibits muscle differentiation.

Role of CT1
Cardiotrophin-1 (CT1) is a cytokine belonging to the IL-6 family. It is expressed at high levels in
embryonic limb bud development and is secreted by differentiated myotubes. CT1 promotes
cardiac myocyte survival, regeneration of extraocular muscle, exhibits increased immunoreactivity
in regenerating muscle and promotes motoneuron survival [58-66]. In this study we observed that
addition of CT1 to basal medium/ vitronectin/ B27 promoted formation of small myotubes. It
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indicates that CT1 by itself has the potential to initiate myotube formation but supports from other
growth factors is required.

Role of GDNF and BDNF
Glial cell line derived neurotrophic factor (GDNF) is a glycosylated, disulfide-bonded homodimer
that is a distantly related member of the transforming growth factor-beta superfamily. GDNF plays
a role in the differentiation and survival of central and peripheral neurons and in kidney
organogenesis. GDNF is widely expressed in developing skeletal muscle and is involved in
regulating the distribution of acetylcholine receptors in mouse primary skeletal muscle cells[67-71].
Brain-derived neurotrophic factor (BDNF) is a ligand for the low-affinity NGF receptor, p75, and for
the high affinity neurotrophin receptor, trkB. It is expressed in developing skeletal muscle,
promotes motoneuron survival and also plays a vital role in the formation of the neuromuscular
junction. BDNF rescues myosin heavy chain IIB muscle fibers after neonatal nerve injury [72-74]
and along with NT4 promotes phenotypic recovery of fast and slow twitch fibers. We believe that
the above mentioned effects of GDNF and BDNF
promotes enhanced myotube formation in the culture.

Role of NT3 and NT4
Neurotrophin-3, or NT-3 is a neurotrophic factor, in the NGF (Nerve Growth Factor)-family of
neurotrophins. It is one of five neurotrophin growth factors which shape the development of the
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nervous system by regulating neuronal survival and differentiation [22]. Recent studies have
indicated that NT-3 has essential non-neuronal function. It plays a key role in cardiac
development[75]. NT4[21, 72, 73] promotes normal development of slow muscle fiber phenotypes
and phenotypic recovery of fast and slow twitch fibers.
Our studies have indicated that addition of NT3 and NT4 results in early contractions of the
myotubes. We are speculating that NT3 and NT4 have a synergistic effect in muscle differentiation.

Co-culture studies
One interesting feature of the differential application of growth factors in formulation IX (F IX) is that
it supported the survival and growth of skeletal muscle, sensory neurons and spinal cord
motoneurons in a three cell co-culture model. While this seems intuitive, it is a crucial finding for
easily building functional muscle-motoneuron, muscle-sensory neuron and muscle-motoneuronsensory neuron constructs and for ultimately reconstructing the stretch reflex arc in vitro. Previous
implementation of the multi-cell type co-culture experiments utilized serum containing mediums
and followed complex culture techniques[76-81]. This defined medium offers a uniform medium
formulation and a simple technique to study the interaction between multiple cell types. Further the
use of defined medium offers a test bed for studying and quantifying the cell-cell interaction in a
much more controlled environment in the absence of serum and in the presence of a synthetic
growth substrate. The use of synthetic growth substrate offers a method to quantify the role of
extracellular matrix structure in forming synapses between nerve and muscle. The use of synthetic
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substrate offers a simple technique to integrate the culture system with bio-MEMS devices for
hybrid system development. Our current efforts are to refine this medium so as to create the
motoneuron-muscle connection, muscle to sensory neuron connections

and to study

neuromuscular junction in a defined system. Current three cell type coculture model includes the
glial cells in the culture. In future studies, we will refine the culture by studying the effect of glial
cells neuromuscular rjucntion formation, muscle differentiation and muscle spindle formation.

This work documents the development of a medium formulation resulting in robust myotube
formation and provides an analysis of the role of the individual factors in that process.
Furthermore, the myotubes develop a MHC profile which results in functional contractile properties.
This is important developmentally, because it shows the system provides for physiological
maturation of the myotubes and facilitates studies regarding the MHC class switching based on
growth factor manipulation. Lastly, the final medium formulation was determined to support the
growth of motoneurons and sensory neurons as well as their co-culture with myotubes. This
finding is critical to developing high throughput bio-MEMS devices aimed at engineering and
studying the stretch reflex arc in vitro. Consequently, this medium will be a powerful tool
for nerve-muscle tissue engineering studies.
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CHAPTER 3: A DEFINED SYSTEM TO ALLOW SKELETAL MUSCLE DIFFERENTIATION AND
SUBSEQUENT INTEGRATION WITH SILICON MICROSTRUCTURES. BIOMATERIALS. 2006
AUG;27(24):4374-80.

Introduction
We are seeking to create hybrid biological/non-biological systems by integrating silicon devices
with cellular components. In particular, we are interested in integrating components of the stretch
reflex arc (skeletal muscle, muscle spindle, motoneuron and sensory neuron) with silicon-based
devices for applications from spinal cord repair and prosthetics to biorobotics systems. To treat a
cell as a component and to take advantage of a cell’s plethora of capabilities requires
understanding and manipulating its requirements in a controlled and reproducible fashion [1]. Cells
can then be used as building blocks to create functional hybrid systems. In this report, we
demonstrate the control of myocyte differentiation to create functional myotubes in a totally serumfree defined environment on a modified silicon dioxide substrate and on cantilever microstructures.
This advance should allow the integration of this system with our previously published results
regarding neuronal systems in order to begin investigating motoneuron to muscle actuation and
their use in control systems [2-4]. Electrophysiological characterization indicates the myotubes
have normal electrical activity. We believe by controlling the growth substrate and the composition
of the medium the differentiation of the myocytes could be manipulated and one can now consider
the idea of evolving functional hybrid materials from progenitor cells [5].
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Primary culture of skeletal muscle has been a model system to study cell differentiation for many
years [6-8]. Apart from its clinical relevance to myopathies and limb regeneration, primary muscle
culture has recently received enormous attention from multi-disciplinary fields such as tissue
engineering, cell-patterning and robotics [9-12].

Differentiation of skeletal muscle is a highly controlled multi-step process, during which single
muscle cells initially freely divide and then align and fuse to form multi-nucleated myotubes. This
process of muscle differentiation in vivo is governed by a complex interplay of a wide range of
growth factors and trophic factors. Several such factors have been discovered to date which have
been observed to promote muscle differentiation in vivo [6, 7] . However, very little systematic
research has been undertaken to use this extensive in vivo knowledge of growth factors to develop
a chemically defined medium, without serum, which promotes muscle differentiation in vitro.

Most of the existing in vitro culture methods rely on the use of animal serum and biological growth
substrates to promote skeletal muscle differentiation [13]. The presence of many unknown
components in serum-containing medium, and the technical difficulties in creating reproducible
biological substrates, has led to extensive variations in results from experiment to experiment. In
order to remove this inherent drawback of serum containing medium and biological substrates, we
attempted to develop a defined culture system consisting of a novel serum-free medium based on
the extensive in vivo knowledge of growth factors and a synthetic silane substrate to study skeletal
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muscle differentiation.

This work reports the development of such an in vitro cell culture system to study fetal rat skeletal
muscle differentiation. The system had three novel features with respect to all other previously
reported systems. First, a chemically defined, serum-free medium supplemented with specific
growth factors was developed to study the muscle differentiation process. Second, a synthetic,
non-biological, patternable, cell growth promoting substrate, N-1[3-(tri- methoxysilyl) propyl]
diethylenetriamine (DETA) coated on glass coverslips, was use to grow the skeletal muscle cells.
Third, we demonstrated that when the dissociated muscle cells were plated on fabricated
microcantilevers, they aligned along the long axis of the cantilever and subsequently formed
myotubes.

This in vitro system successfully demonstrated the differentiation of dissociated skeletal muscle
cells (obtained from the hind limb of embryonic rat fetus) to form robust, contracting, multinucleated myotubes. These myotubes were further characterized by morphological analysis, using
fetal myosin heavy chain and alpha-sarcomeric actin antibodies and electrophysiology. This novel
system would not only find applications in skeletal muscle differentiation studies and
biocompatibility studies but also in bioartificial muscle engineering, hybrid actuation system
development, biorobotics as well as a defined test bed for better understanding of myopathies and
neuromuscular disorders.
67

Methods and Materials
Surface Modification
Glass coverslips (Thomas Scientific 6661F52, 22x22mm No.1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 minutes at 100 mTorr. The DETA (United Chemical
Technologies Inc. T2910KG) film was formed by reaction of the cleaned surface with 0.1% (v/v)
mixture of the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated coverslips
were heated to just below the boiling point of the toluene, rinsed with toluene, reheated to just
below the boiling temperature, and then oven dried. Surfaces were characterized by contact angle
measurements using an optical contact angle goniometer (KSV Instruments, Cam 200) and by Xray photoelectron spectroscopy (Kratos Axis 165) by monitoring the N 1s peak.

Cantilever Fabrication
The fabrication process for the devices in Figure 7 and 10 was straight-forward. The design for the
cantilevers was generated using AutoCAD 2004, and was used to create the photomask which
consisted of a fused silica wafer coated with chromium. The cantilevers were fabricated from
crystalline silicon wafers using a deep reactive ion etching (DRIE) process. A double-sided
polished 10 µm thick crystalline silicon wafer was bonded to a 500 µm SiO2 handle wafer and the
crystalline silicon surface was coated with a 1.3 µm layer of AZ 5214 photoresist. The photoresist
was exposed to a soft bake followed by contact exposure with the mask. The photoresist was then
developed, hard baked, and then mounted on a 6” handling substrate for DRIE. After DRIE, the
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photoresist was removed via a wet strip followed by plasma cleaning. The wafer was cut into 10
mm x 10 mm pieces, contained the cantilever arrays, by dicing followed by HF release and
supercritical CO2 drying. The processing was done through the MEMS Exchange of Reston, VA. A
rectangular cantilever was used so that the spring constants could be easily calculated and it was
hoped that the shape would aid and direct in the adhesion of the myotubes. The stated dimensions
were chosen based partly on previous observations of average myotube size in culture and partly
on the tolerances dictated by the current fabrication process.
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Figure 7. SEM micrograph of the fabricated cantilever.
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Muscle Cell Isolation and Culture
The skeletal muscle was dissected from the thighs of the hind limbs of embryonic rat fetus at the
indicated age (embryonic rat ages E15, E16 and fetal rat ages E17, E18). The tissue was collected
in a sterile 15-ml centrifuge tube containing 1 ml of phosphate-buffered saline (calcium- and
magnesium-free) (Gibco 14200075). The tissue was enzymatically dissociated using 1 ml of 0.05%
of trypsin-EDTA (Gibco 25300054) solution for 30 minutes in a 37°C water bath (100 rpm). After 30
minutes the trypsin solution was removed and 2 ml of L15 + 10% fetal calf serum (Gibco
16000044) was added to terminate the trypsin action. The tissue was then mechanically triturated.
The supernatant was then transferred to a 15-ml centrifuge tube. The same process was repeated
two times by adding 2 ml of L15 + 10% FBS each time. The 6 ml cell suspension obtained after
mechanical trituration was suspended on a 2 ml, 4% BSA (Sigma A3059) (prepared in L15
medium) cushion and centrifuged at 300 g for 10 minutes at 4°C. The pellet obtained was
resuspended in 1 ml of serum-free medium and plated in 100 mm uncoated dishes for 30-45
minutes. The non-attached cells were removed, centrifuged on a 4% BSA cushion, and either
plated directly or further processed using an additional purification protocol (see below). The cells
were plated at a density of 700-1000 cells/mm2. The cells attached to the substrate in 1 hour. The
serum-free medium was added to the culture dish after 1 hour and the cells were maintained in a
5% CO2 incubator (relative humidity 85%).
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For E18 cells, we followed an additional purification protocol consisting of plating the cells in 100
mm dishes coated with a 2% gelatin solution (Type B from bovine skin, Sigma G1393) in serumfree medium and maintained them for 30-48 hours in a 5% CO2 incubator. After 30-48 hours,
spindle-shaped myoblasts were detached with neutral protease (0.6 unit/ml Dispase II, Roche
92517500) treatment for 2-5 minutes [13], then centrifuged on a BSA cushion, and replated onto
the DETA coverslips.

Myotube yield quantification
Myotube yield was quantified using the fusion index, which is defined as the number of nuclei
contained in the myotubes divided by the total number of nuclei counted in a given microscope
field. Cultures, which were used for immunostaining, were simultaneously counterstained with 4',6Diamidino-2-phenylindole (DAPI) which is a classic fluorescent nuclear and chromosome
counterstain, and was used to identify nuclei and show the chromosome-banding patterns. DAPI
binds selectively to dsDNA and thus shows little to no background staining of the cytoplasm. Nuclei
were counted in 20 randomly chosen microscope fields from at least six separate muscle culture
experiments.

Immunocytochemistry
Embryonic myosin heavy chain: Coverslips were rinsed with PBS, fixed in -20°C methanol for 5-7
minutes, washed in PBS, incubated in PBS supplemented with 1% BSA and 0.05% saponin
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(permeabilization solution), and blocked for 30 minutes with 10% goat serum and 1% BSA. Cells
were incubated overnight with primary antibody against embryonic MHC (F1.652, IgG,
Developmental Studies Hybridoma Bank) diluted (1:5) in the permeabilization solution. Cells were
washed with PBS and incubated with the secondary antibody (Cy3 conjugated anti-mouse,
Jackson Labs., 1:200 dilution in PBS) for 2 hours[14].

α-actin: Coverslips were rinsed in PBS, fixed in 100% cold ethanol for 30 minutes, and rinsed
again in PBS. The cultures were then blocked using 5% BSA (Sigma) in PBS for two hours. The
primary antibody (mouse anti-α-actin, Sigma A2172, 1:800 dilution in blocking solution) was added
for 12 hours at 4˚C. The secondary antibody (Alexa Fluor 488-conjugated donkey anti-mouse,
Molecular Probes, A21202, 1:200 dilution in PBS) was then added to the cultures for two hours.
After a final rinse with PBS, the coverslips were mounted with Citiflour-mounting solution (Ted
Pella) onto slides (Fisher). The coverslips were visualized using a Zeiss LSM 510 confocal
microscope.

Electrophysiology
Whole-cell patch clamp recordings were performed in a recording chamber located on the stage of
a Zeiss Axioscope 2FS Plus upright microscope. The chamber was continuously perfused (2
ml/min) with the extracellular solution (Leibovitz medium, 35°C). Patch pipettes were prepared from
borosilicate glass (BF150-86-10; Sutter, Novato, CA) with a Sutter P97 pipette puller and filled with
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intracellular solution (in mM: K-gluconate 140, EGTA 1, MgCl2 2, Na2ATP 2, Phosphocreatine 5,
Phosphocreatine kinase 2.4 mg, Hepes 10; Ph = 7.2). The resistance of the electrodes was 6-8
Mohm. Voltage clamp and current clamp experiments were performed with a Multiclamp 700A
amplifier (Axon, Union City, CA). Signals were filtered at 2 kHz and digitized at 20 kHz with an
Axon Digidata 1322A interface. Data recording and analysis were performed with pClamp 8
software (Axon). Membrane potentials were corrected by subtraction of a 15 mV tip potential,
which was calculated using Axon’s pClamp 8 program. Membrane resistance and capacitance
were calculated using 50 ms voltage steps from –85 mV to –95 mV without any whole-cell or series
resistance compensation. Sodium and potassium currents were measured in voltage clamp mode
using voltage steps from a –85 mV holding potential. Action potentials were evoked with 1s
depolarizing current injections from a –85 mV holding potential.
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Results and Discussion
Surface Modification and Characterization
In the present study we used glass coverslips coated with DETA. The modified surfaces were
analyzed by contact angle and X-ray photoelectron spectroscopy (XPS). XPS has previously been
shown to be a good quantitative indicator of monolayer formation [1, 3, 15-17]. The contact angle
and XPS data indicated that the glass surfaces were covered by a complete monolayer of DETA.

The first step in creating this defined system was to develop a synthetic surface to control cellsubstrate interactions. The current biological substrates (collagen, gelatin, fibronectin) offer little
hope to create quantifiable cell-substrate interactions with systematic modifications [13]. It was also
our objective that our surface modification method should be integratable with silicon
microstructures, compatible with surface patterning methods (stamping and photolithography) and
it should enable relatively high throughput and flexible production of functionalized surfaces [1, 3].
Coating surfaces with self-assembled monolayers (SAMs) is a flexible and effective method to
engineer surface characteristics of materials [18]. It has been shown that biological molecules can
be incorporated into SAMs through crosslinkers, which could also enable selective study of specific
contact signaling pathways [19]. SAM coated surfaces have also been used to grow and pattern
hippocampal neurons, adult spinal cord neurons, motoneurons, cardiomyocytes, endothelial cells
and muscle cell lines [2-4, 15, 19-22].
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We chose DETA as the synthetic culture surface in our pilot study. Our earlier experiments proved
that DETA is an appropriate surface to grow and pattern neurons [1, 3, 4, 16, 22] and endothelial
cells [15], and it is our hope to integrate the motoneuron and skeletal muscle culture by having a
common surface modification.

The cell-attachment promoting feature of DETA is possibly a result of its hydrophilic properties and
the presence of a primary amine group as indicated in earlier publications for neurons and
endothelial cells [1, 3, 4, 15-17, 22].

Development of Serum-Free Defined Medium
Our next aim was to formulate a defined medium which promoted muscle cell survival and
differentiation on the DETA synthetic surface. The empirically-developed serum-free medium
utilized our extensive experience in culturing mammalian cellular systems (Table 3). The basal
medium consisted of L15 and Medium 199 in a 3:1 ratio. The B27 supplement and four growth
factors (FGF-2, Cardiotrophin-1, GDNF, BDNF) were added to the medium. B27 is an optimized
serum-free medium substitute generally used for neuronal culture. It consists of 27 different
components, which include lipids, vitamins, hormones, antioxidants, and a few other miscellaneous
components [23]. One of the B27 components is retinoic acid, which plays a key role in muscle
differentiation [24]. Basic fibroblast growth factor (FGF-2) is a 17-kDa member of the heparin
binding growth factors [25]. It plays a complex yet poorly understood role in muscle differentiation.
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On one hand it stimulates limb development [26], but on the other hand tissue culture studies
indicate that it is a mitogen and inhibits muscle differentiation [27]. In our study we found that even
in the presence of basic FGF, the myocytes differentiate to form myotubes. Cardiotrophin-1 is a
cytokine belonging to the IL-6 family. It is expressed at high levels in embryonic limb bud
development and is secreted by differentiated myotubes [28, 29]. It is a potent cardiac survival
factor and supports long-term survival of spinal motoneurons [30]. Glial cell line derived
neurotrophic factor (GDNF) is a glycosylated, disulfide-bonded homodimer that is a distantly
related member of the transforming growth factor-beta superfamily [31]. GDNF plays a role in the
differentiation and survival of central and peripheral neurons and in kidney organogenesis. GDNF
is widely expressed in developing skeletal muscle [32]. Brain-derived neurotrophic factor (BDNF) is
a ligand for the low-affinity NGF receptor, p75, and for the high-affinity neurotrophin receptor, trkB.
It is expressed in developing skeletal muscle, promotes motoneuron survival and also plays a vital
role in the formation of the neuromuscular junction [33, 34].
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Table 3: Composition of the Serum-Free Medium for a 500ml Sample
Component

Source

Catalogue #

Amount

Leibovitz Medium (L15)

Invitrogen

11415064

375 ml

Medium 199

Invitrogen

11150059

125 ml

B27 Supplement (50x)

Invitrogen

17504044

10 ml

Basic Fibroblast Growth Factor

Invitrogen

13256029

10ng/ml

Brain Derived Neurotrophic Factor

Invitrogen

10908019

1ng/ml

Glial Derived Neurotrophic Factor

Invitrogen

10907012

1ng/ml

Cardiotrophin-1

Cell Sciences

CRC700B

10ng/ml

Sodium Bicarbonate

Fisher

5233500

0.93 mg

Osmolarity

320-325 mOsm

pH

7.3
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Skeletal Muscle Culture
We used primary cultures of embryonic rat skeletal muscle at four different embryonic stages of rat
development for the experiments. Mononucleated muscle cells were obtained by trypsinizing the
hind limb muscle obtained from 14, 15, 17 and 18-day old rat embryos (E14, E15, E17 and E18).
We selected these ages because all of the genes involved with limb development are expressed by
the E14 stage [8]. In all experiments the cells were plated at a density of 700-1000 cells/mm [3].
Muscle cells obtained from the limb-bud of E14 and E15 fetuses formed only small, spindle shaped
contractile structures (consisting of 2-3 nuclei). When we obtained the muscle cells from E18
fetuses, multinucleated myotubes were formed on top of a monolayer of other contaminating cells
(mostly fibroblasts, Figure 8. A). In order to remove the fibroblast contamination we used a twostep panning protocol [13, 35]. After this purification step, myotubes were formed in direct contact
with the DETA surface (Figure 8. B). Preparing the rat skeletal muscle cultures from 17-day old
embryos resulted in a relatively pure culture (Figure 8. C, D). We obtained similar results using
purified E18 (n = 5) or non-purified E17 (n = 20) rat skeletal muscle cultures. Our experiments
demonstrated that DETA coated surfaces not only allowed the skeletal muscle cells to differentiate
and promoted myotube formation, but also enabled them to maintain their contractile properties in
the new medium formulation.
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Multinucleated myotubes first appeared at the beginning of the second day of culture. Spontaneous
contractions of the myotubes were observed by the end of the second day. Purified E18 and nonpurified E17 myotubes were cultured to day 5.

In the E17 cultures, myoblast fusion began after 24 hours in the defined system and after 36-48
hours maximal fusion was reached (59% ± 5.7, mean ± SD, of the nuclei were in the myotubes,
averaged from 10 separate cultures, n = 10). In the E18 double step-purified culture, myoblast
fusion began after 36 hours in the defined system and after 96 hours reached maximal fusion (36%
± 5.5, mean ± SD, of the nuclei were in the myotubes, averaged from 6 separate cultures, n = 6).

Immunocytochemistry
Immunocytochemistry combined with confocal microscopy and electrophysiological methods were
used to characterize the myotubes. Myotubes were labeled by skeletal muscle markers for α-actin
and the embryonic myosin heavy chain [14], to facilitate unambiguous identification (Figure 8. E,
F).
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Figure 8. Representative pictures of myotubes formed in our defined system at day 4 and 5. A: E18
non-purified culture. Myotubes were formed on the top of a monolayer of other cell types. B:
Myotubes in E18 purified cultures. C, D: Multinucleated myotubes in E17 cultures. E: Myotubes
immunostained for myosin heavy chain. F: Myotubes immunostained for α-actin. A, B, C, D: Phase
contrast 40x, scalebar: 25 μm. E: Confocal 40x, scalebar: 75 μm. F: Confocal 63x, scalebar: 40
μm.
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Electrophysiology
Patch-clamp recordings were obtained from the contractile myotubes on the 4th day in vitro (Figure
9) [36]. The large membrane capacitance of the myotubes indicated that they consisted of many
fused muscle cells. Voltage-clamp recordings showed the presence of voltage dependent inward
and outward currents in the cell membrane that are consistent with sodium and potassium
channels, respectively. In the current clamp recordings most of the myotubes were able to
generate action potentials. Upon stimulation (depolarization) all recorded myotubes demonstrated
contraction. Some myotubes showed spontaneous contractions after the medium was changed.
There was a significant difference in the electrophysiological parameters between E18 non-purified
and E18 purified /E17 cultures. In E18 non-purified cultures the membrane potential was more
negative (- 61 ± 1.8 mV, mean ± SEM, n = 6) compared to the pure cultures (- 49.4 ( 1.7 mV, n =
8). The membrane capacitance of the myotubes was significantly higher in the non-purified cultures
(1349 ± 241 pF) compared to the pure cultures (566 ± 177 pF). This indicates that the average
size of the myotubes in the non-purified cultures was larger. This points out that there may be
some influence from the fibroblasts in myotube differentiation. In all the electrophysiological
recordings from the myotubes, independent of the purity of the culture, there were voltagedependent inward and outward currents present (Figure 9). The electrophysiology results indicate
the formation of robust, functional myotubes in our defined system that would have the correct
properties to serve as actuators in hybrid systems.
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Figure 9. Representative electrophysiological recordings obtained from 4-day-old myotubes. (A)
Voltage-clamp experiments indicated that myotubes formed on a DETA surface in the serum-free
medium formulation expressed functional voltage-dependent sodium and potassium channels. (B)
Current-clamp mode depolarization with evoked action potentials, which were associated with
visible contractions.
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Myotube on Silicon Microstructures
In ten different experiments, we plated the dissociated muscle cells (obtained from E17 rat fetus)
on unpatterned, DETA-coated microcantilevers (Fig. 7). In 50% of the cantilevers from each
experiment, we observed that dissociated muscle cells aligned along the long axis of the cantilever
to form contracting myotubes. It should be noted that no discernable preference was found for any
particular dimension set. While the myotubes were observed to be contractile, it was not possible
to visually confirm that they were bending the cantilevers. This is due to the fact that the spring
constants of the cantilever were too high compared to the conductive strength of the myotubes.
However, it cannot be said that the cantilevers did not bend at all, because no measurements
sensitive enough to detect such a deflection were performed. These experiments have been
reserved for future work. At this point we feel that the investigations of the myotubes integrated
with the microstructures, as indicated in Fig. 10, now facilitate the future development of hybrid
actuation systems for applications in biorobotics, prosthesis and bioartificial muscle engineering.

84

Figure 10. Myotubes forming on fabricated microcantilevers in serum-free medium in two separate
experiments (middle and right). Note: the myotubes generally lined up with the long axis of the
cantilever.
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In conclusion, in this study we have developed a defined system (synthetic substrate, serum-free
medium and specific cellular preparation) which promotes muscle differentiation and functional
myotube formation. Using this approach, the myotubes could be easily integrated with siliconbased microstructures, and used in model systems, specifically the reflex arc, or as actuators in
hybrid systems. Our serum-free medium and defined system, we believe, will become essential for
tissue engineering and biocompatibility studies. It is also compatible with surface patterning
methods, and therefore it will enhance the integration of our muscle constructs with
microelectromechanical systems (MEMS) to create hybrid devices for robotic and prosthetic
applications. These are the first studies whereby simultaneously controlling both the growth
substrate and the composition of the medium, the differentiation of the myocytes could be
manipulated and one can now consider the idea of evolving functional hybrid materials from
progenitor cells[5].
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CHAPTER 4: DIFFERENTIATION OF SKELETAL MUSCLE AND INTEGRATION OF
MYOTUBES WITH SILICON MICROSTRUCTURES USING SERUM-FREE MEDIUM AND A
SYNTHETIC SILANE.NATURE PROTOCOLS 2007;2(7):1795-801

Introduction
This protocol describes a cell culture model to study the differentiation of fetal rat skeletal muscle
cells. The model uses serum-free medium, a non-biological substrate (N-1[3 (trimethoxysilyl)
propyl] diethylenetriamine; DETA) and fabricated microcantilevers to promote the differentiation of
dissociated rat myocytes into robust myotubes. In this protocol we also describe how to
characterize the myotubes based on morphology, immunocytochemistry and electrophysiology.
Four major techniques are employed: fabrication of cantilevers; surface modification of the glass
and cantilever substrates with a DETA SAM; a serum-free medium and refined culture techniques.
This culture system has potential applications in biocompatibility studies, bioartificial muscle
engineering, skeletal muscle differentiation studies and for better understanding of myopathies and
neuromuscular disorders. The model can be established in 26-33 days.

Differentiation of skeletal muscle is a highly-controlled, multi-step process, during which single
muscle cells initially freely divide and then align and fuse to form multinucleated myotubes. This
process of muscle differentiation in vivo is governed by a complex interplay of a wide range of
growth and trophic factors. Several such factors have been discovered which have been observed
to promote muscle differentiation in vivo[1-3]. However, very little systematic research efforts have
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been undertaken to use this extensive in vivo knowledge of growth factors to develop a chemically
defined medium which promotes muscle differentiation in vitro.

Most of the existing in vitro culture methods for studying skeletal muscle differentiation use serum
containing medium as well as a biological growth substrate[4-6]. The presence of many unknown
components in serum-containing medium and the technical difficulties in creating reproducible
biological substrates has led to extensive variations in the results from experiment to experiment.
In order to remove the inherent drawback of utilizing serum containing medium and biological
substrates, a defined culture system consisting of a serum-free medium based on the extensive
knowledge of growth factors from in vivo studies and a synthetic silane substrate to study skeletal
muscle differentiation, was developed[7].

The system has three features that differentiate it from all other previously reported systems. First,
a unique chemically defined serum-free medium supplemented with specific growth factors was
developed to study the muscle differentiation process. Second, a synthetic, non-biological,
patternable[8, 9], cell growth promoting substrate, N-1[3 (trimethoxysilyl) propyl] diethylenetriamine
(DETA), coated on glass coverslips[10-12], was used as a template to grow the skeletal muscle
cells. Third, it was demonstrated that when the dissociated muscle cells were plated on fabricated
microcantilevers, they aligned along the long axis of the cantilever to form aligned myotubes.
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In this protocol step-by-step instructions on how to fabricate and modify the cantilever and glass
substrates and then grow the muscle cells on the chemically modified substrates, using this serumfree medium, to form robust myotubes, is described. Figure 11 shows a diagram of the general
outline of the whole procedure, while Figure 12 outlines the microcantlever manufacture process.
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Figure 11. General outline of the entire procedure.
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Note that all fabrication procedures should be performed in a clean room. The protocol consists of
two figures: Figure 13, which shows a microcantilever array micrograph, and Figure 14, which
outlines the cell culture process; as well as substrate modification of either a cantilever or a glass
substrate (Steps 1-22), preparation of the serum-free medium, as well as both intracellular and
extracellular solutions (Reagent Setup), dissection of the skeletal muscle tissue (Steps 23-24),
purification of the tissue and the culture of the myocytes to form myotubes (Steps 25-38), and
characterization

of

the

myotubes

morphologically,

electrophysiologically (Steps 39-40 A,B,C).
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immnunocytochemically

and

Materials and Methods
List of Reagents
Charles River or Sprauge Dawley, Fetal Rats age E18.
Caution: Experiments involving live animals must conform to appropriate National and Institutional
regulations
*H2S04 (EMD)
*HCl (EMD)
* Caution toxic and corrosive. Use gloves, goggles and other chemical use safety measures that
are recommended by the appropriate concerned agencies.
Countertop oven (VWR)
Toluene (BDH) Caution toxic
Hydrofluic acid (Sigma) Caution Toxic
Diethylenetriamine trichmethoxysilane (United Chemical Technologies)
4 inch silicon on insulator (SOI) wafers (MXF)
AZ 5214E photoresist (Clariant Corporation)
AZ 9245E photoresist (Clariant Corporation)
AZ 400K photoresist developer (Clariant Corporation)
Deep reactive ion etcher (PlasmaTherm)
Ethanol
4',6-Diamidino-2-phenylindole (DAPI)
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Leibovitz medium (L15)Invitrogencat no. 11415064
Medium 199Invitrogencat no. 11150059
B27 Supplement (50×)Invitrogencat no. 17504044
Basic fibroblast growth factor (b-FGF)Invitrogencat no. 13256029
Brain-derived neurotrophic factor (BDNF)Invitrogencat no. 10908019
Glial-derived neurotrophic factor (GDNF)Invitrogencat no. 10907012
Cardiotrophin-1 (CT-1)Cell sciences cat no. CRC700B
Sodium bicarbonate Fishercat no. 5233500
Trypsin EDTA
Phosphate-buffered saline (PBS)
Fetal calf serum (FBS)
Bovine serum albumin (BSA)
Embryonic MHC (F1.652, IgG, Developmental Studies Hybridoma Bank)
Primary antibody (mouse anti-α-actin, Sigma A2172
Secondary antibody (Alexa Fluor 488-conjugated donkey anti-mouse Molecular Probes, A21202
Citiflour-mounting solution (Ted Pella)
Clean glass coverslips (Thomas Scientific 6661F52, 22×22 mm No. 1)
O2 plasma cleaner (Harrick PDC-32G)
DETA (United Chemical Technologies Inc. T2910KG)
0.1% (v/v) mixture of organosilane in freshly distilled toluene (Fisher T2904).
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Phosphate-buffered saline (calcium- and magnesium-free) (Gibco 14200075).
Trypsin-EDTA (Gibco 25300054)
Fetal calf serum (FBS) (Gibco 16000044)
L15 medium Invitrogen (Cat # 41300021).
BSA (Sigma A3059)
Alexa Fluor 488-conjugated donkey anti-mouse antibody, Molecular Probes, A21202, for
immunocytochemistry only
Mouse anti-α-actin, Sigma cat no A2172, for immunocytochemistry only
Borosilicate glass pipettes (BF150-86-10, Sutter), for electrophysiology only
HEPES (Fisher, BP310), for electrophysiology only
HEPES-sodium (Fisher, BP410), for electrophysiology only
EGTA (Fisher, O2783), for electrophysiology only
K-Gluconate (Sigma, G4500), for electrophysiology only
MgCl2 (Fisher, S320), for electrophysiology only
Na2ATP (Fisher, BP413), for electrophysiology only (CRITICAL Keep at -20°C)
Secondry antibody against embryonic MHC (F1.652, IgG, Developmental Studies Hybridoma
Bank)

List of Equipment
Pyrex bottles (VWR)
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Pyrex beakers (VWR)
Hotplate (VWR)
Ceramic racks (VWR)
Glove Box (MBraun)
Thermometer (VWR)
Dissecting instruments
Dissecting hood
Laminar flow hood
Microscope – regular and confocal
Carbon dioxide incubator
Pasteur pipette
Contact angle goniometer (KSV Instruments, Cam 200 (or similar instrument))
X-ray Photoelectron Spectrometer (Kratos Axis 165 (or similar instrument))
Axioscope 2 FS Plus upright microscope (Zeiss, Jena, Germany), for electrophysiology only
PCS-5000 piezoelectric 3D micromanipulator (Burleigh/EXFO, Quebec, Canada), for
electrophysiology only
Gibraltar platform (Burleigh EXFO, Quebec, Canada), for electrophysiology only
Vibration isolation table (TMC, Peabody, MA, USA), for electrophysiology only
Multiclamp 700B patch clamp amplifier (Axon/Molecular Devices Sunnyvale, CA, USA), for
electrophysiology only
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Digidata 1320 A/D converter (Axon/Molecular Devices Sunnyvale, CA, USA), for electrophysiology
only
pClamp 9.0 software (Axon/Molecular Devices Sunnyvale, CA, USA), for electrophysiology only
P97 pipette puller (Sutter, Novato, CA), for electrophysiology only
In-line solution heater (self-made but available from Warner Instruments, Hamden, CT, USA), for
electrophysiology only
pH meter (Beckman), Balance (Mettler-Toledo), Osmometer (Fiske), for electrophysiology only

Reagent Setup
Serum-free medium
Combine the 375 ml Leibovitz medium (L15), 125 ml Medium 199, 10 ml B27 Supplement (50X),
10 ng/ml of basic fibroblast growth factor (B-FGF), 1 ng/ml of brain derived neurotrophic factor
(BDNF), 1 ng/ml of glial derived neurotrophic factor (GDNF), 10 ng/ml of cardiotrophin-1 (CT-1)
and 0.70 g of sodium bicarbonate. Adjust the pH of the medium to 7.3 with 1N NaOH and the
osmolarity to 320-325 mOsm with D.V. The components can be added all at once, in no particular
order. Store in 50 ml sterile polycarbonate tubes at 4°C. The medium will last 2 months.

Intracellular solution
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Combine 0.15ml HEPES-sodium salt (from a 1M solution), 11.4mg EGTA, 983.6mg K-Gluconate,
0.3ml MgCl2 (from a 200mM stock solution), 30.7mg Na2ATP and 30ml deionized water. Adjust the
pH to 7.2 with HEPES, and adjust the osmolarity to 276 mOsm, with D.V.
Critical: The intracellular solution should be prepared in the given order. EGTA dissolves only at
basic pH. Store the aliquot intracellular solution in 1 ml freezing vials at -20°C.

Extracellular solution
Take 50 ml of the Leibovitz medium (L15), check the pH and adjust to 7.34 with HEPES, also
adjust the osmolarity to 320 mOsm with D.V.

Procedure
Microcantilever fabrication and surface modification of microcantilevers and glass coverslips.
Timing 2-3 weeks
1) Fabrication of microcantilevers (Figures 12 and 13). Start procedure with a 4” double-sided
polished silicon-on-insulator (SOI) wafers that contain a 5 mm thick top layer of crystalline silicon
bonded onto a 500 mm thick silicon dioxide layer.
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Figure 12. Outline of microcantilever manufacture procedures.
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Figure 13. SEM micrographs of microcantilever array. (a) Top down view of cantilevers. (b) 45°
angle view of cantilever array.
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Critical step: All fabrication procedures must be performed in the clean room.
2) Perform photoresist spinning and developing in a Suss ACS200 wafer coater/developer (or
similar instrument). First, prime the device layer (5 mm silicon) with a 100 Å layer of
hexamethyldisilazaine (HMDS). Then place the wafer, silicon layer up, on a resist spinner vacuum
holder. Center the wafer and apply the AZ5214e photoresist to the center of the wafer. Begin
spinning the wafer to spread the resist to a final thickness of 2.1 mm (spin at 1900 rpm).
3) Bake the resist at 110oC for 50 minutes.
4) Expose the wafer on a Suss MA6 aligner to the photomask containing the pattern for the
cantilever. After exposure, develop the resist in a 1:1 mixture of AZ320 and deionized water.
5) Perform a Deep Reactive Ion Etching (DRIE) in a PlasmaTherm 770 DRIE etcher (or similar
instrument) at a rate of 4 mm/min. Etch the 5 mm device layer through to the silicon dioxide layer.
Remove the photoresist using a Metroline M4L Plasma Resist Etcher (or similar instrument).
Troubleshooting
6) Flip the wafer over and prime the silicon dioxide layer with a 100 Å layer of HMDS. Next coat
with AZ9245 photoresist to a final thickness of 10 mm (1000 rpm) and softbake at 100oC for 2
minutes. Place the coated wafer in a Suss MA6 Aligner (or similar instrument) and expose the
resist to the mask containing the pattern for the back side pattern. Note: The Suss MA6 Aligner is
capable of front/back alignment. For this process it is necessary to incorporate the alignment marks
in the photomasks.
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7) After exposure immerse the wafer in AZ 400K developer to develop the patterned resist. This is
followed by a hard bake at 120oC for 30 minutes. Etch until approximately 50um etch depth is left.
8) Mount the wafer on a dummy wafer using Nitto Model 3195V thermal release tape. Complete
the DRIE etching.
9) Demount the wafer by heating to 170oC on a hotplate. Remove the photoresist by plasma
etching in a Metroline M4L Plasma Resist Etcher (or similar instrument). Perform the final etch in
49% HF for 10 minutes to remove the buried oxide layer (Caution: HF is extremely toxic).

Surface modification of the cantilevers with DETA Timing 2-3 days
10) Immerse the cantilever die in a 1:1 solution of absolute MeOH and concentrated HCl for 15-30
minutes, followed by a 3x wash in deionized water. Next, place the die in a bath of concentrated
sulfuric acid for 30-45 minutes. Note that at this point you need to ensure that the die are not
touching as they may stick together during this step.
11) Gently rinse the cantilever die in deionized water. Finally, boil the cantilever die in deionized
water for 30 minutes. Then place the cantilevers in a 120oC oven overnight.
12) Prior to the surface modifications prepare all glassware and reagents for the reaction. Clean all
glassware in a base bath (saturated KOH in 100% methanol) overnight and then rinse in deionized
(18 MΩ resistance) water. Bake the glassware overnight in a 120oC oven. Distill Toluene over
metallic sodium in order to ensure minimal water content. CRITICAL STEP This is necessary to

106

minimize the presence of water in the reaction mixture. Note that excess water causes the
polymerization of the silane monomer.
13) Transfer the desired volume of toluene to a clean/dry (see step 2) Pyrex bottle. Before sealing
the bottle, blow dry nitrogen into the unused volume in order to minimize the gaseous oxygen. Seal
the bottle and place in the antechamber of the glove box. Evacuate the antechamber for 10
minutes and then vent with dry nitrogen, repeat 3 times. Transfer the toluene to the main chamber
of the glove box.
14) Add stock DETA solution to the toluene for a final concentration of 0.1% (e.g. 0.2 ml in a final
volume of 200 ml). Immediately remove the 0.1% DETA solution from the glove box and transfer
into a glass beaker containing the cantilever die.
15) Place the reaction mixture on a hot plate and heat to ~80o for 30 minutes. After 30 minutes
remove the reaction mixture from the hot plate and cool for 30 minutes or until the reaction mixture
can be handled with bare hands.
16) Rinse the die 3 times in clean/dry toluene. Transfer the cantilever die into a fresh beaker and
cover with distilled toluene.
17) Place the beaker back onto the hotplate and heat to ~80oC for 30 minutes. Finally, remove the
cantilevers from the beaker and bake overnight at 120oC.
Cleaning glass coverslips and subsequent surface modification with DETA
18) Clean glass coverslips (22×22 mm No. 1) using an O2 plasma cleaner for 20 min at 100 mTorr.
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19) Form the DETA film by reacting the cleaned surface with a 0.1% (v/v) mixture of organosilane
in freshly distilled toluene
20) Heat the DETA coated coverslips to just below the boiling point of the toluene, rinse with
toluene, reheat to just below the boiling temperature, and then dry in an oven.

Characterizing the glass coverslips using contact angle measurements and X-ray photoelectron
spectroscopy (XPS)
21) Characterize surfaces by contact angle measurements using an optical contact angle
goniometer.
22) Use XPS to characterize the monolayer of DETA by monitoring the N 1s peak[9, 13].
Pausepoint: Samples should be stored in dessicator prior to use. DETA monolayers should be
stable under anhydrous conditions for several weeks to months. Samples more than a couple
months old should be reanalyzed to ensure the monolayer has not degraded.

Muscle Cell Isolation and Culture : Isolation of the myoblasts Timing 4-6 hrs (Figure 14)
23). Dissect the skeletal muscle from the hind limb thighs of a rat fetus at fetal rat age of E18.
24) Collect the tissue samples in a sterile 15-ml centrifuge tube containing 1 ml of phosphatebuffered saline (calcium- and magnesium-free).
25) Enzymatically dissociate the tissue samples using 3 ml of 0.05% of trypsin-EDTA solution for
60 minutes in a 37°C water bath, with agitation of 100 rpm.
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26) After 60 minutes, remove the trypsin solution and add 6 ml of L15 containing 10% fetal calf
serum (FBS) to terminate the trypsin action.
27) Mechanically triturate the tissue using a sterile narrow bore Pasteur pipette. Critical step:
Please make sure not to form air bubbles, as formation of air bubbles damages the dissociating
cells.
28) Allow the dissociated tissue to settle for 3 minutes.
29) Transfer the 6 ml supernatant to a 15-ml centrifuge tube.
30) Repeat the same process (steps 26-29) two times by adding 6 ml of L15 + 10% FBS each time.
31) Suspend the 18 ml cell suspension obtained after mechanical trituration on a 6 ml, 4%
weight/volume (w/v) BSA (prepared in L15 medium) cushion and centrifuge at 300 g for 10 minutes
at 4°C.
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DEFINED SYSTEM FOR GROWING
SKELETAL MUSCLE

Figure 14. Defined system for growing skeletal muscle. Outline of the cell culture process.
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32) Resuspend the obtained pellet in 10 ml L15 + 10% FBS and plate in 100 mm uncoated dishes
for 20-30 minutes depending upon the amount of tissue. During this step, remove the
contaminating fibroblasts. The fibroblasts should settle down and attach to the bottom of the 100
mm dish faster than the myocytes. The supernatant should contain pure myocytes.
33) Gently remove the non-attached cells that are present in the supernatant after 20-30 minutes
by using a sterile Pasteur pipette.
34) Transfer the supernatant onto the top of a 6 ml 4% BSA cushion, and centrifuge at 300 g for 10
minutes at 4°C.
35) Resuspend the pellet in 1 ml of serum-free medium.
36) The cells are now ready for plating. At this point, conduct a cell count and plate the cells at a
density of 500-800 cells/mm2 on either coverslips or fabricated cantilevers.
37) Add the medium 1 hour after plating. Maintain the cultures in a 5% CO2 incubator (relative
humidity 85%).
38) Change half of the medium after every 4 days.

Refer to Table 4 for Troubleshooting Steps 23-28 as outlined above.
Characterization of the myotubes: Morphological quantification and fusion index
39) Quantify the myotube yield using the fusion index, which is defined as the number of nuclei
contained in the myotubes divided by the total number of nuclei counted in a given microscope
field.
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40) The myotubes can now be immunostained for alpha-actin (option A) or embryonic myosin
heavy chain antibody[5, 7] (option B) or characterized using electrophysiology (option C).
A) Immunostaining myotubules for alpha-actin Timing 2 days
i) Rinse coverslips in PBS, fix in cold ethanol (100%) for 20 minutes, and rinse again in PBS.
ii) Block the cultures by incubating in 5% BSA in PBS for two hours at 4˚C.
iii) Add the primary antibody (mouse anti-α-actin, 1:800 dilution in blocking solution) and incubate
for 12 hours at 4˚C.
iv) Then add the secondary antibody (Alexa Fluor 488-conjugated donkey anti-mouse, 1:200
dilution in PBS) to the cultures and incubate for two hours 37˚C.
v) Rinse with PBS.
vi) Mount the coverslips with Citiflour-mounting solution onto slides.
vii) Visualise the coverslips, we use a Zeiss LSM 510 confocal microscope; a similar instrument
could be used.

B) Immunostaining myotubes with the embryonic myosin heavy chain antibody: Timing 2 days
i) Rinse coverslips with PBS,
ii) Fix the cells in -20°C methanol for 5-7 minutes.
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iii) After 5 minutes gently wash the coverslips in PBS in order to remove the excess fixing agent
and then further incubate in PBS supplemented with 1% BSA and 0.05% saponin (permeabilization
solution) for 5 minutes.
iv) Block the cells for 30 minutes with 10% goat serum and 1% BSA.
v) Incubate the cells overnight with the primary antibody against embryonic MHC (F1.652, IgG,)
diluted (1:5) in the permeabilization solution.
vi) Wash the cells with PBS and incubate with the secondary antibody (Cy3 conjugated antimouse, 1:200 dilution in PBS) for 2 hours
vii) After incubating in the secondary antibody for 2 hoursm the coverslips are finally rinsed with
PBS and then mount the coverslips with Citiflour-mounting solution onto slides. Visualize the
coverslips using a confocal microscope or similar instrument. Cultures used for immunostaining
are simultaneously counterstained with 4',6-Diamidino-2-phenylindole (DAPI), a classic fluorescent
nuclear and chromosome counterstaining marker, and used to identify the nuclei and indicate the
chromosome-banding patterns. DAPI selectively binds to dsDNA and, thus, shows little to no
background staining in the cytoplasm. Immuno stained coverslips can be stored for more than one
year. The counting is done at the time of fusion index analysis of the success of the culture system.
Generally, we perform this analysis soon after preparing the coverslips. Count nuclei in 20
randomly chosen microscope fields from a minimum of six separate muscle culture experiments.
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C) Electrophysiological characterization of the myotubes using patch-clamp electrophysiology
Timing 1 day
i) Place the glass coverslips with the cultured skeletal muscle myotubes in a chamber on the
microscope stage.
ii) Continuously perfuse the chamber (2 ml/min) with the extracellular solution through the in-line
heater (35°C) by gravity.
iii) Pull a glass pipette (3 - step pull, Heat = Ramp Value, Pull = 0, Velocity = 30, Time = 200,
Pressure = 300) with the electrode puller and fill with the intracellular solution. The electrode
resistance should be 6-8 MΩ. Critical step: Electrode resistance can be slightly influenced by the
Heat settings (±10). If there are less or more than 3 steps, change the Velocity value (±5).
Electrode properties are highly dependent on the properties of the glass tube. We prefer to use a 3
mm wide box heating filament (more evenly heats) in the puller than the traditional u-shape
filament.
iv) Place the electrode into the headstage; apply positive pressure (about 2cc from a 10cc syringe)
to the pipette before touching the extracellular solution.
v) Bring the electrode close to the target cell; compensate for the pipette offset; touch a cell with
the tip of the electrodes (seal position) under visual control.
vi) Apply a –5 mV seal test; compensate pipette capacitance.
vii) Apply a –70 mV holding (voltage clamp mode).
viii) Form a gigaseal.
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ix) Rupture the cell membrane by the application of short suction pulses; measure resting
membrane potential in I = 0 mode; compensate for whole cell capacitance and resistance.
x) Set the Amplifier gain to 2 and apply a 2 kHz low-pass filter. Digitize signals at 20 kHz.
xi) Correct all membrane potential data by subtracting a 15 mV tip potential. This is calculated
using the Axon’s pClamp 8 program.
xii) Measure membrane resistance and capacitance using 50 ms voltage steps, from –85 mV to –
95 mV, without any whole-cell or series resistance compensation followed by single-exponential
fitting (τ = RmCm).
xiii) Measure the sodium and potassium currents in voltage clamp mode using 10 mV voltage steps
from a –85 mV holding potential. Measure the sodium channel current amplitude at –25 mV, where
no potassium channel activation is observed. Measure the potassium channel current at +15 mV at
the end of the voltage step, when sodium channels are inactivated.
ix) Evoke action potentials with 1s depolarizing current injections from a –85 mV holding potential.

Timing
From microcantilever fabrication through immunocytochemical and electrophysiological
characterization:
Days 1-14/21 (2-3 weeks) Microcantilever fabrication (Steps 1-8)
Days 14-21 (2-3 days) Clean and coat the microcantilevers and glass coverslips with DETA (Steps
10-22)
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Days 16-23 (4-6 hours) Cell culture including dissection, tissue isolation and plating (Steps 23-40)
Days 26-33 (1 day) electrophysiological characterization, (2 days) immunocytochemical
characterization and (2 days) immunostaining myotubes for alpha-actin (Steps 40 A, B, C)
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Table 4: Troubleshooting
Step
5

Problem
A cloudy film
developing on the
cantilever dice or
on
the
glass
coverslip

Possible cause
Polymerization of the DETA
monomer; excess ambient
humidity;

2324

Contamination of
cells after plating

Contamination introduced prior
to plating, possibly in the
dissection

2527

Difficult trituration

Tissue was
enough

2527

Low yield of cells
with unnecessary
debris in culture
Low yield of cells
with tissue pieces
remaining intact
Unhealthy
cells
after plating

Over-trituration or excessive air
during trituration

Solution
Make sure all excess water is removed from
the reaction mixture; ensure glassware is
properly cleaned and oven dried (120°C);
ensure atmospheres are 60% relative humidity
or less, if humidity is too high, perform the
reaction in a controlled glovebox
Prior to dissection spray instruments with
ethanol (70%); perform dissection under a
hood; change gloves between dissection and
culture of the cells
Confirm water bath temperature is 37°C; in
regards to the enzymes – check the expiration
date, confirm length of time in water bath
before use (less than 1 hour)
Use a larger-bore pipette; reduce bubbles
created in the process by being more vigilant

Under-trituration

Use a smaller-bore pipette

Wrong pH of medium, wrong
temperature/atmosphere
in
incubator; over-trituration or
digestion

Verify medium pH adjust to 7.4 as necessary;
verify incubator temperature and CO2
pressure (37°C and 5%); reduce trituration
and digestion time

2527
2338

not

digested
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Results and Discussion
Glass coverslips and cantilevers coated with DETA are analyzed by contact angle and XPS. XPS
has been shown to provide a good quantitative indicator of monolayer formation. The contact
angle, along with XPS data, indicates that the surfaces are covered by a complete monolayer of
DETA.

In the cultures, myoblast fusion begins after 24 h in the defined culture system and after 36–48 h
maximal fusion is reached. Spontaneous contractions of the multi-nucleated myotubes are
observed by the end of the second day (Figure 15).
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Figure 15. Phase pictures of myotubes. A. Phase picture of 7 day old myotubes. B. Phase picture
of a 7 day old myotube with a patch-clamp electrode on its surface for electrophysiological studies.
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Immunocytochemistry combined with confocal microscopy and electrophysiological methods are
then used to characterize the myotubes. Myotubes are observed to be labeled by the skeletal
muscle markers for α-actin and the embryonic myosin heavy chain, to facilitate unambiguous
identification (Figure 16).
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Figure 16. Immunostaining pictures of myotubes. A. Alpha-actin immunostained picture of 7 day
old myotubes B. Embryonic myosin heavy chain stained picture of a 7 day old myotube.
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In 50% of the cantilevers from each experiment, one will observe that dissociated muscle cells
aligned along the long axis of the cantilever to form contracting myotubes (Figure 17).
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Figure 17. 7 days old pictures of the myotubes growing on the cantilevers. Myocytes are aligning
along the long axis of the cantilever and forming contracting myotubes.
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Electrophysiological recordings from the myotubes indicate the presence of, voltage-dependent
inward and outward currents in voltage clamp mode. In current clamp mode the myotubes fire
single action potentials (Figure 18).
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Figure 18. Electrophysiological recordings. Panel A indicates the representative voltage clamp
traces obtained after patching a 7 day old myotube. Panel B showing the representative current
clamp traces obtained after patching a 7 day old myotube.
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CHAPTER 5: SKELETAL MUSCLE TISSUE ENGINEERING: AN IMPROVED MODEL
PROMOTING LOMG TERM SURVIVAL OF MYOTUBES, STRUCTURAL DEVELOPMENT OF
EXCITATION-CONTRACTION (E-C) COUPLING APPARATUS AND NEONATAL MYOSIN
HEAVY CHAIN (NHMC) EXPRESSION

Introduction
Skeletal muscle differentiation and maturation is a complex process that involves the synergy of
different growth factors and hormones interacting over a broad time range [1-11]. The
differentiation process is further complicated by neuronal innervation, where neuron to muscle cell
signaling can regulate myosin heavy chain (MHC) gene expression and acetylcholine receptor
clustering [12-18]. Consequently, a basic understanding of how growth factors, hormones and
other cell types influence skeletal muscle differentiation will be a key step in the creation of
functional tissue engineered constructs, development of advance strategies for regenerative
medicine as well as integrating functional muscle with bio-hybrid MEMS devices for non-invasive
interrogation.

One approach in understanding the role of growth factors and hormones in muscle differentiation is
to develop an in vitro model system that consists of a chemically defined medium supplemented
with different growth factors and hormones. This model will offer the opportunity to evaluate the
role of each factor.

Furthermore, this basic understanding will provide the opportunity to

manipulate both components of the medium as well as their temporal application in order to
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manipulate the maturation of a slow twitch or fast twitch, extrafusal fibers or intrafusal fiber
subtypes.

In vivo, during muscle fiber development, several critical changes occur that indicate functional
maturation of the myotubes. These changes include myosin heavy chain (MHC) class switching
[19], sarcomere organization [20-23], clustering and colocalization of ryanodine (RyR) and
dihydropyridine (DHPR) receptors [24]. A major prerequisite for a successful in vitro model for
skeletal muscle development needs to satisfy these muscle development requirements mentioned
above.

Previously, we had developed a defined system, which promoted differentiation of different skeletal
muscle phenotypes and resulted in the formation of contractile myotubes. We showed short-term
survival of the myotubes [25, 26]. A novel bio-hybrid technology was developed to integrate the
functional myotubes into the cantilever based bio-MEMS device utilized to study muscle
physiology, neuromuscular junctions, biorobotics and the stretch reflex arc [27]. More recently,
using our defined model system, we achieved a major breakthrough by creating the sensory
element of the stretch reflex arc in a petri dish, the intrafusal fibers. The intrafusal fibers are the
building blocks of the muscle spindle, which functions as the sensory receptor of the stretch reflex
circuit [16]. This was achieved by manipulating the growth factor requirements of the myotubes in
our defined system [28].
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Although, during the past five years, we have utilized our model system for different applications, it
still needs further improvement. The life span of the myotubes in culture needs to be increased, in
order to study the development and maturation of slow twitch or fast twitch, extrafusal fibers or
intrafusal fiber subtypes, expression of a more mature isoforms of myosin heavy chain proteins in
culture and retaining most of the functional characteristics of a mature muscle.

In this paper, we have significantly improved our previous models. This improved model system,
with a new modified medium formulation, has the following advantages over the previously
published models:
1. This model promotes long-term survival of the myotubes. In this modified culture system the
myotubes survived for 50 to 70 days, where in our previous model myotubes survived for 20-24
days.
2. The myotubes exhibited characteristic striations, which has been a common feature with mature
skeletal muscle and not observed in our previous model. This lacuna was due to short-time survival
of the myotubes in the previous model.
3. In this improved model system, a small fraction of myotubes expressed neonatal myosin heavy
chain antibody (N3.36), which is a more mature phenotypic marker for skeletal muscle. In our
previous model, we did not observe the expression of these neonatal myosin heavy chain proteins.
4. In this improved model system, most of the myotubes exhibited clustering of ryanodine receptor
and dihydropyridine binding complex ( 1-Subunit) proteins. These DHPR/RyR clusters
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corresponded to the junctional domains of the transverse tubules (T-tubules) and sarcoplasmic
reticulum (SR), respectively, and were key in the excitation-contraction (E-C) coupling.

This improved model system, along with the new findings, support our goal of creating functional,
tissue engineered, muscle constructs and puts within reach the goal of skeletal muscle grafts.
Furthermore, we believe this improved model will be a powerful tool in developing advanced
strategies for regenerative medicine in muscular dystrophy and integrating muscle with bio-hybrid
prosthetic devices.
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Methods and Materials
Surface modification
Glass coverslips (Thomas Scientific 6661F52, 22 x 22mm No.1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 minutes at 100 mTorr. The DETA (United Chemical
Technologies Inc. T2910KG) films were formed by the reaction of the cleaned surface with a 0.1%
(v/v) mixture of the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated
coverslips were heated to just below the boiling point of the toluene, rinsed with toluene, reheated
to just below the boiling temperature, and then oven dried [25].

Surface characterization
To characterize the surfaces, contact angle measurements were taken using an optical contact
angle goiniometer (KSV Instruments, Cam 200) and by X-ray photoelectron spectroscopy (XPS)
(Kratos Axis 165). XPS survey scans, as well as high-resolution N1s and C1s scans, utilizing
monochromatic Al Kα excitation, were obtained [25].

Skeletal muscle culture and serum free medium
The skeletal muscle was dissected from the thighs of the hind limbs of fetal rat (17-18 day-old).
The tissue was collected in a sterile 15-ml centrifuge tube containing 1 ml of phosphate-buffered
saline (calcium- and magnesium-free) (Gibco 14200075).
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The tissue was enzymatically

dissociated using 1 ml of 0.05% of trypsin-EDTA (Gibco 25300054) solution for 30 minutes in a
37°C water bath (100 rpm). After 30 minutes the trypsin solution was removed and 2 ml of L15 +
10% fetal calf serum (Gibco 16000044) was added to terminate the trypsin action. The tissue was
mechanically triturated and the supernatant was then transferred to a 15 ml centrifuge tube. The
process was repeated two times by adding 2 ml of L15 + 10% FBS each time. The 6 ml cell
suspension obtained after mechanical trituration was suspended on a 2 ml, 4% BSA (Sigma
A3059) (prepared in L15 medium) cushion and centrifuged at 300 g for 10 minutes at 4°C. The
pellet obtained was washed 5 times with L15 medium, then resuspended in 10 ml of L15 and
plated in 100 mm uncoated dishes for 30 min. The non-attached cells were removed and
centrifuged on a 4% BSA
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Figure 19. Schematic diagram showing the culture protocol.
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cushion [25]. According to the protocol illustrated in Figure 19, the pellet was resuspended in the
serum-free medium and plated on the coverslips. The cells were plated at a density of 700-1000
cells/mm2 and attached to the substrate in 1 h. The serum-free medium that contained different
growth factors and hormones was added to the culture dish after 1 h. The serum-free medium was
prepared by mixing Medium 1 (Table 5) and Medium 2 (Table 6) in a 1:1 v/v ratio. Figure 19 shows
the flowchart of the improved culture protocol. Table 5 and Table 6 indicate the growth factor and
hormone supplemented compositions of Medium 1 and Medium 2. The cells were maintained in a
5% CO2 incubator (relative humidity 85%). The full medium was replaced at day 4 with NB4 Activ
medium [29] (according to the protocol in Figure 19). Thereafter three-fourths of the medium was
changed every three days with NB4 Activ. The protocol was validated in more than fifty trials
(n>50).
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Table 5: Composition of medium 1.
S.
No

Component

Amount

Catalogue #

Source

References

1.

Neurobasal A

500 ml

10888

Gibco/ Invitrogen

[30]

2.

Antibiotic-Antimycotic

5 ml

15240-062

Gibco/ Invitrogen

3.

Glutamax

5 ml

35050-061

Gibco/ Invitrogen

4.

B27 Supplement

10 ml

17504-044

Gibco/ Invitrogen

[30, 31]

5.

G5
Supplement (100X)

5 ml

17503-012

Gibco/ Invitrogen

[32-41]

6.

VEGF 165 r Human

10 µg

P2654

Gibco/ Invitrogen

[42-45]

7.

Acidic FGF

12.5 µg

13241-013

Gibco/ Invitrogen

[32, 39, 41, 46-51]

8.

Heparin Sulphate

50 µg

D9809

Sigma

[32, 39, 41, 46-51]

9.

LIF

10 µg

L5158

Sigma

[52-60]

10.

Vitronectin
(Rat Plasma)

50 µg

V0132

Sigma

[61, 62]

11.

CNTF

20 µg

CRC 401B

Cell Sciences

[63-67]

12.

NT 3

10 µg

CRN 500B

Cell Sciences

[15]

13.

NT 4

10 µg

CRN 501B

Cell Sciences

[68, 69]

14.

GDNF

10 µg

CRG 400B

Cell Sciences

[70-74]

15.

BDNF

10 µg

CRB 600B

Cell Sciences

[69, 75, 76]

16.

CT-1

10 µg

CRC 700B

Cell Sciences

[77-85]
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Table 6: Composition of medium 2
S. No

Component(s)

Amount

Catalogue

Source

References

1.

Neurobasal A

500 ml

10888

Invitrogen/Gibco

[30]

2.

Glutamax

5 ml

35050-061

Invitrogen/Gibco

3.

Antibiotic-antimycotic

5 ml

15240-062

Invitrogen/Gibco

4.

B27 supplement

10 ml

17504-044

Invitrogen/Gibco

[30, 31]

5.

Cholesterol (250X)

5ml

12531

Invitrogen/Gibco

[86]

6.

TNF-alpha, human

10 µg

T6674

Sigma-Aldrich

[23, 87, 88]

7.

PDGF BB

50 µg

P4056

Sigma-Aldrich

[52, 89-92]

8.

Vasoactive intestinal peptide

250 µg

V6130

Sigma-Aldrich

[93]

(VIP)
9.

Insulin-like growth factor 1

25 µg

I2656

Sigma-Aldrich

[58, 59, 88]

10.

NAP

1mg

61170

AnaSpec, Inc.

[94, 95]

11.

Recombinant Apolipoprotein

50 µg

P2002

Panvera, Madison, WI

[96]

E2
12.

Laminin, mouse purified

2 mg

08-125

Millipore

[97-103]

13.

Beta amyloid (1-40)

1mg

AG966

Millipore

[104-106]

14.

Human Tenascin-C protein

100 µg

CC065

Millipore

[107]

15.

rr-Sonic hedgehog,

50 µg

1314-SH

R&D Systems

[7, 108-118]

50 µg

550-AG-100

R&D Systems

[119, 120]

Shh N-terminal
16.

rr (Agrin C terminal)
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Immunocytochemistry of skeletal muscle
Coverslips were prepared for immunocytochemical analysis as previously described. Briefly,
coverslips were rinsed with PBS, fixed in -20°C methanol for 5-7 min, washed in PBS, incubated in
PBS supplemented with 1% BSA and 0.05% saponin (permeabilization solution) for 10 minutes,
and blocked for 2h with 10% goat serum and 1% BSA. Cells were incubated overnight with primary
antibodies against embryonic myosin heavy chain (F1.652) (dilution>1:5), neonatal myosin heavy
chain (N3.36) (dilution>1:5) (Developmental Studies Hybridoma Bank), ryanodine receptor
(AB9078, Millipore) (dilution>1:500) and dihydropyridine binding complex ( 1-Subunit) (MAB
4270, Millipore) (dilution>1:500) diluted in the blocking solution. Cells were washed with PBS and
incubated with the appropriate secondary antibodies for 2 hours in PBS. After 2 hours, the
coverslips were rinsed with PBS, mounted on glass slides and observed in a confocal microscope
[25, 26, 121].

AChR labeling of the myotubes
AChRs were labeled as previously described [12, 121] by incubating cultures with 5*10-8 M of
alpha-bungarotoxin, Alexa Fluor® 488 conjugate (B-13422; Invitrogen/Molecular Probes, Carlsbad,
CA, USA) for 1.5 h at 37°C before observation. Following incubation in α-bungarotoxin, the
cultures were fixed, as mentioned above, for further staining with embryonic myosin heavy chain
(F1.652) antibodies.
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Patch clamp electrophysiology of the myotubes
Whole-cell patch clamp recordings were performed in a recording chamber located on the stage of
a Zeiss Axioscope 2FS Plus upright microscope, as previously describe. The chamber was
continuously perfused (2 ml/min) with the extracellular solution (Leibovitz medium, 35˚C). Patch
pipettes were prepared from borosilicate glass (BF150-86-10; Sutter, Novato, CA) with a Sutter
P97 pipette puller and filled with intracellular solution (in mM: K-gluconate 140, EGTA 1, MgCl2 2,
Na2ATP 2, Phosphocreatine 5, Phosphocreatine kinase 2.4 mg, Hepes 10; pH = 7.2). The
resistance of the electrodes was 6–8 MΩ. Voltage clamp and current clamp experiments were
performed using a Multiclamp 700A amplifier (Axon, Union City, CA). An Axon Digidata 1322A
interface filtered the signals at 2 kHz and digitized at 20 kHz. pClamp 8 software (Axon) recorded
and analyzed the data. Membrane potentials were corrected by the subtraction of a 15 mV tip
potential, which was calculated using Axon’s pClamp 8 program. Sodium and potassium currents
were measured in voltage clamp mode using voltage steps from a -85 mV holding potential. Action
potentials were evoked with 1 s depolarizing current injections from a -85 mV holding potential [25,
26].
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Results and Discussion
DETA surface modification and characterization
Static contact angle and XPS analysis was used to validate the surface modifications and for
monitoring the surface quality. Stable contact angles (40.64° ± 2.9 /mean ± SD) throughout the
study indicated a high reproducibility and quality of the DETA coatings. This was similar to
previously published results [25, 26, 31, 121, 122]. Based upon the ratio of the N (401 and 399 eV)
and the Si 2p3/2 peaks, XPS measurements indicated that a complete monolayer of DETA formed
on the coverslips.
Development of serum free medium formulation and the culture technique
The serum-free medium composition was developed empirically. The final medium was derived
from two different medium compositions enumerated in Tables 5 and 6. Table 5 constituted the
same medium composition that we had previously used for the motoneuron-muscle co-culture and
adult spinal cord neurons culture [121, 123-125]. Table 6 constituted twelve additional factors,
which had been shown to promote skeletal muscle growth and neuromuscular junction formation.
The final medium was prepared by mixing these two mediums in a 1:1 v/v ratio. After the first 4
days of culture, the whole medium was replaced with NB4Activ medium [29]. Thereafter, threefourth medium was changed after every three days with NB4Activ. Figure 19 shows the culture
technique in the flowchart.
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Long-term survival and maturation of myotubes
Using our new medium formulation, we were able to successfully culture myotubes for more than
50 days days. Figure 20 shows 50-day-old myotubes in culture. As the myotubes aged and grew,
they began to form the characteristic anisotropic (A band) and isotropic (I band) banding pattern
seen on in vivo muscle fibers [21, 22]. This banding pattern was caused by differential light
diffraction due to the organization of myofibril proteins forming sarcomeres within the myotubes
[21, 22]. The arrowheads in the images (Figure 20 A-D) indicate myotubes where sarcomeric
organization has occurred and was visualized by the appearance of A and I bands.
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Figure 20. A, B, C and D: Phase pictures of 50-day-old myotubes in culture. Red arrows show
characteristic striations in most of the myotubes. Scale bar: 75 micron.
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Myotube expression of fetal myosin heavy chain
We evaluated the myotubes formed in this new medium formulation for the expression of fetal
MHC. This was to ensure that the new medium formulation was at least mimicking our previous
medium [25]. In Figure 21 indicated the characteristic types of myotubes formed at approximately
day 50 in vitro. These myotubes range from having clustered nuclei (Figure 21 A-D) to having
diffuse nuclei organization (Figure 21 E-H).

The arrowheads in the images indicate the

characteristic striations.
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Figure 21. Myotubes stained with antibodies against embryonic myosin heavy chain (F 1.652)
proteins at day 50. Scale bar: 75 micron. A. Panel showing phase + fluorescent picture of the
myotubes. B. Panel A observed only under fluorescent light. C. Panel showing phase + fluorescent
picture of the myotubes. D. Panel C observed only under fluorescent light. E. Panel showing phase
+ fluorescent picture of the myotubes. F. Panel E observed only under fluorescent light. G. Panel
showing phase + fluorescent picture of the myotubes. H. Panel G observed only in fluorescent
light. White arrows show the striations in panels B, E, F, G and H.
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Differential expression of neonatal myosin heavy chain (N3.36) protein in the myotubes
In order to determine if the myotubes were maturing as they aged in vitro, we evaluated the
expression of neonatal MHC. After approximately 50 days in vitro, 25% of the myotubes began
expressing neonatal MHC (Figure 22 A-M). Additionally, we stained the myotubes for clustering of
acetylcholine receptors (AChR) using alpha bungarotoxin (Figure 22 B,F). This clustering of AChR
receptors are the hot spots where a muscle receives the chemical signals from motoneurons.
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Figure 22. Myotubes immunostained with neonatal myosin heavy chain (N3.36) and alphabungarotoxin at day 50. Scale bar: 75 micron. A. Phase picture of 2 myotubes shown by the white
arrows. B. Both myotubes shown in phase (Fig A) have acetylcholine receptor clustering shown by
alpha-bungarotoxin staining. C. Only one myotube out of the two seen in Fig A stained for N3.36.
D. Double stained picture of the Fig A with alpha-bungarotoxin and N3.36.E. Phase picture of 6
myotubes, shown by white arrows. F. All the myotubes shown in phase (Fig E) have acetylcholine
receptor clustering shown by alpha-bungarotoxin staining. G. None of the myotubes in Fig E
stained for N3.36. H, I, J. Differential staining of the myotubes with N3.36. K, L, M. Differential
staining of the myotubes with N3.36.
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Ryanodine receptor and dihydropyridine receptor expression and colocalization
The presence of ryanodine (RyR) and dihydropyridine (DHPR) receptor clusters, as well as their
colocalization in vivo, represents the development of excitation-contraction coupling apparatus in
skeletal muscle myotubes [20-22, 24]. We observed the clustering of both RyR and DHPR
receptors on the myotubes at 30-day-old in culture (Figure 23 A-D).

The clustering and

colocalization of RyR + DHPR clusters was observed on different morphologies of the myotubes
(Figure 23 E-L). This functional adaptation illustrated that the medium formulation facilitated not
only the structural maturation, but also the functional maturation of myotubes in this in vitro system.
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Figure 23. Ryanodine receptor and DHPR receptor clustering in 30-day-old skeletal muscle culture.
Scale bar 75 micron. A. Phase and fluorescent-labeled picture of the myotubes. B. Merged
fluorescent picture of the Ryanodine receptor (Green) and DHPR receptor (Red) clustering on the
myotubes shown in panel A. C. Ryanodine receptor (Green) on the myotubes shown in panel A. D.
DHPR receptors on the myotubes shown in panel A. E. Phase and fluorescent labeled picture of
the myotubes. F. Merged fluorescent picture of the Ryanodine receptor (Green) and DHPR
receptor (Red) clustering on the myotubes (Panel E). G. Ryanodine receptor (Green) on the
myotubes (Panel E). H. DHPR receptors on the myotubes (Panel E). I. Phase and fluorescentlabeled picture of the myotubes. I. Phase and fluorescent-labeled picture of the myotubes. J, K and
L. Merged fluorescent picture of the Ryanodine receptor (Green) and DHPR receptor (Red)
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clustering on the myotubes (Panel I) on three different planes. White arrows show the striations
and the receptor clustering along the striations.
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We also observed the clustering of the RyR + DHPR receptors in 100-day-old myotubes, indicating
that the older myotubes also maintained their functionality (Figure 24 A-F).
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Figure 24. Ryanodine receptor and DHPR receptor clustering in 100-day-old skeletal muscle
culture. Scale bar: 75 micron. A. Phase and fluorescent-labeled picture of the myotubes. B. Merged
fluorescent picture of the Ryanodine receptor (Green) and DHPR receptor (Red) clustering on the
myotubes (Panel A). C. Ryanodine receptor (Green) on the myotubes (Panel A). D. DHPR
receptors on the myotubes (Panel A). E and F. Same panels at different plane showing the merged
fluorescent picture of the Ryanodine receptor (Green) and DHPR receptor (Red) clustering on the
myotubes.
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Electrophysiological activity of day 48 myotubes
Motubes contracted spontaneously in the culture. The contractions were initiated by day 4 in the
culture and continued until we maintained the culture. Most of the myotubes expressed functional
voltage gated sodium, potassium and calcium ion channels as previously reported [25]. The
voltage clamp electrophysiology of the myotubes showed both inward and outward currents,
indicating functional sodium and potassium channels (Figure 25 A). The current clamp study
showed the single action potential fired by the myotubes (Figure 25 B).
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Figure 25. Patch clamp electrophysiology of the myotubes. A. Representative voltage clamp trace
obtained after patching a 48-day-old myotube in culture (n>20) B. Representative current clamp
trace of the same myotube, which a voltage clamp trace had been obtained (n>20). Inset showing
the picture of patched myotubes. (n= number of myotubes which were patched during the course of
study)
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Our previous studies have shown the biocompatibility of the DETA silane substrate. One
interesting feature about DETA silane is that, it partially mimics the three dimensional features of
the extra-cellular matrix, which may be partly responsible for the robust growth of the different cell
types on a synthetic substrate [25, 26, 31, 121-125].

We have empirically developed a serum-free medium that supports the survival, proliferation and
fusion of fetal rat myoblasts into contractile myotubes. The rational for selecting these growth
factors was solely based on the distribution of their receptors within the developing myotubes of a
rat fetus [1-11]. In Tables 5 and 6, we have referenced the literature where these individual growth
factors, hormones and neurotransmitters had been observed to support muscle and neuromuscular
junction development. The composition of Table 5 is same as what we had previously used for the
motoneuron-muscle co-culture and adult spinal cord neuron culture [121, 123-125]. In Table 6, we
have added twelve more factors, which had been indicated in muscle and neuromuscular junction
formation. The other key change in our culture protocol is that we had used NB4Activ [29] for
maintenance of the culture. NB4Activ is a specialized medium used for fetal hippocampal neuron
growth in culture [29]. We observed that this medium supported the survival of skeletal muscle.

In our previous model, we observed embryonic myosin heavy chain (EMHC) expression. In this
study, apart from EMHC, we observed that 25% of the myotubes expressed neonatal myosin
heavy chain (NMHC) proteins. NHMC is a more mature marker of the muscle [19]. We believe that
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the myotubes were more mature in this culture due to two reasons: 1), the long-term survival was
due to a modified protocol and advance medium formulation, and 2) the additional growth factors
promoted more mature myotube formation.

The expression of co-localized RyR and DHPR clusters in the myotubes at approximately 50 days
and 100 days in culture showed that this modified medium formulation supports the functional
maturation of the fibers and formation of excitation-contraction coupling apparatus. Excitationcontraction (E-C) coupling is the signaling process in muscle that membrane depolarization leads
to force production [126]. E-C coupling in striated, skeletal muscle is a fast process in which a brief
depolarization causes an immediate elevation of the cytosolic Ca2+ [127]. This process is brought
about by a close interaction between the dihydropyridine receptor (DHPR), L-type Ca2+ channel
and the ryanodine receptor type 1 (RyR1) present in the skeletal muscle. Close proximity between
the DHPR and RyR complexes occurs at specialized junctions established between the transverse
tubular and sarcoplasmic reticulum (SR) membranes [128]. At these junctions, voltage-dependent
movements of the electrical charges in the skeletal DHPR are coupled to the opening of the RyR1
channel [129-131]. This further leads to the force generation in a striated muscle. This structural
adaptation represents a significant functional change due to the fact that excitation-contraction
coupling is required for successful muscle development as well as neuromuscular junction
formation [20-22, 24]. Therefore, a better understanding of E-C coupling is extremely important in
regenerative medicine. In the past for a better understanding of the molecular mechanism of E-C
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coupling, researchers had relied heavily on myotube models. But, there was no defined, serum-free
model in order to study this supramolecular assembly of E-C coupling apparatus. This improved
model offers the potential to study E-C coupling in a defined system. Patch-clamp
electrophysiology provided further evidence that the muscle maintained their functional, voltage
gated ion channel in the system.

This improved model system along, with these new findings, support our goal for creating
functional, tissue engineered, muscle constructs and puts within reach the goal of skeletal muscle
grafts. Furthermore, we believe this improved model will be a powerful tool in developing advance
strategies for regenerative medicine in muscular dystrophy and integrating muscle with bio-hybrid
prosthetic devices.
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CHAPTER 6: EMBRYONIC MOTONEURON-SKELETAL MUSCLE CO-CULTURE IN A
DEFINED SYSTEM. NEUROSCIENCE. 2007 MAY 11;146(2):481-8.

Introduction
In vitro co-culture of mammalian nerve and muscle cells is a popular model system to study
neuromuscular junction (NMJ) formation, function and maintenance, as well as nerve-muscle
disorders, signal computation at the nerve-muscle interface and a plethora of other applications
ranging from biorobotics and tissue engineering to drug screening [1-4]. Currently, all the known in
vitro nerve-muscle co-culture models use serum containing media [1, 3-6]; this provides a
functional model system, but the use of serum adds unwanted variability. Thus, the use of serum
makes it impossible to describe or quantify the minimum factors needed to recreate the
mammalian NMJ in vitro. In this work, we describe the development of a defined motoneuron and
muscle co-culture system resulting in the formation of NMJs including: 1) a new culture technique,
2) a novel serum-free medium formulation and 3) a synthetic SAM substrate (N-1 [3(trimethoxysilyl) propyl] diethylenetriamine - DETA). We characterized the culture by morphology,
immunocytochemistry, electrophysiology and videography. This model system provides a better
understanding of the necessary growth factor and substrate interactions in NMJ formation and
provides an enhanced system for nerve-muscle tissue engineering, regenerative medicine and
development of limb prosthetics.
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Methods and Materials
Surface modification
Glass coverslips (Thomas Scientific 6661F52, 22×22 mm No. 1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 min at 100 mTorr. The DETA (United Chemical Technologies
Inc. T2910KG) film was formed by the reaction of the cleaned surface with 0.1% (v/v) mixture of
the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated coverslips were
heated to just below the boiling point of the toluene, rinsed with toluene, reheated to just below the
boiling temperature, and then oven dried. Surfaces were characterized by contact angle
measurements using an optical contact angle goniometer (KSV Instruments, Cam 200) and by
XPS (Kratos Axis 165) by monitoring the N 1s peak [7-13].

Rat embryonic motoneuron isolation.
Rat spinal motoneurons were purified from ventral cords of embryonic day 14 (E14) embryos.
Briefly, rats were anaesthetized and killed by inhalation of an excess of CO2. This procedure was in
agreement with the Animal Research Council of Clemson University and the University of Central
Florida, which adheres to IACUC policies. Ventral spinal cells from the embryo were collected in
cold Hibernate E/ GlutaMAX™ / antibiotic-antimycotic/ B27. The cells were dissociated with 0.05%
trypsin-EDTA (Invitrogen) treatment. The dissociated cells were layered over a 4 ml step gradient
(Optipep diluted 0.505: 0.495 (v/v) with Hibernate E/ GlutaMAX™ / antibiotic-antimycotic/ B27 and
then made to 15%, 20%, 25% and 35% (v/v) in Hibernate E/ GlutaMAX™/ antibiotic-antimycotic/
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B27) followed by centrifugation for 15 min, using 800g, at 4°C. This is modified from the previously
described protocols due to non-availability of metrizamide [10, 12, 14]. After centrifugation, four
bands of cells were obtained. The motoneurons constituted the uppermost band with large somas.
These cells were further purified by immunopanning. The motoneurons were selected using the
immune interaction between the motoneurons and MAB192 antibody (1:2 dilution, ICN
Biomedicals, Akron, OH) coated on the dishes[12, 15, 16] . The antibody recognized the low affinity
NGF receptor that is only expressed by ventral motoneurons at this age [17]. Purified motoneurons
were plated on top of muscle cells at a density of 50 cells/mm2.

Muscle cell isolation and culture
The skeletal muscle was dissected from the thighs of the rat fetus (E17) hind limbs. The tissue was
collected in a sterile 15 ml centrifuge tube containing 1 ml of phosphate-buffered saline (calciumand magnesium-free) (Gibco 14200075). The tissue was enzymatically dissociated using 2 ml of
0.05% of trypsin-EDTA solution for 60 min in a 37 °C water bath (100 rpm). After 30 min the trypsin
solution was removed and 4 ml of Hib. E +10% fetal calf serum (Gibco 16000044) was added to
terminate the trypsin action. The tissue was then mechanically triturated and the supernatant
transferred to a 15 ml centrifuge tube. The same process was repeated two times by adding 2 ml of
Hib. E +10% FBS each time. The 6 ml cell suspension obtained after mechanical trituration was
suspended on a 2 ml, 4% BSA (Sigma A3059) (prepared in Hib. E medium) cushion and
centrifuged at 300g for 10 min at 4 °C. Finally, the cell pellet was suspended in 1 ml of serum-free
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medium and plated on 100 mm uncoated dishes for 30 min. The non-attached cells were removed,
centrifuged on a 4% BSA cushion, and plated at a density of 700–1000 cells/mm2 on DETA coated
coverslips. The cells attached to the substrate in 1 h [11].

Plating the embryonic motoneuron on top of muscle
The immuno-pure embryonic motoneurons were plated at a density of 50 cells/mm2 on the top of
the muscle layer. The serum-free medium was added to the culture dish after 1 h and the cells
were maintained at 37°C in a 5% CO2 incubator (relative humidity 85%) (Figure 26).
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Figure 26. Defined model system for the embryonic motoneuron-muscle co-culture.

187

Immunocytochemistry
Embryonic myosin heavy chain
Coverslips were rinsed with PBS, fixed in −20 °C methanol for 5–7 min, washed in PBS, incubated
in PBS supplemented with 1% BSA and 0.05% saponin (permeabilization solution), and blocked for
30 min in a permeabilization solution + 10% goat serum (blocking solution). Cells were incubated
overnight with primary antibody against fetal MHC (F1.652, IgG, Developmental Studies
Hybridoma Bank) diluted (1:5) in the blocking solution. Cells were washed with PBS and incubated
with the secondary antibody (diluted in PBS) for 2 h. The secondary antibody solution was
removed and the cells were rinsed using PBS. The coverslips were dried and mounted on glass
slides using VectaShield+DAPI mounting medium (Vector Laboratories H-1200) and viewed on a
confocal microscope (UltraVIEW™ LCI, PerkinElmer)[11, 18].

Double staining with Neurofilament 150 and Embryonic myosin heavy chain
Co-cultures were processed for immunocytochemistry as described above. Next, cells were
incubated overnight at 4°C with rabbit anti-neurofilament M polyclonal antibody, 150 kD,
(Chemicon, AB1981, diluted 1:2000) and fetal MHC (F1.652, IgG, Developmental Studies
Hybridoma Bank, diluted 1:5). After overnight incubation, the coverslips were rinsed three times
with PBS and then incubated with the appropriate secondary antibodies for 2h. After rinsing three
times in PBS, the coverslips were mounted with Vectashield+DAPI mounting medium onto glass
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slides. The coverslips were visualized and images collected using a confocal microscope
(UltraVIEW™ LCI, PerkinElmer). Controls without primary antibody were negative.
AChR labeling and observation of co-cultures.

AChRs were labeled as described previously [5] by incubating cultures with 5 × 10

8

M

-

bungarotoxin, Alexa Fluor® 488 conjugate (Molecular Probes, B-13422) for 1.5 hr at 37°C before
observation. Labeled cultures were fixed with glacial acetic acid and ethanol, washed with PBS,
dried, mounted and examined by confocal microscopy.
Colabeling AChRs with α-bungarotoxin and synaptophysin.
AChRs were labeled as described above. The AChRs labeled coculture coverslips were also
processed for immunocytochemistry as described above. Cells were incubated overnight with the
primary antibody against major synaptic vesicle protein p38, anti-synaptophysin (Chemicon,
MAB368, diluted 1:1000) in the blocking solution. Cells were washed with PBS and incubated with
the secondary antibody (diluted in PBS) for 2 h. The secondary antibody solution was removed and
the cells were rinsed using PBS. The coverslips were dried and mounted on glass slides using
VectaShield+DAPI mounting medium (Vector Laboratories H-1200) and viewed on a confocal
microscope (UltraVIEW™ LCI, PerkinElmer.

Staining for glial cells and fibroblasts
189

Co-cultures were processed for immunocytochemistry as described above. Next, cells were
incubated overnight at 4°C with mouse anti-GFAP, (Chemicon, MAB360, diluted 1:1000) and
mouse anti-fibroblasts antibody, clone TE-7 (Chemicon, CBL271, diluted 1:100). After overnight
incubation, the coverslips were rinsed three times with PBS and then incubated with the
appropriate secondary antibodies for 2h. After rinsing three times in PBS, the coverslips were
mounted with Vectashield+DAPI mounting medium onto glass slides. The coverslips were
visualized and images collected using a confocal microscope (UltraVIEW™ LCI, PerkinElmer).
Controls without primary antibody were negative.

Electrophysiology
Whole-cell patch clamp recordings were performed in a recording chamber located on the stage of
a Zeiss Axioscope 2FS Plus upright microscope. The chamber was continuously perfused
(2 ml/min) with the extracellular solution (Leibovitz medium, 35 °C). The patch pipettes were
prepared from borosilicate glass (BF150-86-10; Sutter, Novato, CA) with a Sutter P97 pipette puller
and filled with intracellular solution (in mM: K-gluconate 140, EGTA 1, MgCl2 2, Na2ATP 2,
Phosphocreatine 5, Phosphocreatine kinase 2.4 mg, Hepes 10; pH = 7.2). The resistance of the
electrodes was 6–8 MΩ. Voltage clamp and current clamp experiments were performed with a
Multiclamp 700A amplifier (Axon, Union City, CA). Signals were filtered at 2 kHz and digitized at
20 kHz with an Axon Digidata 1322A interface. Data recording and analysis were performed with
pClamp 8 software (Axon). Membrane potentials were corrected by the subtraction of a 15 mV tip
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potential, which was calculated using Axon's pClamp 8 program. Membrane resistance and
capacitance were calculated using 50 ms voltage steps from −85 to −95 mV without any whole-cell
or series resistance compensation. Sodium and potassium currents were measured in voltage
clamp mode using voltage steps from a −85 mV holding potential. Action potentials were evoked
with 1 s depolarizing current injections from a −85 mV holding potential [10-13].

Video recordings
Determination of the effect of (+) – tubocurarine chloride pentahydrate (d-tubocurarine or Curare)
on the NMJ by video recording: 5 µM of the nicotinic cholinergic antagonist, (+) – tubocurarine
chloride pentahydrate (Cat no. 93750, Sigma), was applied in the bath solution in order to block the
acetylcholine receptors present in the NMJ.
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Results and Discussion
We used embryonic motoneurons and skeletal muscle cells to initiate a developmentally relevant
system for the study of NMJ formation. The motoneurons were obtained from the spinal cord of
embryonic, day 14, rat embryos. The detailed protocol for motoneuron isolation [12, 15, 16, 19] and
muscle isolation [11] has been discussed and reported previously. Briefly, purified motoneurons
were isolated in two steps. First, ventral horn motoneurons were separated on an opti-prep density
gradient [12, 14]. Then, they were further purified by immunopanning [12, 15]. These purified
motoneurons were co-cultured with dissociated skeletal muscle obtained from the hind limb of the
day 18 rat fetuses [11]. Current co-culture models call for plating of motoneurons only after
myotube formation, adding time and complexity to the system [1, 20, 21]. In the current system,
dissociated myocytes were plated and after one hour the motoneurons were added on top of the
adherent myocytes. This facilitated the development of both cell types concurrently, yielding a
robust culture (Figure 26).

In order to understand the fundamental soluble factors required for NMJ formation, a serum-free,
chemically defined media was developed by systematically integrating components from our
independently developed culture media for spinal cord motoneurons [10, 12], skeletal muscle [11]
and cardiac muscle [13]. Individually, these media provide for the culture of adult and embryonic
motoneurons and embryonic myocytes on a synthetic substrate (DETA - a self-assembled
monolayer or SAM). We combined certain different factors from these defined media systems and
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showed that it provides for the co-culture of embryonic motoneuron-muscle cell types. The cultures
were initiated in the defined medium (Table 7). Half of the medium was changed every 4-5 days
with Neurobasal+B27+Glutamax+antibiotic/antimycotic and the system provided a maximum
survival of 3 weeks.
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Table 7: Serum-free co-culture medium composition
Component

Amount/concentration

Company

Catalog number

Neurobasal

500 ml

Invitrogen

10888

B27

10 ml

Invitrogen

17504-044

G5 (100x)

1 ml

Invitrogen

17503-012

aFGF

10 μg

Invitrogen

13241-013

VEGF 165

10 μg

Invitrogen

P2654

Human BDNF

10 μg

Cell Sciences

CRB 600B

Human GDNF

10 μg

Cell Sciences

CRG 400B

Rat CNTF

25 μg

Cell Sciences

CRC 401B

Human CT-1

10 μg

Cell Sciences

CRC 700B

NT-3

10 μg

Cell Sciences

CRN 500B

NT-4

10 μg

Cell Sciences

CRN 501B

Human LIF

10 μg

Sigma

L5283

D- N-acetylated heparin sulfate

40 μg

Sigma

D9809

Vitronectin

50 μg

Sigma

V0132

Glutamax (100×)

5 ml

Invitrogen

35050-061

Antibiotic-antimycotic 100×

5 ml

Invitrogen

15240-062
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This system uses a patternable [8, 22], non-biological, cell growth promoting, organosilane
substrate (DETA) [7, 9-13, 23, 24], coated on a glass surface, facilitating variable control and
reproducibility of the growth surface. Quality of the surface modified coverslips used for the cell
culture was evaluated using static contact angle measurements and X-ray photoelectron
spectroscopy (XPS) analysis as previously described [9-13, 24, 25]. Stable contact angles (40.64°
± 2.9/mean ± SD) throughout the study indicated high reproducibility and quality of the DETA
coatings and were similar to previously published results [9-13, 24]. Based on the ratio of the N
(401 and 399 eV) and the Si 2p3/2 peaks, XPS measurements indicated that a complete monolayer
of DETA was formed on the coverslips (Figure. 26 Blue Box).

Using immunocytochemistry, myotubes were stained using fetal myosin heavy chain antibodies
[18] (Figure 27 A, B) at day 12. The immunopure motoneurons were visualized using an antibody
to the cytoskeletal protein neurofilament-150 kDa. (Figure 27 C, D).
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Figure 27. Immunostaining of the myotubes and the motoneurons separately in co-culture. A,B.
Myotube morphology and immunocytochemistry in co-culture was done using the fetal myosin
heavy chain antibody and appear green. Myotubes and characteristic nuclei can be easily seen. C,
Motoneuron morphology in co-culture was visualized using phase contrast microscopy and the cell
soma and processes are easily distinguished. D, Motoneuron immunocytochemistry using the NF150 antibody. Cell soma and processes appear red. Scale bars: 20 microns in all panels.
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Co-cultures were visualized by double staining the cultures with fetal myosin heavy chain and
neurofilament-150 antibodies (Figure 28 A, B, C, D). The postsynaptic acetylcholine receptor was
verified by alpha-bungarotoxin staining of the acetylcholine receptor clustering at the nerve-muscle
synapse [5, 26] (Figure 28 E, F).
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Figure 28. Phase contrast and immunocytochemical characterization of myotubes and
motoneurons in co-culture. A,B, Myotubes stained for fetal myosin heavy chain (green) and
motoneurons stained for neurofilament 150 (red) are shown in proximity to each other with
neuronal processes touching the myotubes in two planes (blue arrows). C,D, Phase contrast and
confocal images of a myotube (green) innervated by multiple neuronal processes (red) and in
proximity to a motoneuron (red). E,F, phase contrast and alpha-bungarotoxin staining of
motoneuron-myotube co-culture, where the blue arrow points to the motoneuron, and red arrows
and green dot clusters indicate areas of acetylcholine receptor clustering.
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Immunocytochemical evidence for synapse formation between the embryonic motoneuron and
myotube at the NMJ was shown by close proximity of the presynaptic marker, synaptophysin
(synaptic vesicle protein) and the clustering of the acetylcholine receptors (eg. by alphabungarotoxin labeling) in Figure 29 A, B, C, D.
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Figure 29. Immunocytochemical evidence for synapse formation at the NMJ. A. Phase picture of a
motoneuron in close proximity to a myotube. The motoneuron was stained with synaptophysin
(red). B. The motoneuron labeled with synaptophysin (red) and the myotube labeled with alphabungarotoxin (green) was observed at a specific plane in the confocal image. C, D. The process of
the motoneuron appears to be synapsing on the myotube to form a NMJ in two different planes as
seen by the close proximity of the presynaptic marker, synaptophysin (red), and the postsynaptic
acetylcholine receptor clustering was indicated by alpha-bungarotoxin labeling (green). Scale bar is
25µ.
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Apart from the neurons and myotubes we observed there were other cells present in the culture
which neither manifested myotube nor neuronal morphologies. A large fraction of such cells were
mostly individual myocytes which did not fuse to form myotubes. But apart from that we found a
small fraction of cells that stained for a glial cell marker (GFAP). We believe that these GFAP
positive cells originated from a small fraction of glial cells initially present in the culture and that
possibly proliferated in the culture overtime. Two representative pictures of the GFAP positive glial
cells are shown in the Figure 30.
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Figure 30. Figure A and B shows the contaminating glial cells (GFAP positive cells are shown in
red) present in the co-culture.
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We did not find any fibroblast positive cells after staining the culture with mouse anti-human
fibroblast monoclonal antibody as seen in Figure 31. In our future studies we will further
characterize the role of glial cells in NMJ formation.
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Figure 31. Figure A shows the phase picture of the coculture stained with an anti-fibroblast marker.
Figure B indicates the absence of a fibroblast in the coculture after staining with an anti-fibroblast
marker (green).
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Using patch clamp electrophysiological recordings it was shown that the motoneurons (Figure 32
[A]) as well as the skeletal muscle (Figure 32 [B]) maintained their electrical properties as
previously described [11, 12, 27].
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Figure 32.[A]. Electrophysiological properties of a single motoneuron in co-culture. A, voltage
clamp recording of the patched motoneuron showing active Na+ and K+ currents. B, Phase
contrast image of patched motoneuron (red arrow) in proximity to a myotube (green arrow). C,
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Current clamp recording of the patched motoneuron showing a repetitively firing action potential.
These recordings are representative of 95% of the neurons present in the culture.[B].
Electrophysiological properties of a single myotube in co-culture. A. Voltage clamp recording of the
patched myotube showing active Na+ and K+ currents. B, Phase contrast image of patched
myotube (green arrow) in proximity to a motoneuron (red arrow). C, Current clamp recording of the
patched myotube showing a single action potential. These recordings are representative of 80% of
the myotubes present in the culture.
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Figure 33. Figure A and B indicate the phase picture of the embryonic motoneuron and myotube
pair forming a NMJ. The myotube has been shown to contract rhythmically in Video 2. After the
application of the nicotinic cholinergic antagonist d-tubocurarine, the rhythmic contraction of the
myotube stopped. Video 2 recorded for 1 minute and 54 seconds. The antagonist d-tubocurarine
was applied 45 seconds after the recording started. We observed that the rhythmic contraction of
the myotube gradually stopped within the next 10 seconds. Although recordings continued for an
additional minute, no further contractions of the myotubes were observed.

210

Additionally, five representative videographs provide additional evidence for the presence of
functional NMJs. All the videos 1, 2, 3, 4 and 5 can be found in the attached disk.

Video 1 shows contracting myotubes surrounding a motoneuron. Coculture of embryonic
motoneuron and fetal skeletal muscle at Day 12

Video 2 indicates a myotube contracting rhythmically for the first 45 s. Then d-tubocurarine (also
known as curare), an antagonist to the nicotinic acetylcholine receptors present at the NMJ, was
added to the recoding bath. Soon after the addition of the d-tubocurarine, the rhythmic contraction
of the myotube stopped. We recorded for an additional 1 min and 15 s and did not observe any
further contractions of the myotube. We concluded that the d-tubocurarine blocked the synaptic
transmission from the motoneuron to myotube. 8A and B, indicates the phase pictures of the
embryonic motoneuron/myotube pair which formed the NMJ in Video 2 both before and after
addition of the d-tubocurarine.

Video 3 was recorded from a co-culture of embryonic motoneuron and fetal skeletal muscle at day
10. Video 3 indicates that the contraction of one myotube in close proximity to a motoneuron was
stopped after curare was applied, but the contractions in another myotube distant from the
motoneuron continued. In Video 3 d-tubocurarine was applied at 44 s and then the recording
continued for another 1 min and 32 s. Video 3 shows that the contraction of one myotube in close
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proximity of a motoneuron was stopped after curare was applied, but the contractions in another
myotube away from the motoneuron continued due to spontaneous contractions.

Video 4 was recorded from a co-culture of embryonic motoneuron and fetal skeletal muscle at day
10. In Video 4, similar to Video 3, contractions of one myotube stopped after d-tubocurarine
application, but the continued contraction of another myotube was noted even after the dtubocurarine application. The total time for the Video 4 recording was 3 min and 13 s, and dtubocurarine application occurred after 1 min.

Video 5 was recorded from a co-culture of embryonic motoneuron and fetal skeletal muscle at day
10. Video 5 (control experiment) shows that myotube contractions were not stopped after the
application of bath solution without d-tubocurarine. The total time of Video 5 is 5 min and 32 s. Bath
solution (without d-tubocurarine) was added at 45 s and the video recording was continued over
the next 4 min and 47 s and myotube contractions were observed during the entire time.. This
application did not stop the contractions of myotubes.

Videos were recorded from 12 different coverslips which were obtained from two different cell
plating experiments. One spot in each coverslip was selected and scanned for myotubes that were
contracting in close proximity of a single motoneuron or multiple motoneurons. The recordings
were made from the pre-selected spot before and after the application of d-tubocurarine or control
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bath solution. Out of the 12 trials, two control experiments were performed where application of the
control bath solution without d-tubocurarine was done. The myotube contractions were not stopped
after the application of bath solution without d-tubocurarine, as indicated in Video 5. In the 10
remaining trials, d-tubocurarine was applied to the bath solution, and in those experiments distinct
effects of d-tubocurarine were observed in three experiments where a contraction of the mytotube
in close proximity of the motoneuron stopped after d-tubocurarine application. The representative
Video 2 shows the distinct effect of d-tubocurarine application on the culture. In the remaining
seven trials, it was observed that even after d-tubocurarine application not all the myotubes at the
selected spot stopped contracting. Some of the myotubes stopped contracting, whereas others
continue to contract. Videos 3 and 4 are representations of the mixed response of the myotubes
after d-tubocurarine application. We concluded from these video experiments that the contraction
of the myotubes which continued, even after d-tubocurarine application, was due to spontaneous
activity, whereas those that stopped contracting after d-tubocurarine application were synapsed to
a motoneuron.

Based on the immunocytochemical, electrophysiological and videograped results obtained, this
novel culture model provides a controlled, highly reproducible system for the study of
neuromuscular junction formation, synaptogenesis and nerve-muscle interactions. Regarding the
available literature, this is the first serum-free model system to recreate mammaliam NMJs on
synthetic substrates in vitro. The advantages of this system are the use of a non-biological
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substrate and a defined medium, and it permits controlled system modification, which can further
current understanding of the NMJ formation phenomenon. Finally, the ease of DETA substrate
patterning will provide a high resolution solution for studying individual neuromuscular junctions,
where direct signaling between a neuron and a myotube will be more readily dissected.
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CHAPTER 7: TISSUE ENGINEERING THE NEUROMUSCULAR JUNCTION: A DEFINED
MODEL SYSTEM

Introduction
The neuromuscular junction (NMJ), formed between motoneurons and skeletal muscle fibers, is
one of the most studied of all synapses. The formation of NMJs in vivo is a multi-step process,
requiring a highly specialized spatial and temporal interaction of growth factors, hormones and
cellular sub-structures, resulting in the formation of a motor endplate. At the motor endplate, a
motoneuron terminal (pre-synaptic terminal) interacts with a specialized site on the muscle (postsynaptic terminal) enriched with acetylcholine receptors (AChRs). These specialized sites are
called neuromuscular junction (NMJ). In a mammalian vertebrate, whenever an action potential is
fired by a motoneuron, it is at these sites that the pre-synaptic vesicles loaded with the
neurotransmitter acetylcholine are released in the synaptic cleft. The released acetylcholine
molecules diffuse across the synaptic cleft and bind to the post-synaptic terminals in the muscle
which are enriched with acetylcholine receptors (AChRs). This leads to depolarization of the
muscle cell membrane and eventually to muscle contraction. In this transmission process the
electrical impulses (action potentials) generated by the motoneuron are converted to chemical
signals. Next, the chemical signal is converted into a mechanical signal in the form of muscle
contraction. Therefore, not only do NMJs represent an important system for studying synapse
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formation and maturation, but also for studying how cells interconvert messages between
electrical, chemical and mechanical modalities[1-4].

In vitro culture models are powerful cell biology tools for studying the role of different growth
factors, hormones and cellular structures relevant to NMJ formation. Furthermore, a system
utilizing defined media and growth substrates makes it easier to understand the effects of
manipulating specific factors within the system.

However, very little research, had been

undertaken in developing cell biological techniques for making mammalian NMJs in the presence
of such a system. This lack of information in cell biological technique is a stumbling block in
successfully tissue engineering the NMJ[1, 2]. The successful creation of a tissue engineered NMJ
construct, requires the development a defined medium and well characterized synthetic biomaterial
promoting NMJ formation. Recently, we attempted to create a tissue engineered construct of NMJ
on a biocompatible silane substrate (DETA) using a defined medium formulation. Though we were
successful in tissue engineering NMJs, the model represented a proof of concept design[5].
Consequently, areas of design improvement were identified and became the focus of further
research.

This manuscript details the following design improvements to the current model: 1) increasing the
longevity of the nerve-muscle co-culture forming NMJs, 2) developing mature phenotypes of
muscle forming NMJs, 3) increasing the number of NMJs in culture. Using an additional group of
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growth factors known to be critical for neuromuscular junction formation and maturation, we have
developed a more robust, long-term model for co-culturing embryonic rat motoneurons and fetal rat
skeletal

muscle.

The

cultures

have

been

characterized

morphologically

and

immunocytochemically. Furthermore, the formation of neuromuscular junctions has been
demonstrated using extensive immunocytochemistry. This model will find extensive applications in
basic research in NMJ, tissue engineering NMJ, bio-hybrid device development for limb prosthesis
and in regenerative medicine.
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Methods and Materials
Surface modification
Glass coverslips (Thomas Scientific 6661F52, 22×22 mm No. 1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 min at 100 mTorr. The DETA (United Chemical Technologies
Inc. T2910KG) film was formed by the reaction of the cleaned surface with 0.1% (v/v) mixture of
the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated coverslips were
heated to just below the boiling point of the toluene, rinsed with toluene, reheated to just below the
boiling temperature, and then oven dried. Surfaces were characterized by contact angle
measurements using an optical contact angle goniometer (KSV Instruments, Cam 200) and by
XPS (Kratos Axis 165) by monitoring the N 1s peak[5-13].

Rat embryonic motoneuron isolation
Rat spinal motoneurons were purified from ventral cords of embryonic day 14 (E14) embryos.
Briefly, rats were anaesthetized and killed by inhalation of an excess of CO2. This procedure was in
agreement with the Animal Research Council of University of Central Florida, which adheres to
IACUC policies. Ventral spinal cells from the embryo were collected in cold Hibernate E/
GlutaMAX™ / antibiotic-antimycotic/ B27. The cells were dissociated with 0.05% trypsin-EDTA
(Invitrogen) treatment for 15 minutes. The dissociated cells were layered over a 4 ml step gradient
(Optiprep diluted 0.505: 0.495 (v/v) with Hibernate E/ GlutaMAX™ / antibiotic antimycotic/ B27 and
222

then made to 15%, 20%, 25% and 35% (v/v) in Hibernate E/ GlutaMAX™/ antibiotic-antimycotic/
B27) followed by centrifugation for 15 min, using 250 g at 4°C. This is modified from the previously
described protocols due to non-availability of metrizamide. After centrifugation, four bands of cells
were obtained. The motoneurons constituted the uppermost band with large somas. These cells
present in the uppermost band were collected in fresh Hibernate E/ GlutaMAX™ / antibioticantimycotic/ B27 and centrifuged for 5 minutes at 200 g and at a set temperature of 4°C. The pellet
formed contains the motoneuron, and theses are further used for culture[10]. Purified motoneurons
were plated on top of muscle cells at a density of 100 cells/mm2. Motoneuron plating was done 30
minutes after plating the muscle cells.

Muscle cell isolation and culture
The skeletal muscle was dissected from the thighs of the rat fetus (E17) hind limbs. The tissue was
collected in a sterile 15 ml centrifuge tube containing 1 ml of phosphate-buffered saline (calciumand magnesium-free) (Gibco 14200075). The tissue was enzymatically dissociated using 2 ml of
0.05% of trypsin-EDTA solution for 60 min in a 37 °C water bath (100 rpm). After 60 min the trypsin
solution was removed and 4 ml of Hib. E +10% fetal calf serum (Gibco 16000044) was added to
terminate the trypsin action. The tissue was then mechanically triturated and the supernatant
transferred to a 15 ml centrifuge tube. The same process was repeated two times by adding 4 ml of
Hib. E +10% FBS each time. The 12 ml cell suspension obtained after mechanical trituration was
suspended on a 2 ml, 4% BSA (Sigma A3059) (prepared in Hib. E medium) cushion and
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centrifuged at 300g for 10 min at 4 °C. Finally, the cell pellet was washed three times with
Hibernate E/ GlutaMAX™ / antibiotic-antimycotic/ B27 and re-suspended in 10 ml of Hibernate E/
GlutaMAX™ / antibiotic-antimycotic/ B27 and plated on 100 mm uncoated dishes for 30 min. The
non-attached cells were removed, centrifuged on a 4% BSA cushion, and plated at a density of
700–1000 cells/mm2 on DETA coated coverslips. After 30 minutes motoneurons were plated on top
of the muscle cells. The cells attached to the substrate in 1 h. After 1 h, serum free medium was
added to the culture wells containing the coverslips. The cultures were maintained at 37°C in a 5%
CO2 incubator (relative humidity 85%)[9, 13].

Serum-free medium composition and medium change technique
Serum-free medium composition was described in table 8 and table 9. Medium change technique
was described in figure 34. The culture model was optimized after more than fifty trials. The current
data was generated from 25 trials (n=25).
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Table 8: Composition of medium 1.
S.

Component

Amount

Catalogue #

Source

References

1.

Neurobasal A

500 ml

10888

Gibco/ Invitrogen

[14]

2.

Antibiotic-Antimycotic

5 ml

15240-062

Gibco/ Invitrogen

3.

Glutamax

5 ml

35050-061

Gibco/ Invitrogen

4.

B27 Supplement

10 ml

17504-044

Gibco/ Invitrogen

[11, 14]

5.

G5 Supplement 100X

5 ml

17503-012

Gibco/ Invitrogen

[15-24]

6.

VEGF 165 r Human

10 µg

P2654

Gibco/ Invitrogen

[25-28]

7.

Acidic FGF

12.5 µg

13241-013

Gibco/ Invitrogen

[15, 22, 24, 29-34]

8.

Heparin Sulphate

50 µg

D9809

Sigma

[15, 22, 24, 29-34]

9.

LIF

10 µg

L5158

Sigma

[35-43]

10.

Vitronectin

50 µg

V0132

Sigma

[44, 45]

No

(Rat

Plasma)
11.

CNTF

20 µg

CRC 401B

Cell Sciences

[46-50]

12.

NT 3

10 µg

CRN 500B

Cell Sciences

[51]

13.

NT 4

10 µg

CRN 501B

Cell Sciences

[52, 53]

14.

GDNF

10 µg

CRG 400B

Cell Sciences

[54-58]

15.

BDNF

10 µg

CRB 600B

Cell Sciences

[53, 59, 60]

16.

CT-1

10 µg

CRC 700B

Cell Sciences

[61-69]
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Table 9: Composition of medium 2
S. No

Component(s)

Amount

Catalogue

Source

References

1.

Neurobasal A

500 ml

10888

Invitrogen/Gibco

[14]

2.

Glutamax

5 ml

35050-061

Invitrogen/Gibco

3.

Antibiotic-antimycotic

5 ml

15240-062

Invitrogen/Gibco

4.

B27 supplement

10 ml

17504-044

Invitrogen/Gibco

[11, 14]

5.

Cholesterol (250X)

5ml

12531

Invitrogen/Gibco

[70]

6.

TNF-alpha, human

10 µg

T6674

Sigma-Aldrich

[71-73]

7.

PDGF BB

50 µg

P4056

Sigma-Aldrich

[35, 74-77]

8.

Vasoactive

250 µg

V6130

Sigma-Aldrich

[78]

intestinal

peptide

(VIP)
9.

Insulin-like growth factor 1

25 µg

I2656

Sigma-Aldrich

[41, 42, 72]

10.

NAP

1mg

61170

AnaSpec, Inc.

[79, 80]

11.

Recombinant Apolipoprotein E2

50 µg

P2002

Panvera, Madison,

[81]

WI
12.

Laminin, mouse purified

2 mg

08-125

Millipore

[82-88]

13.

Beta amyloid (1-40)

1mg

AG966

Millipore

[89-91]

14.

Human Tenascin-C protein

100 µg

CC065

Millipore

[92]

15.

rr- Sonic hedgehog, Shh N-

50 µg

1314-SH

R&D Systems

[93-104]

50 µg

550-AG-

R&D Systems

[105, 106]

terminal
16.

Rr (Agrin C terminal)

100

226

Figure 34. The modified protocol for co-culturing motoneuron and skeletal muscle.
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Immunocytochemistry
Neonatal myosin heavy chain (Neonatal MHC)
Coverslips were rinsed with PBS, fixed in 20 °C methanol for 5–7 min, washed in PBS, incubated
in PBS supplemented with 1% BSA and 0.05% saponin (permeabilization solution), and blocked for
30 min in a permeabilization solution + 10% goat serum (blocking solution). Cells were incubated
overnight with primary antibody against neonatal MHC (N3.36, IgG, Developmental Studies
Hybridoma Bank) diluted (1:5) in the blocking solution. Cells were washed with PBS and incubated
with the secondary antibody (diluted in PBS) for 2 h. The secondary antibody solution was
removed and the cells were rinsed using PBS. The coverslips were dried and mounted on glass
slides using VectaShield+DAPI mounting medium (Vector Laboratories H-1200) and viewed on a
confocal microscope (UltraVIEW™ LCI, PerkinElmer)[5, 107, 108]. Immunocytochemistry results
were verified in three different experiments.

Double staining with Neurofilament 150 and Neonatal myosin heavy chain
Co-cultures were processed for immunocytochemistry as described above. Next, cells were
incubated overnight at 4°C with rabbit anti-neurofilament M polyclonal antibody, 150 kD,
(Chemicon, AB1981, diluted 1:2000) and neonatal MHC (N3.36, IgG, Developmental Studies
Hybridoma Bank diluted 1:5). After overnight incubation, the coverslips were rinsed three times
with PBS and then incubated with the appropriate secondary antibodies for 2h. After rinsing three
times in PBS, the coverslips were mounted with Vectashield+DAPI mounting medium onto glass
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slides. The coverslips were visualized and images collected using a confocal microscope
(UltraVIEW™ LCI, PerkinElmer). Controls without primary antibody were negative[5].
Immunocytochemistry results were verified in three different experiments.

AChR labeling, AChR + Synaptophysin co-labeling and observation in co-cultures
AChRs were labeled as described previously by incubating cultures with 5 × 10-8 M of αbungarotoxin, Alexa Fluor® 488 conjugate (Molecular Probes, B-13422) for 1.5 hr at 37°C before
observation. Labeled cultures were fixed with glacial acetic acid and ethanol, washed with PBS,
dried, mounted and examined by confocal microscopy. The coverslips which were used for double
staining with AChR + Synaptophysin for locating the NMJ were processed further. After 1.5 hr of
α-bungarotoxin labeling of AChR receptors, the coverslips were fixed, blocked, permeabilized and
incubated overnight with synaptophysin antibody (MAB368, diluted 1:1000; Millipore/Chemicon),
the pre-synaptic marker present on the motoneurons. Synaptophysin is a major synaptic vesicle
protein, p38, carrying the neurotransmitters[5, 109].
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Results and Discussion
DETA Surface Modification
DETA modified surface supported long-term survival of the co-culture. Since the silane forms a
uniform monolayer hence the cells distrubute evenly upon plating. The formation of monolayer was
verified using x-ray photoelectron spectroscopy (XPS) and contact angle measurement techniques.
The resukts were similar as reported previously[5, 7-13]. The use of synthetic substrate offers a
scope to dissect the role of different extracellular matrix proteins involved in NMJ formation. We are
attempting to pattern the substrate in different geometries in order to orient the myotubes and the
motoneurons in specific directions. This patterning will assist in studying NMJs in a much more
controlled manner and will make it easy to study the electrical activities in a local environment.

Temporal growth factor application
The formation of the maximal number of neuromuscular junctions was observed using the temporal
growth factor application technique described in Figure 34. Basically, upon plating of motoneurons
and skeletal muscle, the cells were given fed with a medium containing factors to promote both
growth and survival as well as to enhance NMJ formation (Table 8 and Table 9). After 3 days in
culture, the whole medium was removed and was switched to a minimal formulation, NB4Activ,
which facilitated long-term survival and further development of NMJs (Figure 34). This media
(Table 8 and Table 9) were formulated empirically. We had provided the references from the
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available literature which indicated that these different factors are involved in motoneuron, muscle
survival as well as in NMJ formation.

Morphology of the cultures showing interaction of motoneurons and skeletal muscle myotubes
Using phase contrast microscopy, we were able to visualize motoneuron axons appearing to
interact with skeletal muscle myotubes between day 12-15 (Figure 35 A-D). Some of the axonal
processes also appear to branch and terminate on the myotubes.
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Figure 35. A-D: Phase contrast pictures of the motoneurons and skeletal muscle in co-culture
between day 12-15. The distinct morphology of motoneuron and the processes were indiczted by
red arrows. The myotubes were shown by green arrows. The sclae bar is 25 μ.
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Furthermore, many of the myotubes exhibited the characteristic striation pattern observed after
sarcomere formation when the fibers reached approximately 25-30 days in culture (Figure 36 A-D).
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Figure 36. Phase contrast pictures of the co-cultures between day 25-30. A,B: The myotubes
showing characteristic striations. C,D: Panels showing myotubes with striations and myotubes
without striations. The red arrows indicate the neuroncell body and the processes. The green arrow
indicated the myotubes. The scale bar for A, B is 40μ. The scale bar for C, D is 25μ.
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Immunocytochmical characterization of motoneuron and skeletal muscle in culture
Next, we wanted to evaluate the characteristic protein expression pattern of the motoneurons and
myotubes in co-culture. We used immunocytochemistry to visual neurofilament protein expression
in the motoneurons and neonatal myosin heavy chain (MHC) for myotube visualization (Figure 37
A-B). The motoneuron processes were seen all over the myotubes. The characteristic striations of
the myotubes were more visible after staining with neonatal myosin heavy chain antibody.
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Figure 37. A,B: Cocultures at day 25 were stained with NF-150 and N3.36. NF-150 (red) stained
the large motoneurons and their processes. The motoneurons were shown by white arrows. The
myotubes (green) stained for N3.36. The neuronal processes were seen all over the myotubes.
The characteristic striations of the myotubes were observed in the pictures. The scale bar was
50μ.
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Neuromuscular junction formation
In order to determine neuromuscular junction formation using this new medium formulation, we
analyzed the clustering of AChRs using alpha bungarotoxin and their colocalization with
synaptophysin vesicles. The colocalization of these two synaptic structures indicates the proximity
of pre-synaptic and post-synaptic structures and is a good indication of NMJ formation. Using this
technique, we were able to identify the colocalization of synaptophysin vesicles with AChR clusters
(Figure 38 A-D).
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Figure 38.A-D: Neuromuscular Junction (NMJ) formation between day 30-40. The embryonic
motoneuron-skeletal muscle coculture were stained with neonatal myosin heavy chain (N3.36)
antibody (Red), alpha-bungarotoxin (post-synaptic marker labeled with green) and synaptophysin
(pre-synaptic marker labeled with blue). Colocalization of pre-synaptic and post-synaptic markers
indicate the synapse formation at NMJ. A. Phase picture of the myotube showing the alphabungarotoxin staining in green. B. Triple stain, showing the close proximity of alpha-bungratoxin
(green) and synaptophysin (blue) indicating synapse formation at a specific plane and the striations
of the muscle were seen in red (NMHC). C-D. Observing the NMJ at two different planes using the
confocal microscopy. A much more dense clustering of synaptophysin and alpha-bungarotoxin was
observed at these planes.
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We also identified axon + myotube interactions that did not result in the colocalization of presynaptic and post-synaptic structures (Figure 39 A-B). The observation of the negative result
defines the difference between colocalization and non-colocalization emphasizes the positive
observed in this system.
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Figure 39. A, B: No NMJs were observed in these striated muscle. Although alpha-bungarotxin was
observed on the surface of the myotubes indicating the clustering of the acetylcholine receptors.
But no distinct colocalization of synaptophysin was observed in close proximity of acetylcholine
recptor clusters. A. The phase picture of the myotube. B. Immuno-stained picture of the same
myotube with alpha-bungarotoxin, N3.36 and synaptophysin. The scale bar for both the pictures is
50μ.
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In figure 40 (A-D), we showed that NMJ formation took place on a myotube in culture which did not
stained for neonatal myosin heavy chain.
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Figure 40. Formation of NMJ on a myotube which was not positive for N3.36. the cultures was
stained with alpha-bungarotoxin, N3.36 and synaptophysin. A. Phase picture showing the different
morphologies of myotubes in the co-culture. B-D. NMJ formation was observed on a myotube
which was not positive for N3.36. Possibly the myotube on which NMJ was formed was still
immature and did not express the neonatal myosin heavy chain (N3.36).
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Previously, we developed the first defined system model to co-culture embryonic motoneuron and
fetal skeletal muscle[5]. Our previous model was not suitable for long-term tissue engineering
studies and the muscle in the culture only expressed the early muscle marker, fetal MHC. In this
study, we have documented significant improvement over our previous motoneuron-skeletal
muscle co-culture model system. This new improved culture model supported long-term co-culture
of the motoneuron and muscle, resulted in more adult like morphology of the muscle and exhibited
higher density of the neuromuscular junction (NMJ) formation. Our findings were supported by
morphological and immunocytochemical evidence.

We have improved the medium composition. This new, improved medium consisted of 12
additional growth factors which promote motoneuron, skeletal muscle and neuromuscular junction
differentiation. Additionally, we have made certain modification in the culture methodology (Figure
7.1). We have introduced the use of a specialized medium called NB4Activ for maintaining the
cultures. In our previous model we had used Neurobasal/B27 as the changing medium. NB4Activ
medium was developed recently for culturing brain neurons by Gregory J. Brewer in order to
replace Neurobasal/B27. NB4Activ improved the electrical properties of the hippocampal neurons
in the culture[110]. We started to use this medium for in order to enhance the survival of the
motoneurons in pure culture. Interestingly, when we introduced this medium in our co-culture
system, we observed long-term motoneuron and muscle survival and enhanced development of
muscle. Specifically, 90% of the myotubes exhibited expression of a more mature marker of the
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skeletal muscle, neonatal MHC (N3.36). In our previous motoneuron-skeletal muscle co-culture
model, we did not observe the expression of neonatal MHC proteins in the myotubes[5].
Interestingly when this same medium and the same protocol was used to culture pure skeletal
muscle we observed certain striking differences. The pure muscle culture survived longer,
exhibited characteristic striations, but only a very small percentage of myotubes expressed N3.36
(unpublished data). Current research suggests, the N3.36 expression in skeletal muscle in the
culture is either influenced by the motoneurons or by certain factors secreted by the motoneurons.
The MHC class switching occurring in this system has been influenced by the presence of the
Nb4Activ base medium and the additionally growth factors. This needs further studies in order to
dissect the specific factors responsible for the activation of the molecular pathways regulating
N3.36 expression in pure skeletal muscle culture and in the skeletal muscle-motoneuron coculture.

As shown in Figure 38 and 40 this newly developed system resulted in enhanced NMJ
development at later days due to extended life of the culture. The development of additional NMJs
is likely a combination of both the enhanced medium formulation and the increased culture
longevity. These improvements facilitate the study of NMJ maintenance, a process known to be
influenced by Schwann cells. The improved understanding of the factors or cell-cell interactions
required for NMJ maintenance would be a significant finding.
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In summary, this work successfully demonstrated the development of a defined, novel bio-hybrid
technology to tissue engineer neuromuscular junctions in the presence of a chemically defined
medium and a synthetic silane substrate. This model system provides a better understanding of
the minimal growth factor and substrate interactions necessary for NMJ formation. It also provides
a basic system that in the future can be utilized for nerve-muscle and stretch reflex arc
investigations, regenerative medicine and development of limb prosthetic devices.
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CHAPTER 8: ADULT RAT SPINAL CORD CULTURE ON AN ORGANOSILANE SURFACE IN A
NOVEL SERUM-FREE MEDIUM. IN VITRO CELL DEV BIOL ANIM. 2005 NOV-DEC;41(10):3438.)
Introduction
Culture models have only been able to study the spinal cord regeneration of inframammalian
vertebrates [1], amphibians [2] and achieved limited success in mammalian systems[3-5].
Recently, Brewer [6, 7] has cultured adult mammalian cortical and hippocampal neurons and
shown that these adult central nervous system neurons are capable of survival and proliferation in
vitro. However, a robust cell culture model of adult spinal cord neurons has remained elusive, until
now. Previously, we have successfully created an in vitro defined model system for studying
embryonic rat spinal cord motoneurons [8]. Here, we have advanced the scope of our previously
developed model in order to culture adult rat spinal cord neurons.

This study documents the development of a defined in vitro culture system that promotes the
regeneration and growth of dissociated adult rat spinal cord neurons. This culture system is
comprised of a patternable [9], non-biological, cell growth promoting organosilane substrate, N-1[3(trimethoxysilyl)propyl]-diethylenetriamine (DETA) coated on glass surface [8-14] and an
empirically derived novel serum-free medium, supplemented with specific growth factors. We show
the feasibility of using this synthetic silane substrate, combined with a novel serum-free medium, to
create a long-term cell culture model from the dissociated cells of adult rat spinal cord. This culture
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system will be a useful tool to study adult mammalian spinal neuron patterning, repair, myelination,
degeneration and to screen different putative drug candidates for spinal cord repair and
degenerative diseases of the spinal cord such as multiple sclerosis and amyotrophic lateral
sclerosis (ALS).
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Methods and Materials
Surface modification
Glass coverslips (Thomas Scientific 6661F52, 22×22 mm2 No.1) were cleaned using an O2 plasma
cleaner (Harrick PDC-32G) for 20 min at 100 mTorr. The DETA (United Chemical Technologies
Inc. T2910KG) films were formed by the reaction of the cleaned surface with a 0.1% (v/v) mixture
of the organosilane in freshly distilled toluene (Fisher T2904) according to Ravenscroft [9]. The
DETA coated coverslips were heated to just below the boiling point of toluene, rinsed with toluene,
reheated to just below the boiling temperature, and then oven dried (Figure 41 a).
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Figure 41. (a) Structure of a N-1(3-[trimethoxysilyl]propyl)-diethylenetriamine (DETA) molecule.
Cartoon showing the DETA coating on a glass coverslip. (b) Isolated fragment of adult rat spinal
cord (left). Major band of spinal cord cells obtained after optiprep gradient centrifugation (right).
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Surface characterization
Surfaces were characterized by contact angle measurements using an optical contact angle
goniometer (KSV Instruments, Cam 200) and by X-ray Photoelectron Spectroscopy (XPS) (Kratos
Axis 165). XPS survey scans, as well as high-resolution N1 s and C1 s scans, utilizing
monochromatic Al K excitation, were obtained.

Isolation and culture of rat spinal cord
Spinal cords were isolated from adult rats and the meninges were removed from the spinal cord.
The spinal cord was then cut into small pieces and collected in cold Hibernate A, glutamine
(0.5mM) and B27. Next, the tissue was enzymatically digested for 30 minutes in papain (2mg/ml).
The tissue was triturated in 6 ml of fresh Hibernate A (www.BrainBits.com), glutamine (0.5mM) and
B27 (Invitrogen). The 6 ml cell suspension was layered over a 4 ml step gradient (Optipep diluted
0.505: 0.495 (v/v) with Hibernate A/glutamine 0.5mM/B27) and then made to 15%, 20%, 25% and
35% (v/v) in Hibernate A/ glutamine 0.5mM/B27 followed by centrifugation for 15 min, using 800g,
at 4°C. The top 7 ml of the supernatant was aspirated. The next 2.75 ml from the major band and
below was collected and diluted in 5ml Hibernate A/B27 and centrifuged at 600 g for 2 minutes
(Figure 8.1.b). The pellet was resuspended in Hibernate A/B27, and after a second centrifugation,
the pellet was resuspended in the culture medium (see Table 8.1 for the specific composition).
Three-fourths of the culture medium was changed during the first 2-3 days in culture and thereafter
half of the medium was changed after every three days [6, 7].
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Table 10: Composition of 500 ml serum-free medium
Component

Source

Catalogue #

Amount

Neurobasal A

Invitrogen

11415064

500 ml

Gluta Max (100X)

Invitrogen

35050-061

5ml

B27 Supplement (50x)

Invitrogen

17504044

10 ml

Acidic Fibroblast Growth Factor
(aFGF)

Invitrogen

13256029

10ng/ml

Brain Derived Neurotrophic Factor
(BDNF)

Invitrogen

10908019

10ng/ml

Glial Derived Neurotrophic Factor
(GDNF)

Invitrogen

10907012

10ng/ml

Neurotrophin 3
(NT-3)

Sigma

N1905

5ng/ml

Cardiotrophin-1
(CT-1)

Cell Sciences

CRC700B

10ng/ml

Vitronectin

Sigma

V0132

100ng/ml

Heparin Sulphate

Sigma

D9808

10ng/ml

Antibiotic-Antimycotic (100X)

Invitrogen

15240-062

5ml

pH
Osmolarity

7.3 and
320 milliOsm

Immunocytochemistry
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In preparation for staining with anti-neurofilament 150 and anti-GFAP antibodies the coverslips
were rinsed free of medium with PBS and fixed for 20 min at room temperature with 10% glacial
acetic acid and 90% ethanol. The staining of coverslips using anti-neuron specific enolase and
anti-Islet antibody 4D5 were similarly rinsed free of medium with PBS but fixed with 4%
paraformaldehyde in PBS for 20 min. After rinsing twice with PBS, cells were permeabilized for 5
min with 0.5% Triton X-100 in PBS. After rinsing with PBS, the non-specific sites were blocked and
cells permeabilized with 5% normal donkey serum and 0.5% Triton X-100 in PBS. Cells were
incubated overnight at 4°C with rabbit anti-neurofilament M polyclonal antibody, 150 kD,
(Chemicon, AB1981, diluted 1:100) and mouse anti-GFAP monoclonal antibody (Chemicon
MAB360, diluted 1:400), mouse anti neuron-specific enolase gamma-gamma monoclonal antibody
(Chemicon, MAB 314, diluted 1:10) and Anti-Islet antibody 4D5 [15] (Developmental Studies
Hybridoma Bank, diluted 1:50), in the blocking solution. After overnight incubation, the coverslips
were rinsed four times with PBS and then incubated with the appropriate secondary antibodies for
2h. After rinsing four times in PBS, the cover slips were mounted with Vectashield mounting
medium (H1000, Vector Laboratories) onto slides. The coverslips were visualized and
photographed using a Zeiss LSM 510 Confocal microscope. Controls without primary antibody
were negative.

Electrophysiology
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Whole-cell patch clamp recordings were performed in a recording chamber placed on the stage of
a Zeiss Axioscope 2 FS Plus upright microscope in Neurobasal culture medium (pH was adjusted
to 7.3 with HEPES) at room temperature. Patch pipettes (6-8 Mohm) were filled with intracellular
solution (in mM: K-gluconate 140, EGTA 1, MgCl2 2, Na2ATP 5, HEPES 10; pH = 7.2). Voltage
clamp and current clamp experiments were performed with a Multiclamp 700A (Axon, Union City,
CA) amplifier. Signals were filtered at 3 kHz and digitized at 20 kHz with an Axon Digidata 1322A
interface. Data recording and analysis was performed with pClamp 8 (Axon) software. Sodium and
potassium currents were measured in voltage clamp mode using voltage steps from a –70 mV
holding potential. Whole cell capacitance and series resistance was compensated and a p/6
protocol was used. The access resistance was less than 22 Mohm. Action potentials were
measured with 1 s depolarizing current injections from the –70 mV holding potential [8].
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Result and Discussion
Surface modification
Static contact angle and XPS analysis were used for the validation of the surface modifications and
for monitoring the quality of the surfaces. Stable contact angles (40.64° ± 2.9/mean ± SD)
throughout the study indicated high reproducibility and quality of the DETA coatings and were
similar to previously published results [8-14]. Based on the ratio of the N (401 and 399 eV) and the
Si 2p3/2 peaks, XPS measurements indicated that a complete monolayer of DETA was formed on
the coverslips [8-14] (Figure 42).
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Figure 42. Surfaces were characterized by contact angle measurements using an optical contact
angle goniometer (KSV Instruments, CAM 200) (data not shown) and by X-ray photoelectron
spectroscopy (XPS; Kratos Axis 165) by monitoring the N 1 s peak. This figure shows an XPS
survey scan of the N-1(3-[trimethoxysilyl]propyl)-diethylenetriamine monolayer.
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Adult spinal cord culture and immunocytochemistry
Dissociated cells from normal adult rat spinal cord were grown for periods of 3 to 5 weeks on DETA
in the presence of a serum-free defined medium (Table 10). The neurons began to send out
processes by day 6 (±3) (Figure 43 a) and indicated extensive neurite outgrowth by day 18 (±3) in
culture (N > 80, where N = # of rats) (Figure 43 b). The double staining of the culture with antineurofilament and anti GFAP antibodies on day 25 of the experiment showed that the culture
contained a mixture of neuronal (73% (SD = 4.0), n = 6, where n = # of coverslips) and glial (27%
(SD = 4.5), n = 6) cells (Figure 43 c). The neurons were further characterized by staining with antineuron specific enolase (Figure 43 d) and anti-Islet-1 antibodies (Figure 43 e). A smaller fraction
of neurons (10% (SD = 3.5), n = 7) stained for anti-Islet-1 antibody, a specific marker for
motoneurons [15].

Electrophysiology
Whole cell patch clamp experiments were performed on 10 day old cultures. About 30% of the
recorded cells expressed voltage dependent sodium and potassium currents (Figure 8.3.f) and
generated single action potentials (data not shown).
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Figure 43. a. Phase contrast picture of neuronal and glial cells in the adult spinal cord culture (day
6 in vitro), Scale bar: 50 micron. b. Phase contrast picture of neuronal and glial cells in the adult
spinal cord culture (day 25 in vitro), Scale bar: 50 micron.c. Immunostaining with anti-neurofilament
150, a neuron specific marker (red) and anti-GFAP, a glial cell marker (green) (day 25 day in
vitro).d. Second neuronal specific marker for anti-NSE (red) (day 15 in vitro). e. Anti-Islet-1 staining
of cells that exhibited a neuronal morphology (day 25 in vitro). The nucelus is brightly stained with
Islet-1 (green) which is a putative motoneuron marker. f. Representative voltage clamp recordings
obtained from neuronal cells on day 10 in vitro. Voltage dependent ionic currents were evoked by
voltage steps from –40 to +20 mV.
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Use of an Engineered Synthetic Substrate: DETA
The engineered growth substrate consisted of a glass surface coated with a DETA self-assembled
monolayer, which had previously been shown to support neuronal, endothelial and cardiac cell
growth [8-14] and had also been used in creating high resolution, in vitro patterned circuits of
embryonic hippocampal neurons [9]. There are three major rational for using the synthetic DETA
substrate in this study.

First, the DETA substrate can be subsequently patterned at a high resolution to study engineered
in vitro spinal cord neuron networks, which is difficult to achieve with regular biological substrates
like laminin [8]. Previously, the creation of such engineered networks was shown to be feasible with
embryonic hippocampal neurons [9] and embryonic rat motoneurons (unpublished data). Currently,
we are working on developing a patterned network of adult spinal cord neurons in order to
understand the complex information processing taking place at the level of the spinal cord.

Secondly, DETA substrate can be coupled with specific extracellular matrix molecules [16], and
different contact signaling molecules, in order to systematically study the specific role of such
molecules in remyelination, neurodegeneration and axonal growth inhibition during spinal cord
injury and recovery [17].
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Finally, high resolution patterned DETA substrates have been shown to promote guided axonal
growth and direct axonal and dendritic process extension at the level of a single neuron [9, 18]. In
the future, such surface modification techniques could be used as a powerful tool to create a
neuro-electric interface chip in order to bridge the injured fragment of the spinal cord [19-23].

Cell Culture
The spinal cord culture techniques followed in this study were similar to the techniques developed
by Brewer [6, 7] in order to culture adult rat hippocampal and cortical neurons. Currently, we have
a mixed culture of neuronal and glial cells. We are using different cell separation techniques in
order to isolate different cell types of the spinal cord and study their respective physiology. One of
the challenging issues in such an in vitro cell culture model is to reduce the amount of cellular
debris during cell plating. The cellular debris also contains several growth inhibitory molecules
which can result in a slow recovery of the surviving neurons [24-29]. During the initial ten days of
culture we observed very limited growth, but this improved with time. As half of the medium was
changed every 3-4 days, the inhibitory cellular debris could have been slowly washing away and, in
support of this hypothesis, after day 18 we observed extensive neurite outgrowth from most of the
neurons. The growth continued for the next 3-4 weeks. In our future studies we will develop
different techniques to reduce the initial plating debris so as to promote faster regeneration.

Development of the Serum-Free Medium
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The serum-free medium has been developed based on our previous results and published results
from others outlined below. The defined serum-free medium consists of Neurobasal A, B27
supplement [6, 7], a-FGF [30-33] (10ng/ml), heparin sulphate [30] (10ng/ml), neurotrophin-3 (NT-3)
[34-38] (5ng/ml), glial derived neurotrophic factor (GDNF) [29, 39] (10ng/ml), brain derived
neurotrophic factor (BDNF) [29, 34] (10ng/ml), cardiotrophin-1 (CT-1) [29, 40, 41] (10ng/ml) and
vitronectin (100ng/ml). The rational for selecting these growth factors is based on the distribution
of their receptors in the CNS and their therapeutic role in mammalian adult and embryonic spinal
cord regeneration [34, 35, 37, 38, 42-44].

We, and others, had shown previously [8, 45, 46] that embryonic spinal motoneurons can be grown
in a defined system using neurobasal medium, B27 supplement, GDNF (1ng/ml), BDNF (1ng/ml)
and CT-1 (10ng/ml). In this study we have added four additional factors: a-FGF [30-33], heparin
sulphate [30], NT-3 [34-38], vitronectin, and have now demonstrated long term survival and growth
of adult spinal cord neurons in a defined media using this new formulation.

Analysis of the distribution of a-FGF in the adult rat nervous system indicated that a-FGF-like
bioactivity was very high in the periphery and unevenly distributed in the CNS, with the highest aFGF levels being observed in spinal cord [30]. Further, a strong immunohistochemical localization
of a-FGF is found in all adult motoneurons. No staining for a-FGF was observed for non-neuronal
cells [30]. We believe that a-FGF leaking from an injured motoneuron may be involved in initiating
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repair responses in the motoneuron in an autocrine manner, as previously proposed by Eckenstein
et al [30]. Motoneuron survival in vivo can be supported by FGFs. Eckenstein has also shown that
a-FGF requires exogenous heparin [30]. This led to the addition of heparin sulphate along with aFGF to the medium.

Hasse et al [36] had demonstrated that adenovirus-mediated gene transfer of NT-3 can produce
substantial therapeutic effects in mouse mutant PMN (progressive motor neuronopathy). We had
also observed that NT-3, along with vitronectin, improved the health of the embryonic motoneuron
cultures and was the reason NT-3 and vitronectin were used. Similar neuroprotective effects had
been observed in adult injured motoneurons by the adenoviral gene transfer of GDNF and BDNF
[29]. Recently, the therapeutic effect of in vivo electrotransfer of the CT-1 gene into skeletal
muscle had demonstrated the slowing down of motor neuron degeneration in PMN mice [41].
These recent findings led us to add GDNF, BDNF and CT-1 to the medium.

One of the major components of the B27 supplement [6, 7] is retinyl acetate, an analog of proretinoic acid. Retinoic acid and its receptor, beta2, has been shown to promote neurite outgrowth
in the adult mouse spinal cord in vitro [47, 48]. We believe that the presence of retinyl acetate in
the B27 supplement has further accelerated the regeneration process by activating retinoic acid
receptors. One future line of work is to understand the role of individual growth factors and to
further refine the medium for studying remyelination of spinal neurons after injury.
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Electrophysiology
Preliminary electrophysiology experiments indicated that 30% of the recorded cells expressed
voltage dependent sodium and potassium currents and were able to generate single action
potentials. Previously, similar single action potentials were observed in mitogen expanded neural
precursor cells of adult rat spinal cord by Liu et al [49].

Further electrophysiological

characterizations are being undertaken to determine synaptic connectivity events between
motoneurons and their targets.

These are the first studies to demonstrate that adult rat spinal cord cells can be cultured in a
completely defined serum-free medium and on a synthetic silane substrate. This in vitro culture
system will be a useful tool to study adult mammalian spinal neuron repair, myelination,
degeneration, as well as to screen different novel and putative drug candidates for spinal cord
repair and degenerative diseases of spinal cord.
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CHAPTER 9: AUTO-CATALYTIC CERIA NANOPARTICLES OFFER NEUROPROTECTION TO
ADULT RAT SPINAL CORD NEURONS. BIOMATERIALS. 2007 APR;28(10):1918-25)

Introduction
In this study we have demonstrated that auto-catalytic nano-Ceria particles will enhance survival of
adult spinal cord neurons in a unique, defined in vitro system. Ultra fine, non-agglomerated Cerium
oxide nanoparticles (2-5 nm) were synthesized by a microemulsion process [1] for their suitability
for neuroprotective applications in spinal cord injury and degenerative diseases of the central
nervous system (CNS). To test the general biocompatibility and neuroprotection capability of the
synthesized nanoparticles, we evaluated the activity of nano-Ceria in a novel serum-free cell
culture model of adult rat spinal cord [2]. Administration of a single dose of nano-Ceria (10 nM) at
the time of cell plating promotes significantly higher neuronal survival as compared to control
cultures. Nanoparticle treated neurons indicated normal electrical activity as compared to the
control culture to demonstrate functional biocompatibility. Nano-Ceria treated cells also had
significantly higher cell survival upon hydrogen peroxide-induced oxidative injury in the adult spinal
cord model system. Based on our cell culture assays, UV-visible spectroscopic studies, a hydrogen
peroxide-induced oxidative injury assay and our proposed working hypothesis, we conclude that
the supplementation of adult neuronal cultures with auto-catalytic Ceria nanoparticles has a
significant effect in neuronal survival and retention of function.
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Cerium oxide is a rare earth oxide that is found in the lanthanide series of the periodic table. It is
used in various applications such as: histochemistry [3, 4] electrolytes for solid oxide fuel cells [5],
ultraviolet absorbents [6], oxygen sensors [7, 8], and automotive catalytic converters [9].
Nanocrystalline Cerium oxide exhibits a blue shift in the ultra violet absorption spectrum [6], the
shifting and broadening of Raman allowed modes [10] and lattice expansion as compared to bulk
cerium oxide [6, 11]. It was these attributes of this material that were an early indicator that it has
unique properties.

These results demonstrate that the use of nano-Ceria could prove beneficial for the in vivo repair of
spinal cord neurons based on our experiments evaluating the nano-ceria in a more realistic in vitro
model of spinal cord utilizing adult CNS cells. It is also anticipated that they could be good
candidates for drug delivery and imaging applications. Based on the surface chemical properties of
Ceria nanoparticles [12] we propose a hypothesis to explain the neuroprotective role of this
material.
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Methods and Materials
Nanoparticle Synthesis
Cerium oxide nanoparticles were prepared by a microemulsion method. The nanosized micelles
act as reactors for particle formation. The microemulsion system consisted of the surfactant,
sodium bis(2-ethylhexyl) sulphosuccinate (AOT), toluene and water. All the chemicals were
purchased from Aldrich Chemicals Company, Inc. Details of the synthesis are published elsewhere
[1]. The particles obtained in toluene were re-dispersed in water by evaporating the toluene prior to
use in the cell culture studies.

Nanoparticles Characterization
The particle morphology was studied using HRTEM. The surface chemistry of the nano-Ceria
particles was studied using XPS. The Ceria nanoparticles were deposited on the carbon coated
copper grid for HRTEM analysis by the dip coating method. The HRTEM images of the as
prepared particles were obtained with a Philips (Tecnai Series) transmission electron microscope
operating at 300 keV. The XPS data was obtained using a 5400 PHI ESCA (XPS) spectrometer.
The base pressure during XPS analysis was 10-9 Torr and Mg-Kα X-ray radiation (1253.6eV) at a
power of 200 watts was used. The binding energy of Au (4f7/2) at 84.0 ± 0.1 eV was used to
calibrate the binding energy scale of the spectrometer. Any charging shift produced in the spectrum
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was corrected by referencing to the C (1s) position (284.6 eV) [[13]. XPS spectra smoothening and
baseline subtraction was carried out using PeakFit (Version 4) software.

Cell Culture
Surface modification of the coverslips for cell culture: The DETA (United Chemical Technologies
Inc. T2910KG) films were formed by the reaction of the cleaned glass surface with a 0.1% (v/v)
mixture of the organosilane in freshly distilled toluene (Fisher T2904). The DETA coated coverslips
were heated to just below the boiling point of toluene, rinsed with toluene, reheated to just below
the boiling temperature, and then oven dried. The detailed procedure is described elsewhere [14,
15]

Surface characterization of the coverslips: Surfaces were characterized by contact angle
measurements using an optical contact angle goniometer (KSV Instruments, Cam 200) and by
XPS (Fisions 220i). XPS survey scans, as well as high-resolution N 1s and C 1s scans, utilizing
monochromatic Al Kα excitation, were obtained according to our previously published procedures
[2, 14-17].

Isolation and culture of rat spinal cord: Spinal cords were isolated from euthanized adult rats
(average age was 3-4 months) and the meninges were removed from the spinal cord. One single
spinal cord from an adult rat weighs 1.10 g (+/- 0.05). The harvested spinal cord was cut into small
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pieces and collected in cold Hibernate A [[18] (www.BrainBits.com), GlutaMAX™, an antibioticantimycotic and B27 (Invitrogen). Next, the tissue was enzymatically digested for 30 minutes in
papain (2mg/ml). The tissue was dissociated in 6 ml of fresh Hibernate A, GlutaMAX™, an
antibiotic-antimycotic and B27. The 6 ml cell suspension was layered over a 4 ml step gradient
(Optipep diluted 0.505: 0.495 (v/v) with Hibernate A/ GlutaMAX™ / antibiotic-antimycotic/ B27 and
then made to 15%, 20%, 25% and 35% (v/v) in Hibernate A/ GlutaMAX™/ antibiotic-antimycotic/
B27) followed by centrifugation for 15 min, using 800g, at 4°C. The top 7 ml of the supernatant was
aspirated. The next 2.75 ml from the major band and below was collected and diluted in 5ml
Hibernate A/ GlutaMAX™/ antibiotic-antimycotic/ B27 and centrifuged at 600 g for 2 minutes. The
pellet was resuspended in Hibernate A/ GlutaMAX™/ antibiotic-antimycotic/ B27, and after a
second centrifugation, the pellet was resuspended in the culture medium. Approximately 12,00013,000 live cells are harvested from one adult rat spinal cord. 1000 cells were plated on each
coverslip (22 X 22 mm2) at 2 cells/mm2. The culture medium was changed completely after the first
2 days in culture and thereafter half of the medium was changed every four days [2, 19]. A
molecular Probe's L-3224 Live/Dead Assay kit was used for the live-dead assays [16].

Immunocytochemistry for quantification of neuronal and glial cells in control and nanoparticle
treated culture: Rabbit anti-neurofilament M polyclonal antibody, 150 kD, (Chemicon, AB1981,
diluted 1:100) and mouse anti-GFAP monoclonal antibody (Chemicon MAB360, diluted 1:400),
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were used for staining the neuronal and gial cells. The method for immunostaining is described in
detail elsewhere [2].

Electrophysiology of nanoparticle treated culture: Voltage clamp and current clamp experiments
were performed with a Multiclamp 700A (Axon, Union City, CA) amplifier. Signals were filtered at 3
kHz and digitized at 20 kHz with an Axon Digidata 1322A interface. Data recording and analysis
was performed with pClamp 8 (Axon) software. The detailed protocols are documented in our
previous work [2, 16].
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Results and Discussion
A microemulsion process was used to synthesize the cerium oxide nanoparticles (Figure 44.a) and
they were characterized for morphology and surface chemistry by high-resolution transmission
electron microscopy (HRTEM) and X-ray photoelectron spectroscopy (XPS). HRTEM indicated the
formation of uniformly distributed, non-agglomerated nanoparticles of Cerium oxide in the range of
3-5nm as shown in the image in Figure 44.1b. Figure 44.c shows a XPS spectrum that indicates a
mixed valence state (Ce3+ and Ce4+) for the synthesized Cerium oxide nanoparticles. These results
are similar to our previously published results [1, 12, 20].
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Figure 44. Synthesis and Characterization of Cerium oxide Nanoparticles. (a) Outline of the
microemulsion technique to synthesize the nano-Ceria (b) XPS analysis of synthesized Cerium
oxide nanoparticles showing the presence of both Ce3+ and Ce4+ valence states (c) HRTEM image
of the synthesized nanoparticles showing uniform particle size in the range of 3-5 nm.
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The in vitro studies with the synthesized nanoparticles were carried out in a serum-free cell culture
model of adult rat spinal cord (Figure 45) which has been shown to promote growth and long-term
survival of dissociated adult rat spinal cord neurons [2]. This system consists of a patternable [15],
non-biological, cell growth promoting organosilane substrate, N-1 [3-(trimethoxysilyl) propyl]
diethylenetriamine (DETA)[2, 16, 17, 21, 22], coated on a glass surface combined with an
empirically derived, novel serum-free medium and a reproducible cellular isolation and pre-plating
methodology. The serum-free medium consisted of neurobasal A supplemented with B27 [23],
GlutaMAX™, acidic fibroblast growth factor, heparin sulphate, neurotrophin-3, neurotrophin-4,
ciliary neurotrophic factor (CNTF), brain derived neurotrophic factor, glial derived neurotrophic
factor, cardiotrophin-1, vitronectin and an antibiotic-antimycotic (Figure 45.b). The quality of the
surface modified coverslips used for cell culture was monitored using static contact angle
measurements and XPS analysis as previously described [2, 14, 16, 17]. Stable contact angles
(40.64° ± 2.9/mean ± SD) throughout the study indicated high reproducibility and quality of the
DETA coatings and were similar to previously published results [2, 14, 16, 17, 24]. Based on the
ratio of the N 1s (401 and 399 eV) and the Si 2p3/2 peaks, XPS measurements indicated that a
monolayer of DETA (Figure 45.c) was formed on the coverslips [2, 14, 16, 17]. The cell isolation
process from dissected adult rat spinal cord is briefly described in the methods.

The outline of the cell isolation and cell plating is shown in Figure 45.a and documented in detail in
our previous work [2]. In each experiment, an equal volume of the cell suspension (1000 live cells
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at a density of 2 cells/mm2) was plated on each coverslip. Of the total number of coverslips plated
with cells, half of the coverslips were used for control cultures and the other half received a single
dose of 10nM nano-Ceria at the time of cell plating. At two different time intervals, day 15 and day
30, live-dead assays and neuron-glia immunostaining assays were conducted to quantify cell
viability and the surviving cell types in both the control and nano-Ceria treated cultures. A student’s
T-test was used for statistical analysis. The results are expressed as mean ± SE, n = 6, where n
stands for number of coverslips.
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cord (b) Development of serum-free culture medium using various growth factors (c) Surface
modification of the glass cover slips for cell culture.
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The total number of coverslips used for these assays were drawn from six different experiments.
Live-dead cell assays (Figure 46.a) indicated a significantly higher cell survival at day 15 (617 ±
34, n = 6) and at day 30 (472 ± 35, n = 6) in nano-Ceria treated cultures as compared to the
control cultures at day 15 (479 ± 37, n = 6) and day 30 (328 ± 32, n = 6). We also observed a
significantly lower cell death at day 15 (59 ± 7, n = 6) and day 30 (48 ± 7, n = 6) in nano-Ceria
treated cultures as compared to the control cultures on day 15 (110 ± 9, n = 6) and day 30 (72 ± 8,
n = 6). Neurons and glial cells were identified by immunoreactivity for neurofilament 150 (neuronal
marker) and glial fibrilliary acidic protein (GFAP) (glial marker) antibodies respectively. The
neuronal population was significantly higher in nano-Ceria treated cultures at day 15 (191 ± 40, n =
6) and at day 30 (221 ± 12, n = 6) compared to the control cultures on day 15 (71 ± 26, n = 6) and
day 30 (148 ± 9, n = 6). There was no significant difference in glial cell population or populations of
cells which stained for both neuron and glial markers in treated cultures compared to control
cultures at either time interval (Figure 46.b).
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Figure 46. Live-Dead Assay, Neuron-Glial Cell Assay and Electrophysiological Studies of Control
and nano-Ceria Treated Cultures of Adult Rat Spinal Cord (a) Live-dead cell assays indicated that
nano-Ceria treated cultures had significantly higher cell survival and significantly less cell death at
day 15 and day 30 in culture as compared to the control cultures (b) Neuron-glial cell assays
indicated that a significantly high neuronal survival in treated cultures at day 15 and day 30 as
compared to the control cultures. (Data are presented as Mean ± SE, n = 6; * p < 0.05; ** p <
0.01).
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Electrical activities of the nano-Ceria treated cultures were assessed using patch-clamp
electrophysiology at day 30 in culture. The treated neurons expressed voltage dependent inward
and outward currents (Figure 47.a) and generated single action potentials (Figure 47.b), similar to
that observed for the controls and in other adult rat CNS cultures [2], [25].
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Figure 47. Voltage-clamp recording from a treated culture at day 30 (left) Current clamp recording
indicating a single action potential in a nano-Ceria treated culture at day 30 (right).
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We propose that the presence of the mixed valence states of Ce3+ and Ce4+ on the surface of the
nano-Ceria act as an anti-oxidant that allow the nanoparticles to scavenge free radicals from the
culture system. Another complex set of surface chemical reactions [26] between the ions in the cell
culture medium and the nano-Ceria then appear to be involved in reversing the oxidation state from
Ce4+ to Ce3+. We believe that this is indicative of a cyclical regenerative, or auto-catalytic, reaction
of the Ceria nanoparticles. The proposed mechanism is shown in Figure 48.
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Figure 48. Schematic Detailing the Proposed Regenerative Properties of nano-Ceria and probable
mechanism of Cerium oxide nanoparticles’ free radical scavenging property and auto-catalytic
behavior.
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To demonstrate the auto- catalytic spectrum of a sample of the nano-Ceria solution was used as a
control (black trace in the graph). We property of the engineered nano-Ceria particles, we carried
out a UV-visible spectroscopic study of a nano-Ceria sol treated with 10mM hydrogen peroxide
(Figure 49).
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In this reaction, hydrogen peroxide provides a source of hydroxyl radicals to mimic oxidative stress
found in vivo. The UV-Visible added hydrogen peroxide to this solution and observed a shift in the
spectrum to the right or to the lower energy portion of the spectrum (pink trace). This shift is
postulated to be due to a change in the oxidation state [27] from Ce3+ to Ce4+. The nano-Ceria
sample treated with hydrogen peroxide was then kept in the dark for 30 days. UV-Visible spectra of
these samples were then taken at day 15 and day 30 (blue and red traces for the day 15 and day
30 spectra, respectively). A gradual shift in the spectra to the left was seen over time. This gradual
higher energy shift reflects the regeneration (Ce4+ → Ce3+) of the cerium oxide nanoparticles.
When an additional hydrogen peroxide dose was administered to the solution on day 30, the UVVisible spectrum again shifted to lower energy (green trace) which was followed by a gradual shift
to the lower wavelength, as seen previously. The shift to a higher energy state on exposure to
hydrogen peroxide with a recovery toward a lower energy state indicates that the nano-Ceria
particles have the capacity for catalytic oxidative recovery (Ce3+ → Ce4+ → Ce3+) This indicates
that nano-ceria exhibits a mechanism in which the engineered particle provides a new material for
life science applications with unprecedented antioxidant activity and pseudo-infinite half-life. The
auto-regenerative anti-oxidant property of these nanoparticles appears to be the key to its
neuroprotective action.

The auto-catalytic properties of the ceria oxide particles were further demonstrated in a hydrogen
peroxide-induced oxidative injury model utilizing the adult spinal cord model system. A 100 mM
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hydrogen peroxide solution was added for 1h to both a control culture and a nano-Ceria treated
culture at day 30. After 1h of hydrogen peroxide treatment, the cell viability was assayed using a
live-dead assay kit. The nano-Ceria treated cultures had a significantly higher number of live cells
(82 ± 18, n = 6) as compared to the control (29 ± 6, n = 6). We did not observe any significant
difference in the number of dead cells between nano-Ceria treated (362 ± 73, n = 6) and control
(309 ± 44, n = 6) cultures after hydrogen peroxide treatment. This result indicates that the nanoCeria treated cultures had a significantly higher peroxide detoxification ability (Figure 50) and this
may also be a significant indicator of its potential protection abilities after ischemic insult.
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Spinal cord neurons and other CNS neurons are prone to damage due to oxidative stress [28, 29]
both in vitro [30] and in vivo [31-33]. To maintain healthy in vitro cultures of spinal neurons and
other CNS neurons, several antioxidants are generally used in culture medium. The major source
of anti-oxidant molecules in serum-free neuron culture medium is the B27 supplement [23, 34]. B27
contains five antioxidants; vitamin E, vitamin E acetate, superoxide dismutase, catalase, and
glutathione [23]. However, the half-life of these antioxidants is limited and they have to be
replenished each time the medium is changed to maintain a healthy culture [34]. In nano-Ceria
treated cultures, we observed a significant rise in neuron survival as compared to the control
culture, which were supplemented only with B27. The auto-regenerative antioxidant properties of a
single dose of the autocatalytic nano-Ceria in this in vitro model is the most probable explanation of
the significant neuroprotective effect observed in the treated culture.

Based on our cell culture assays, UV-visible spectroscopic studies, hydrogen peroxide-induced
oxidative injury assay and our proposed working hypothesis, we conclude that the supplementation
of neuronal cultures with a single dose of the Ceria nanoparticles has a significant synergistic effect
in a realistic model system of spinal cord injury. Future studies will focus on elucidating the
biological mechanism of action of the nano-Ceria. The use of nano-Ceria with other antioxidants
may, in the future, prove beneficial for the in vivo mitigation of ischemic events after spinal cord
injury as well as possibly being a new therapeutic agent for oxidation injury in the other
neurodegenerative diseases or injury.
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CHAPTER 10: TEMPORAL NEUROTRANSMITTER CONDITIONING RESTORES THE
FUNCTIONAL ACTIVITY OF ADULT SPINAL-CORD NEURONS IN LONG-TERM CULTURE.
EXP NEUROL. 2008 JAN;209(1):171-80

Introduction
Spinal cord injury (SCI) and disease are debilitating conditions that have seen limited progress in
the full repair of damaged neurons in the CNS [1, 2]. Therefore, much effort has been undertaken
to develop in vivo models of SCI and study the cellular and molecular mechanisms of synaptic
connections and information processing in the spinal cord. However, in vitro models of SCI using
dissociated adult cells have not been as extensively investigated due to the difficulties associated
with culturing adult CNS neurons. Fully functional in vitro model systems could be useful not only in
spinal cord injury studies but possibly also for models of amyotrophic lateral sclerosis (ALS),
multiple sclerosis (MS) and neuropathic pain. Recent advancements in the culture of adult
mammalian spinal cord [3, 4] and brain neurons [5-7] in a completely defined serum-free medium,
suggest outstanding potential for answering questions that relate to maturation, aging,
neurodegeneration and injury, as well as the ability to screen different novel and putative drug
candidates for CNS repair and degenerative diseases of the CNS. Prominent features of the
survival of adult CNS neurons in these culture systems have been ascribed to a permissive growth
promoting substrate and defined culture medium [3-7].
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However, there are few reports on the evaluation of the electrical functionality and regeneration of
adult CNS neurons in long-term culture [3, 4, 7, 8]. Recent electrophysiological studies on adult
spinal cord neurons in a defined culture indicated that only approximately 30% of the total surviving
neurons were electrically active [3, 4]. In all cases, the neurons showed a very weak inward and
outward current in voltage clamp studies and only fired single action potentials with limited culture
duration [3, 4].

We report here on the development of a robust and long-term culture model of adult rat spinal-cord
neurons by the addition of four more growth factors (i.e. VEGF [9, 10], G5 supplement [11], NT-4
[12, 13] and CNTF [14-16]) to a previously developed model [3, 4]. In addition, it was discovered
that the electrical functionality of 60% of the neurons could be re-established by long-term temporal
incubation of the cultures with serotonin + glutamate (N-acetyl-DL-glutamic acid) followed by
acetylcholine-chloride, providing in vitro evidence to support the hypothesis that extracellular
neurotransmitters may be involved in shaping synaptic circuits in vivo.
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Methods and Materials
Surface modification of the coverslips:
Glass coverslips (Thomas Scientific 6661F52, 22 × 22 mm2 no. 1) were cleaned using an O2
plasma cleaner (Harrick PDC-32G) for 20 min at 100 mTorr. The DETA (United Chemical
Technologies Inc., Bristol, PA, T2910KG) films were formed by the reaction of the cleaned surface
with a 0.1% (v/v) mixture of the organosilane in freshly distilled toluene (Fisher T2904), according
to Ravenscroft et al. (1998) [17]. The DETA-coated coverslips were heated to just below the boiling
point of toluene, rinsed with toluene, reheated to just below the boiling temperature, and then oven
dried (Figure 51).
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Figure 51. Outline of the defined culture system to study the regeneration of adult mammalian
spinal cord neurons.
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Surface characterization of the coverslips after coating with DETA
Surfaces were characterized by contact angle measurements using an optical contact angle
goniometer (KSV Instruments, Monroe, CT, Cam 200) and by X-ray Photoelectron Spectroscopy
(XPS) (FISONS ESCALab 220i-XL). The XPS survey scans, as well as high-resolution N 1s and C
1s scans, using monochromatic Al Kα excitation, were obtained similar to the previously reported
results [3, 4, 17-20].

Isolation and culture of rat spinal cord
Spinal cords were isolated from adult rats (4-6 months old), and the meninges were removed from
the spinal cord. The spinal cord was then cut into small pieces and collected in cold Hibernate A
(http://www.brainbitsllc.com), glutamine (0.5 mM), and B27 (Invitrogen, Carlsbad, CA). Next, the
tissue was enzymatically digested for 30 min in papain (2 mg/ml). The tissue was triturated in 6 ml
of fresh Hibernate A, glutamine (0.5 mM), and B27. The 6 ml cell suspension was layered over a 4
ml step gradient (Optipep diluted 0.505:0.495 [v/v] with Hibernate A–glutamine 0.5 mM–B27) and
then made to 15, 20, 25, and 35% (v/v) in Hibernate A–glutamine 0.5 mM–B27 followed by
centrifugation for 15 min, using 800 × g, at 4° C. The top 7 ml of the supernatant was aspirated.
The next 2.75 ml from the major band and below was collected and diluted in 5 ml Hibernate A–
B27 and centrifuged at 600 × g for 2 min (Figure 51). The pellet was resuspended in Hibernate A–
B27, and after a second centrifugation, the pellet was resuspended in the culture medium (Table
11 shows the specific composition). Complete culture medium change occurred after the first 2–3 d
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in culture, and thereafter half of the medium was changed after every 5-6 d [3, 4]. Half of the media
was changed on the following days after plating the cells: day 6, 11, 16, 21, 25, 30, 35, 40, 45, 50,
55, 60. Neurotransmitter treatments were started on day 30.
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Table 11: Composition of the serum-free medium.
S. No

Component

Amount

Catalogue #

Source

1.

Neurobasal A

500 ml

10888

Gibco/ Invitrogen

2.

Antibiotic-Antimycotic

5 ml

15240-062

Gibco/ Invitrogen

3.

Glutamax

5 ml

35050-061

Gibco/ Invitrogen

4.

B27 Supplement

10 ml

17504-044

Gibco/ Invitrogen

5.

G5 Supplement (100X)

5 ml

17503-012

Gibco/ Invitrogen

6.

VEGF 165 r Human

10 µg

P2654

Gibco/ Invitrogen

7.

Acidic FGF

12.5 µg

13241-013

Gibco/ Invitrogen

8.

Heparin Sulphate

50 µg

D9809

Sigma

9.

LIF

10 µg

L5158

Sigma

10.

Vitronectin (Rat Plasma)

50 µg

V0132

Sigma

11.

CNTF

20 µg

CRC 401B

Cell Sciences

12.

NT 3

10 µg

CRN 500B

Cell Sciences

13.

NT 4

10 µg

CRN 501B

Cell Sciences

14.

GDNF

10 µg

CRG 400B

Cell Sciences

15.

BDNF

10 µg

CRB 600B

Cell Sciences

16.

CT-1

10 µg

CRC 700B

Cell Sciences
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Throughout the study individual neurotransmitters were added only one time. The details of the
neurotransmitter treatments are described in the following paragraphs.

Neurotransmitter application
The three excitatory neurotransmitters glutamate (A8875, Sigma), serotonin (H9523, Sigma) and
acetylcholine chloride (A2661, Sigma) were used for the study. N-acetyl-DL-glutamic acid was
used as a source for glutamate in the culture because it is naturally occurring in the brain [21]. It is
also more stable [22] and we have found that it improved the cell density of the culture.

In the first series of experiments to study the effect of the individual neurotransmitters, 30 days old
cultures were treated one time with either 25 µM N-acetyl-DL-glutamic acid, 25 µM serotonin or
50 µM acetylcholine chloride. The electrophysiological evaluations were done after 7 and 14 days
of incubation in the neurotransmitters. In the second series of experiments, the combined effect of
serotonin (25 µM) + N-acetyl-DL-glutamic acid (25 µM) was evaluated. The N-acetyl-DLglutamic acid + serotonin combination was applied at day 30 and the electrophysiological
properties of the cells were evaluated after 7 and 14 days of incubation. In the final part of the
experiment, the N-acetyl-DL-glutamic acid (25 µM) + serotonin (25 µM) combination was applied
at day 30 and followed by the addition of acetylcholine chloride (50 µM) after 5 additional days.
The neuron’s electrophysiological properties were evaluated 14 days after the initial treatment of N-
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acetyl-DL-glutamic acid +serotonin. During each experiment neurotransmitter solutions were
freshly prepared.

Immunocytochemistry
In preparation for staining with anti-neurofilament 150, anti-synaptophysin, anti-nestin protein and
the MAP2 a and b antibodies, the coverslips were rinsed free of medium with phosphate-buffered
saline (PBS) and fixed for 20 min at room temperature with 10% glacial acetic acid and 90%
ethanol. The staining of the coverslips with anti MO-1 and anti-Islet antibody 39.4D5 and ChAT
were similarly rinsed free of medium with PBS, but fixed using a different protocol. We added 80 μl
of paraformaldehyde (prepared in PBS) in 2 ml of medium for 5 min. This reaction is done by
keeping the 6 well plate on top of ice. After 5 minutes, the coverslips were rinsed free of medium
with phosphate-buffered saline (PBS) and fixed for 20 min at room temperature with cold fixative
(11.1 ml of Formalin+ 89.9 ml of PBS+ 200 µl of Glutaraldehyde+ 4g of Glucose). The rest of the
steps for staining remain the same. After 20 minutes of fixing, cells were permeabilized for 5
minutes with permebilizing solution (50 mM Lysine+ 0.5% Triton X-100+ 100 ml of PBS). After
rinsing with PBS, the nonspecific sites were blocked with 5% normal donkey serum and 0.5%
Triton X-100 in PBS. The cells were blocked for 2 hours and then the cells are incubated with the
primary antibodies for 12 h at 4ºC. Cells were incubated overnight at 4° C with either rabbit
antineurofilament M polyclonal antibody, 150 kDa (Chemicon, AB1981, diluted 1:1000), anti-nestin
(MAB5326, Chemicon, diluted 1:1000), anti-synaptophysin (MAB368, Chemicon, diluted 1:1000),
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anti-MAP 2 A and B (MAB364, Chemicon, diluted 1:1000), anti-Choline Acetyltransferase (ChAT,
AB143, diluted 1:250), anti-Islet antibody 39.4D5 (Developmental Studies Hybridoma Bank, Iowa
City, IA, diluted 1:50), or MO-1 (Developmental Studies Hybridoma Bank, Iowa City, IA, diluted
1:50), in the blocking solution. After incubating overnight, the coverslips were rinsed four times with
PBS and then incubated with the appropriate secondary antibodies for 2 h. After rinsing four times
in PBS, the cover slips were mounted with Vectashield mounting medium (H1000, Vector
Laboratories, Burlingame, CA) onto slides. The coverslips were observed and photographed using
a Ultra VIEW™ LCI confocal imaging system (Perkin Elmer). Controls without primary antibody
were negative [3, 4].

Electrophysiology
Whole-cell patch clamp recordings were performed in a recording chamber that was placed on the
stage of a Zeiss Axioscope 2 FS Plus upright microscope in Neurobasal culture medium (pH was
adjusted to 7.3 with N-2-hydroxyethylpiperazine-N′-2-ethane-sulfonic acid [HEPES]) at room
temperature. Patch pipettes (6–8 Mohm) were filled with intracellular solution (K-gluconate 140
mM, ethylene glycol-bis[aminoethylether]-tetraacetic acid 1 mM, MgCl2 2 mM, Na2ATP 5 mM,
HEPES 10 mM; pH = 7.2). Voltage clamp and current clamp experiments were performed with a
Multiclamp 700A (Axon, Union City, CA) amplifier. Signals were filtered at 3 kHz and digitized at 20
kHz with an Axon Digidata 1322A interface. Data recording and analysis was performed with
pClamp 8 (Axon) software. Sodium and potassium currents were measured in voltage clamp mode
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using voltage steps of 10 mV from a −70 mV holding potential. Whole-cell capacitance and series
resistance was compensated and a p/6 protocol was used. The access resistance was less than
22 Mohm. Action potentials were measured with 1 s depolarizing current injections from the −70
mV holding potential [3, 4, 18-20].

Statistics
Chi-squared test: Any significant differences (p = 0.05) between treatments as compared to the
control were quantified using the double classification Chi-squared test (Table 10.2).
ANOVA: For pairwise comparisons of the means, we used a one-way ANOVA and statistical tests
assuming unequal variance (Tamhame’s test) (Table 10.3).
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Results and Discussion
Adult spinal-cord neuron regeneration experiments were carried out in a defined culture system
which consisted of an empirically derived serum-free medium, synthetic cell growth promoting
silane substrate and a well defined culture technique (Figure 51). The detailed composition of the
serum-free medium is presented in (Table 11). The culture system was initiated by plating the
dissociated adult rat spinal-cord cells on a synthetic, patternable [17], cell growth promoting
organosilane substrate, N-1[3-(trimethoxysilyl)propyl]-diethylenetriamine (DETA) [3, 4, 18-20, 23].
Detailed protocols for the surface chemical modification of the substrate, characterization of the
substrate, rat dissection, cell isolation and cell culture are discussed elsewhere [3, 4] and
described in detail in the methods section.

The advantages of a synthetic silane substrate are its reproducibility and suitability for high
resolution patterning to allow the development of engineered networks [17],[3, 4, 18, 19, 23] as well
as the ability to couple specific extracellular matrix molecules and different contact signaling
molecules to systematically study the specific role of such molecules in remyelination,
neurodegeneration, and axonal growth inhibition during spinal cord injury. The ability to create
functional in vitro networks of different types of neurons as well as neurons and muscle will allow
detailed study of how these networks can be created or regenerated without having to observe the
processes in vivo. Now the potential to recreate circuits in a defined system with adult cells extends
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this capability enormously. These results reported here, now allow the recreation of this active
network in vitro.

In this culture model we have added four additional growth factors (i.e. VEGF, G5 supplement ,
NT-4 and CNTF) to a previously developed model [3, 4]. The present culture model, with four
additional growth factors, promoted long-term survival (8-10 weeks) of the adult spinal cord cells
(Table 10.1). Previously these individual factors (i.e. VEGF [9, 10], G5 supplement [11], NT-4 [12,
13] and CNTF [14-16] had been shown to improve the survival of spinal cord neurons and glial
cells either or both in vivo and in vitro. Possibly, these growth factors play a synergistic role in
promoting the long-term survival of the regenerating adult spinal cord neurons in culture.

The neurons began their regeneration process within 24 h of plating the cells (Figure 52, upper
panel) and this was characterized by the co-expression of nestin and neurofilament-150 proteins
by the majority of the neurons between day 1-3. By day 4, the neurons only expressed
neurofilament-150 and other neuron specific markers, with nestin expression lost by day 4 (Figure
52 lower panel). Co-expression of nestin and neurofilament-150 during the early stages of cell
growth suggests that these cells may undergo an embryonic ‘reprogramming’ to allow for the
regeneration of axonal and dendritic processes.
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Figure 52. Immunocytochemical evidence of the early events during the initiation of the
regeneration process utilizing nestin and neurofilament-150. Upper panel. The regeneration
process was initiated during the first 24 hours of cell plating and the live/dead assay indicates the
majority of the plated cells are alive. Lower panel. Early regeneration events are characterized by
co-expression of the nestin and neurofilament 150 proteins by most neurons between day 1-3. By
day 4, the neurons only express neurofilament-150 and other neuron specific markers, as the
nestin expression was lost by day 4.
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Specific areas of the spinal cord were not selected for isolation and culture, suggesting that the
culture contains a mixture of ventral horn motoneurons, dorsal horn neurons and interneurons. In
addition, the culture contained 30-40% of GFAP positive cells although the proliferative potential of
these cells was limited by the composition of the defined culture conditions used. The cultures
were immunocytochemically characterized for the different cell types present at two different time
intervals, day 35 and day 45 in culture. We used 6 different neuron specific antibodies (Islet-1,
ChAT, MO-1, NF-150, MAP-2 and synpatophysin) for the immunocytochemistry. The results are
presented in Figure 53, upper and lower panels. At day 35, most of the neurons exhibiting a
smooth-appearing large soma, a multi-polar dendritic tree and a long axon, were later found to be
electrically active. These neurons stained positive for Islet-1, MO-1 and ChAT (Figure 53 A, B, C,
D), the three ventral horn spinal-cord motoneuron markers. In addition, the neurons expressed
MAP-2 a and b, NF-150 proteins and synaptophysin (Figure 53 E, F, G, H).
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Figure 53. Immunostained cultures at day 35 utilizing different neuron specific antibodies. A. Phase
coupled with fluroscence micrograph showing neurons stained with ISLET-1 antibody (a putative
motoneuron marker). B. Fluroscent staining of the ISLET-1 positive cells shown in figure A. C.
Neurons stained with MO-1 antibody (a putative motoneuron marker). D. Neurons stained with
ChAT antibody (a putative motoneuron marker). E. Neurons double-stained with MAP 2a and b
and NF 150 antibodies. F. Neurons double-stained with synaptophysin and NF 150 antibodies. G.
Neurons stained with NF 150 antibody. H. Neurons stained with MAP 2, a and b antibody.
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Whole cell patch clamp experiments were used to evaluate the electrical activity of the neurons.
The duration of the regeneration process was approximately 25-30 days and led to a reticular
network formation by day 35-40. Hence, we specifically choose two time points past this time
period to study the electrical properties, day 37 and 44. In order to minimize electrophysiological
heterogeneity, cells which were morphologically identical to cells previously characterized by
immunocytochemistry were studied. Figure 54 shows representative pictures of the neurons
selected for the study. Morphologically, the neurons selected resembled ventral horn motoneurons.
For comparison, the properties of several large cells with radial symmetry, which most resembled
astrocytes, oligodendroglia or ameboid microglia, were studied.
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Figure 54. Representative phase-contrast pictures of the cells which were used to quantify the
electrical properties. A and B. Phase pictures of the neurons in control culture at day 44. C. Phase
pictures of the neurons after glutamate treatment at day 37 (G37). D. Phase pictures of the
neurons after glutamate treatment at day 44 (G44). E. Phase pictures of the neurons after
serotonin treatment at day 37 (S37). F. Phase pictures of the neurons after serotonin treatment at
day 44 (S44). G. Phase pictures of the neurons after acetylcholine chloride treatment at day 37
(A37). H. Phase pictures of the neurons after acetylcholine chloride treatment at day 44 (A44). I.
Phase pictures of the neurons after glutamate+serotonin treatment at day 37 (GS37). J and K.
Phase pictures of the neurons after glutamate+serotonin treatment at day 44 (GS44).L, M, N and
O. Phase pictures of the neurons after glutamate+serotonin followed by acetylcholine chloride
treatment at day 44 (GSA44).
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Initially, the electrical properties of the neurons in long-term culture were evaluated as controls.
Similar to what has been reported previously, at day 37 (C37) and 44 (C44), 29% and 28% of the
cells exhibited single action potentials (AP), respectively (Table 12).
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Table 12: Comparison of the total number of cells patched and the number of cells which exhibited
APs in control (C37, C44), glutamate treated (G37, G44), serotonin treated (S37, S44),
acetylcholine chloride treated (A37, A44), glutamate+serotonin treated (GS37, GS44), and
glutamate+serotonin→ acetylcholine chloride treated (GSA44). 37 and 44 indicates 7 and 14 days
after culturing the cells in the presence of neurotransmitters respectively. Percentages are
indicated in parentheses.

Total number of
cells patched

Number of cells
which did not fire
any action
potential (NP)

Number of cells
which fired single
action potentials
(SAP)

Number of cells
which fired double
action potentials
(DAP)

Number of cells
which fired
multiple action
potentials (MAP)

C37

24

17

7 (29.1%)

-

-

C44

49

35

14 (28.5%)

-

-

G37

42

28

14 (33.3%)

-

-

G44

14

8

6 (42.2%)

-

-

S37

17

10

7 (41.1%)

-

-

S44

25

14

11 (44.0%)

-

-

A37

30

25

5 (16.6%)

-

-

A44

31

25

6 (19.3%)

-

-

GS37

20

10

10 (50.0%)

-

-

GS44

27

11

14 (56.0%)

2 (12.5%)**

-

GSA44*

107

42

57 (60.7%)

5 (7.6%)**

3 (4.6%)***

*A double classification Chi-squared test was used to test for multiple categories of data. We
compare the X2 value with a tabulated χ2 with one degree of freedom. Our calculated X2 exceeds
the tabulated χ2 value (3.84) for p = 0.05. We conclude that multiple neurotransmitter applications
show significantly more electrically active cells as compared to the control.
**Percentage of neurons as compared to the total number of electrically active neurons which fired
double APs.
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*** Percentage of neurons as compared to the total number of electrically active neurons which
fired multiple APs.
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Research during last two decades have indicated that during the neural circuit development in the
spinal cord, retina, and hippocampus, the electrical stimulation originates due to spontaneous
network activity and paracrine neurotransmitter signaling involved in sculpturing the network
activity [24-26]. Based on this, we speculated that administration of neurotransmitters could mimic
the similar developmental condition and could further improve the functional characteristics of the
regenerating adult spinal cord cells.

We selected three excitatory neurotransmitters, serotonin, glutamate and acetylcholine-chloride for
study. The rational for selecting these three neurotransmitters was to test the hypothesis of
whether the application of extracellular neurotransmitters improve the electrical properties of the
regenerating adult spinal cord neurons. The detailed protocol, dosages and timing of the
neurotransmitter application has been described in the methods section and is outlined in Figure
55 A, B.
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Figure 55. Electrophysiological recordings from glutamate+serotonin→acetylcholine chloride
(GSA44) treated cultures. A. Scheme for single neurotransmitters application. B. Scheme for
multiple neurotransmitters application.
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The first set of electrophysiological experiments was completed by incubating the cultures
separately in three different neurotransmitters: glutamate, serotonin, and acetylcholine-chloride
(Table 12).

The neurotransmitter treatments were performed on 30 day old cultures. The electrical properties
were evaluated at two different time intervals, 7 and 14 days after neurotransmitter incubation. 33%
of the cells fired single AP’s following 7 days of glutamate incubation (G37). There was a 10%
increase in the number of cells firing AP’s following 14 days of glutamate incubation (G44). 41%
and 44% of the total cells exhibited single AP’s after 7 (S37) and 14 (S44) days of serotonin
treatment, respectively. Compared to the control, there was a decrease in the number of cells
exhibiting AP’s after 7 (16% for A37) and 14 (19% for A44) days of acetylcholine chloride
incubation.

In the second set of experiments, the cultures were incubated with multiple neurotransmitters. 50%
of the cells fired single AP’s when co-administered glutamate+serotonin (GS37) and then
incubated in culture for 7 days. Whereas, after 14 days of incubation (GS44), 56% of the cells fired
a single AP, and 2 out of 16 neurons fired double AP’s. To determine if the addition of
acetylcholine-chloride after co-administration of glutamate+serotonin could influence the electrical
properties of the recovering neurons, acetylcholine-chloride was added after 5 days. The electrical
properties were then evaluated at day 14 after the initial co-administration of glutamate+serotonin.
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We observed a significant improvement (p = 0.05) in the electrical properties of the regenerating
neurons using this treatment regime. 60% of the neurons that followed this temporal application of
the three neurotransmitter treatments (GSA44) fired either single, double or multiple actionpotentials (Figure 56 A, B, C). The results are summarized in Table 12 and a double classification
Chi-squared test was used to quantify any significant difference (p = 0.05) between different
treatments as compared to the control.
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Figure 56. A. Representative trace for voltage and current clamp of a neuron firing a single action
potential after multiple neurotransmitter applications at day 44. B. Representative trace for voltage
and current clamp recordings of a double action potential firing neuron after multiple
neurotransmitter applications at day 44. C. Representative trace for voltage and current clamp
recordings of a neuron firing multiple action potentials after multiple neurotransmitter applications
at day 44.
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Interestingly, the inward current was the only parameter that differed significantly (p = 0.01)
between the different groups of neurons (Table 13). As compared to the neurons in the control
culture (C37), the serotonin (S44), glutamate+serotonin (GS44), and glutamate+serotonin→
acetylcholine chloride (GSA44) treated neurons expressed significantly more inward current. We
also observed more inward current from the neurons which were incubated in
glutamate+serotonin→ acetylcholine chloride for 14 days (GSA44) as compared to those cultures
which were incubated in either serotonin (S37), serotonin (S44), acetylcholine chloride (A37) or
acetylcholine chloride (A44).

Similarly, an increase in inward current was also exhibited by neurons which were incubated in
glutamate+serotonin for 14 days (GS44) as compared to those cultures which were incubated in
either S37, S44, G44, A37, or A44. There was also a significant improvement in the electrical
properties of the neurons which were incubated for 14 days in glutamate+serotonin (GS44) as
compared to those which were only incubated for 7 days (GS37) (Table 13). These results illustrate
that full functional recovery was achieved after 14 days following treatment of the cultures with the
multiple neurotransmitter protocol.

The cultures were also analyzed for differences in resting potential, membrane resistance,
membrane capacitance, inward current, outward current, AP height and AP width. These results
are summarized in Table 13 and expressed as mean ± SE. One-way ANOVA and statistical tests,
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assuming unequal variance (Tamhane's test), were used for pairwise comparisons of the mean.
There were no significant differences (p = 0.01) in resting potential, membrane resistance,
membrane capacitance, outward current, AP height and AP width between the different
experimental groups of the cultured neurons.
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Table 13: Comparison of the electrical properties of the neurons which exhibited APs in control
(C37, C44), glutamate treated (G37, G44), serotonin treated (S37, S44), acetylcholine chloride
treated (A37, A44), glutamate+serotonin treated (GS37, GS44), and glutamate+serotonin→
acetylcholine chloride treated (GSA44). Since the neurotransmitters were added on day 30 after
the cells were plated, the numbers 37 and 44 indicate 7 and 14 days respectively after culturing
the cells in the presence of neurotransmitters. The values are expressed as Mean ± SE.
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C37

C44

G37

G44

S37

S44

A37

A44

GS3
7

GS44

GSA4
4

Days in
vitro

37

44

37

44

37

44

37

44

37

44

44

Number of
neurons
(n)

7

14

14

6

7

11

5

6

10

16

65

51.7

48.2

48.9

50.4

50.3

48.9

52.4

52.5

52.8

46.2

44.2

±3.1

±2.9

±3.2

±4.4

±1.5

±1.3

±2.1

±1.7

±2.8

±3.3

±1.3

163.
3

169.1

124.1

130.9

136.9

131.7

237.9

±16.6

±9.2

±12.
9

144.
5

278.9

±11.1

110.
3

±74.0

±23.1

Resting
potential
(Mv)
Input
resistance
(mΩ)

Capacitan
ce (pF)
Peak
inward
current
(pA)
Peak
outward
current
(pA)
Action
potential
height
(mV)
Action
potential
width (ms)

±12.
1

±16.
5

128.2
±7.1

±10.
7

±8.9

18.3

17.0

15.8

14.8

15.71

15.4

15.4

18.5

17.2

18.9

17.7

±1.9

±1.9

±1.1

±1.2

±1.5

±1.5

±1.6

±1.9

±2.8

±1.4

±0.9

657.
1

681.4

674.8

402.1

359.1

525.0

±134.
6

±127.
9

737.
2

±43.
7

±33.
6

713.
9

1376.
4

1090.
4

±95.
2

±105.
2

±79.9

770.
7

833.5
3

883.6

829.3

745.5

±43.
1

±110.
3

±67.
5

1219.
8

930.1

±70.
2

768.
6
±83.
2

±117.
7

26.4

16.6

18.1

20.2

20.7

16.9

18.8

20.2

18.4

25.6

23.84

±2.4

±1.3

±2.3

±3.4

±1.5

±1.3

±2.6

±2.4

±1.8

±2.4

±1.1

3.9

4.4

5.3

3.7

4.2

4.6

4.7

4.7

5.4

5.3

5.80

±0.2

±0.2

±0.7

±0.2

±0.3

±0.3

±0.4

±0.4

±0.5

±0.3

±0.2

±39.
9

±166.
2

±69.
4
855.
0
±77.
3
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450.0
±44.
7
605.0
±37.
4

±70.
4
625.0
±61.
6

P

NS

NS

NS

=
0.01

NS

±41.9

NS

NS

The three neurotransmitters which were used for this study are all excitatory neurotransmitters and
depolarize the cell membrane. Synaptically released glutamate, serotonin, acetylcholine and other
neurotransmitters have been studied in detail [27]. However, very little in vivo information has been
available about the origin and function of the pool of glutamate [28, 29], serotonin [30],
acetylcholine [31-33] and other neurotransmitters which appear to be present in micromolar
concentrations in the extracellular space outside the synaptic cleft [34]. Our results support one
hypothesis in that extracellular neurotransmitters may be involved in shaping synaptic activity in
vivo [28, 29, 35]. Thus, these results raise the distinct possibility that this strategy could also be
exploited to differentiate stem cells to form neurons as well as be applied to establish functional
recovery of damaged neurons in vivo.

Our results now provide one of the missing components that enable full adult CNS neuron
regeneration and demonstrate that the adult CNS neurons can re-establish their
electrophysiological functionality in a fashion similar to that found during embryonic development.
In addition, we have demonstrated for the first time that it is necessary to have an application of
neurotransmitters, as well as growth factors, to enable the injured adult CNS neurons to regain
their full electrical functionality. This new ability to culture functional adult CNS neurons will be of
importance in unlocking molecular pathologies to neurological disorders such as SCI, ALS,
Parkinsons and Alzhiemers which are specific to adult differentiated neurons.
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CHAPTER 11: GENERAL DISCUSSION
Translational research is currently a priority of the National Institutes of Health and other national
and state funding agencies and foundations. In the context of tissue engineering and regenerative
medicine, translational research can refer to the transformation of in vitro tissue engineering and
regenerative medicine technologies and discoveries into practical solutions. One of the key
challenges in translating the in vitro tissue engineering and regenerative medicine results for
clinical applications is the lack of defined model test beds. The non-availability of defined model
test-beds leads to variation in results from laboratory to laboratory. The variation arises due to the
following discrepancies:
1. Lack of uniform cell isolation and cell culture methodology.
2. Poor understanding of the growth factor requirements of the cells and minimum use of microfluidics platform for growth factor delivery.
3. Non-availability of defined mediums and heavily relying on serum supported cultures.
4. Lack of research in understanding cell-cell interactions.
5. Minimum use of surface engineering tools to quantify cell-matrix interactions so as to develop
advance biomaterials.
6. The technological barrier for using photolithography and other surface engineering tools for
controlling cell shape and orientation so as to create two and three-dimensional patterned
substrates.
7. Two or three cell type interaction studies are lacking due to the complexity in handling multiple
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cell types in one system. Micro-fabrication technologies in cell culture laboratories have not been
widely used to create compartmentalized culture systems with micro-fluidics channels for nutrient
and growth factor transfers.

One approach which has been taken to remove these discrepancies is to integrate the knowledge
of cell biology techniques and growth factor biology with modern surface engineering technology,
micro-fabrication technology, micro-fluidics platforms and inter-face technology. The surface
engineering tools provide the state of art technologies to characterize substrates, engineer
substrates at nanometer dimensions and manipulate the surface properties of the substrates.
Micro-fabrication technology offers the scope to develop small bio-hybrid tools and microcompartment chambers to study the interactions of different cell types so as to predict the function
of interacting organ systems of our body. Micro-fluidics platforms offers the scope to control the
delivery of different factors involved in cell growth. Finally interface technology assists in integrating
these different technologies to create functional bio-hybrid devices. In future, such bio-hybrid
devices will be extremely helpful not only for translational research but also addressing basic
problems in biology and medicine and for developing prosthetic devices. This dissertation research
work is an effort in that direction where an attempt has been made to integrate cell culture
technology, growth factor biology, surface engineering strategies, micro-fabrication technology and
interface technology to develop an engineered test bed to study the real time interaction of
motoneuron-skeletal muscle construct.
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In this body of work, the different tissue engineering strategies and technologies have been
addressed to enable the recreation of a in vitro cellular prototype of the stretch reflex circuit with
special emphasis on building the motoneuron to muscle segment of the circuit. In order to recreate
the motoneuron to muscle segment of the stretch reflex arc, a successful methodology to tissue
engineer skeletal muscle and motoneuron was essential. Hence the recreation of the motoneuron
to muscle segment of the stretch reflex circuit was achieved in two parts. In the part 1 (Chapters 25), the challenges in skeletal muscle tissue engineering were examined [1, 2]. In part 2 (Chapters
6-7), apart from tissue engineering the motoneuron[3] to muscle segment, the real time synaptic
activity between motoneuron and muscle segment were studied using extensive video
recordings[4]. In part 3 (Chapters 8-10), an innovative attempt had been made to tissue engineer
the adult mammalian spinal cord neurons so that in future this technology could utilized to replace
the embryonic neurons used in the stretch reflex circuit with adult neurons[5-7]. The advantage of
using adult neurons is that it provides a powerful tool to study older neurons since these neurons
are more prone to age related changes, neurodegenerative disorders and injuries. In the following
paragraphs, the consequences of the individual parts of this work had been discussed.
Furthermore, some challenging questions for future research had been enumerated.

Skeletal muscle differentiation is a common model system to study differentiation process in cell
biology[8]. Although it is a very well studied model, limited success had been achieved in
generating different muscle phenotypes in culture[9-11]. This limited success was mostly due to
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non-availability of a defined culture model. All the culture models relied heavily on the use of
serum[12-15].

This further posed a serious challenge in successful tissue engineering of the

skeletal muscle for therapeutic applications. In order to create tissue engineered constructs for
therapeutic applications, it is essential to have a defined medium formulation. So there existed a
gap in knowledge between basic cell biology and tissue engineering. In order to bridge this gap in
knowledge, there was a serious need to revisit the skeletal muscle differentiation problems from a
tissue engineering perspective. Part 1 aimed at exploring the skeletal muscle tissue engineering
problem from a tissue engineer’s approach. Hence four key goals were set. The goals were as
follows:
1. Developing a uniform skeletal muscle cell isolation and cell culture methodology.
2. Understanding the growth factor requirements of the skeletal muscle cells and developing
defined mediums.
3. Understanding the biocompatibility of the muscle cells on a synthetic substrate.
4. Integrating muscle cells with a cantilever based bio-hybrid device.

The work was documented in four independent experiments (Chapters 2-5). Through this work, a
robust serum-free medium was developed which promoted skeletal muscle differentiation[1, 2].
Myotubes exhibited expression of both embryonic and neonatal myosin heavy chain proteins.
Formation of the excitation-contraction (E-C) coupling apparatus was documented. Myotubes
exhibited physiological electrical properties[2]. Myotubes were also successfully integrated into
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cantilever based bio-hybrid device[2, 16]. This work has thrown some challenging questions for
future studies. Some of those questions had been enumerated below:
1. How to manipulate growth factor requirements so as to generate different fast and slow twitch
muscle phenotypes?
2. How to develope intrafusal fibers for muscle spindle development?[17]
3. How to pattern myotubes in two and three dimensional matrices for tissue engineered
constructs?[18]
4. Could we use a similar cell culture technology to differentiate the satellite cells to form adult
muscle phenotypes?
Currently efforts are going on in order to address some of these challenging questions. This work
had bridged the gap in knowledge that has existed between basic skeletal muscle cell biology and
skeletal muscle tissue engineering. In the future this novel medium formulation could be used for
tissue engineering of skeletal muscle.

In part 2, the key goal was to integrate the tissue engineered muscle developed in part 1 with
embryonic motoneurons, so as to recreate the motoneuron to muscle segment of the stretch reflex
arc. In order to achieve this goal, there was a need to co-culture the skeletal muscle cells with
motoneurons. The major challenges in co-culturing nerve and skeletal muscle were the complexity
of the culture techniques and extensive use of serum in the co-culture. Previously all known
models followed a complex culture technique and used serum in the medium[19]. Hence there was
376

no known defined medium which could be successfully used to coculture mammalian nerve and
muscle cells. This necessitated a need to develop a defined system so as to successfully tissue
engineer the motoneuron to muscle segment of the stretch reflex arc so as to study the
neuromuscular junction. This work was documented in two independent experiments (Chapters 67). A significant biotechnological advancement was made in chapter 6, by using a synthetic
substrate and creating a minimalist serum-free defined system to tissue-engineer the mammalian
neuromuscular junction. A co-culture model of rat mammalian nerve and muscle cells was
achieved which demonstrated the formation of functional neuromuscular junctions[4]. Extension of
this work in experiment B, further demonstrated that expression of more mature myosin heavy
chain proteins in muscle is probably regulated by nerve innervations. This system has given birth to
series of challenging questions for future investigations:
1. How this model could be integrated into a micro-cantilever based bio-hybrid device?[1, 2, 16]
The goal for such integration is to study the encoded electrical signals generated by the
motoneuron, which controls the different muscle movements. Furthermore, using these signals to
design the next generation of robots.
2. How this information could be translated in finding therapies for spinal cord repair, amyotrophic
lateral sclerosis (ALS) and other nerve-muscle disorders and most importantly in regenerative
medicine?

377

Part 3, addressed one of the most intriguing questions: Could we make bio-hybrid circuits of stretch
reflex arc and other complex central nervous system circuits using adult mammalian spinal cord
neurons? This question led to another challenging problem of modern neuronal medicine that is
“How we could protect adult mammalian spinal cord nerve cells, either following injury or in
neurodegenerative diseases”. One of the key prerequisite in in vitro biology to address this
question is to create a serum-free defined in vitro cell culture model of adult mammalian spinal cord
cells. Such a model will not only help in understanding the challenges in incorporating adult spinal
cord neuron in the stretch reflex circuit but would be helpful in understanding the growth factor
requirements to make these adult neurons survive as well as to screen different novel drugs for
spinal cord repair and neurodegenerative disorders of spinal cord like amyotrophic lateral sclerosis
(ALS). In this work, an attempt had been made to develop a culture model to grow adult rat spinal
cord neurons using different growth factors, hormones, anti-oxidant nanoparticles and
neurotransmitters. This work was documented in three independent experiments (chapters 8-10).
In chapter 8, for the first time, it was demonstrated that it was feasible to culture adult mammalian
spinal cord neurons in a chemically defined, serum-free medium and on a synthetic substrate[6].
30% of the total neurons were found to be electrically active and the culture survived for 3-4 weeks.
This offered a simple in vitro tool to study both aging spinal cord neurons and spinal cord injury in
vitro. Further this finding raised some challenging questions for future research:
1. How to enhance the survival of the neurons and how to regain the electrical activity of most of
the neurons ?
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2. Could these adult spinal cord neurons be patterned in specific geometries to study the network
behavior of adult spinal cord neurons?
3. Could these adult neurons be incorporated in functional hybrid devices to create next generation
of neuro-prosthetic devices?
4. Could these adult neurons be remyelinated in the culture with oligodendrocytes and Schwann
cells?
5. Could human spinal cord cells be regenerated using a similar cell culture technology?

These questions set the goal for the next experiment. This goal was to enhance the survival of the
neurons in the culture. In chapter 9, the survival of the adult spinal cord neurons was enhanced by
using a novel, nanoparticle antioxidant; Cerium oxide. The auto-catalytic, anti-oxidant behavior and
biocompatibility of cerium oxide nanoparticles were evaluated in increasing the survival of adult,
mammalian spinal cord neurons in culture[7]. This in vitro experimental evidence raised the
possibility that antioxidant cerium oxide nanoparticle could be administered in animals to evaluate
its efficacy as a nanomedicine for spinal cord repair. Although, significant improvement was made
in the neuronal survival only 30% of the neurons were electrically active. Hence there was a need
to undertake further investigations to improve the electrical activity of the neurons in culture. So
there was a need to discover the missing components in the culture system, which could enhance
the electrical activity of the adult spinal cord neurons. Chapter 10 investigated methods to regain
the electrical maturity of most of the neurons in the culture. In chapter 10, for the first time, it was
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demonstrated that it is necessary to have an application of multiple neurotransmitters in a temporal
fashion, in addition to just growth factors, to enable the injured adult CNS neurons to regain their
full electrical functionality[5]. Due to multiple neurotransmitter treatment, 70% of the neurons were
active in the culture system. These results support one hypothesis in that extracellular
neurotransmitters may be involved in shaping synaptic activity in vivo. Thus, these results raise the
distinct possibility that this strategy could also be exploited to differentiate stem cells to form
neurons as well as be applied to establish functional recovery of damaged neurons in vivo. In
future studies, a mechanistic understanding is essential to understand the exact role by which
neurotransmitters help in functional recovery of adult spinal cord neurons in culture.

This study has successfully demonstrated the recreation of the motoneuron to muscle segment of
the stretch reflex arc and further demonstrated the successful tissue engineering strategies to grow
adult mammalian spinal cord neurons. The different cell culture technologies developed in these
studies could be used as powerful tools in nerve-muscle tissue engineering, neuro-prosthetic
devices and in regenerative medicine.
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2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to the
terms and conditions indicated.
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altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions and/or
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copyright infringement and publisher reserves the right to take any and all action to protect its
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respective officers, directors, employees and agents, from and against any and all claims arising
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All content posted to the web site must maintain the copyright information line on the bottom of
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http://www.elsevier.com , and
417

Central Storage: This license does not include permission for a scanned version of the material to
be stored in a central repository such as that provided by Heron/XanEdu.
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